{| class="wikitable" style="text-align:center; width:50%;"
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Section editor'''
|-
|style="background-color:#F0F0F0"|[[File:Jcvillasboas.jpg|frameless|upright=0.3|center]]
|<big>[[User:Jcvillasboas|J.C. Villasboas Bisneto, MD]]<br>Rochester, MN</big>
|-
|}
''Are you looking for a regimen, such as [[Diffuse_large_B-cell_lymphoma_-_historical#CHOP|CHOP]], but can't find it here? It is possible that we've moved it to the [[Diffuse_large_B-cell_lymphoma_-_historical|historical regimens page]]. If you still can't find it, please let us know so we can add it!''

{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|} 

{{TOC limit|limit=3}}

=Guidelines=
==[http://www.esmo.org/ ESMO]==
*'''2015:''' Tilly et al. [https://www.esmo.org/Guidelines/Haematological-Malignancies/Diffuse-Large-B-Cell-Lymphoma Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]
===Older===
*'''2013:''' Ghielmini et al. [http://annonc.oxfordjournals.org/content/24/3/561.full.pdf+html ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)] [https://www.ncbi.nlm.nih.gov/pubmed/23175624 PubMed]

==[https://www.nccn.org/ NCCN]==
*[https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf NCCN Guidelines - B-cell Lymphomas]

=Untreated, pre-phase=

==Vincristine & Prednisone {{#subobject:3f87a0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, PO vincristine {{#subobject:561457|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30171-5/fulltext Peyrade et al. 2016 (LYSA LNH09-7B)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Vincristine (Oncovin)]] 1 mg PO once on day -7
*[[Prednisone (Sterapred)]] 60 mg PO once per day on days -7 to -4

'''7-day course'''
====Subsequent treatment====
*[[#O-miniCHOP|O-miniCHOP]]

===Variant #2, IV vincristine {{#subobject:722d93|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/104/3/626.long Pfreundschuh et al. 2004 (NHL-B1)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|[http://www.bloodjournal.org/content/104/3/634.long Pfreundschuh et al. 2004 (NHL-B2)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2808%2970002-0/fulltext Pfreundschuh et al. 2008 (RICOVER-60)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|[http://jco.ascopubs.org/content/32/36/4127.full Pfreundschuh et al. 2014 (SMARTE-R-CHOP-14)]
|style="background-color:#91cf61"|Phase II
|-
|}
''Recommended in '''NHL-B1''' and '''NHL-B2''' "to improve the performance status of patients and to ameliorate side-effects of the first chemotherapy cycle." Mandated in '''RICOVER-60''' and '''SMARTE-R-CHOP-14'''. Note: '''NHL-B1''' gave the option of a 5 to 7 day course of prednisone.''
====Chemotherapy====
*[[Vincristine (Oncovin)]] 1 mg IV once (day not specified)
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 7

'''7-day course'''
====Subsequent treatment====
*NHL-B1 and NHL-B2: [[Diffuse_large_B-cell_lymphoma_-_historical#CHOP|CHOP]] versus [[Diffuse_large_B-cell_lymphoma_-_historical#CHOP-14|CHOP-14]] versus [[Diffuse_large_B-cell_lymphoma_-_historical#CHOEP-14|CHOEP-14]] versus [[Diffuse_large_B-cell_lymphoma_-_historical#CHOEP-21|CHOEP-21]]
*RICOVER-60: [[Diffuse_large_B-cell_lymphoma_-_historical#CHOP-14|CHOP-14]] versus [[#R-CHOP-14|R-CHOP-14]]
*SMARTE-R-CHOP-14: [[#R-CHOP-14|R-CHOP-14]]

===References===
# '''NHL-B1:''' Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rübe C, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004 Aug 1;104(3):626-33. Epub 2004 Feb 24. [http://www.bloodjournal.org/content/104/3/626.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14982884 PubMed]
# '''NHL-B2:''' Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004 Aug 1;104(3):634-41. Epub 2004 Mar 11. [http://www.bloodjournal.org/content/104/3/634.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15016643 PubMed]
# '''RICOVER-60:''' Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008 Feb;9(2):105-16. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2808%2970002-0/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18226581 PubMed]
# '''SMARTE-R-CHOP-14:''' Pfreundschuh M, Poeschel V, Zeynalova S, Hänel M, Held G, Schmitz N, Viardot A, Dreyling MH, Hallek M, Mueller C, Wiesen MH, Witzens-Harig M, Truemper L, Keller U, Rixecker T, Zwick C, Murawski N. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group. J Clin Oncol. 2014 Dec 20;32(36):4127-33. Epub 2014 Nov 17. Erratum in: J Clin Oncol. 2015 Jun 10;33(17):1991. [http://jco.ascopubs.org/content/32/36/4127.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25403207 PubMed]
# '''LYSA LNH09-7B:''' Peyrade F, Bologna S, Delwail V, Emile JF, Pascal L, Fermé C, Schiano JM, Coiffier B, Corront B, Farhat H, Fruchart C, Ghesquieres H, Macro M, Tilly H, Choufi B, Delarue R, Fitoussi O, Gabarre J, Haioun C, Jardin F. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. Lancet Haematol. 2017 Jan;4(1):e46-e55. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30171-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28041583 PubMed]

=Untreated, randomized data=

==ACVBP-R {{#subobject:bb17b2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ACVBP-R: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''indesine, '''<u>B</u>'''leomycin, '''<u>P</u>'''rednisone, '''<u>R</u>'''ituximab
<br>R-ACVBP: '''<u>R</u>'''ituximab, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''indesine, '''<u>B</u>'''leomycin, '''<u>P</u>'''rednisone
===Regimen {{#subobject:1cd335|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61040-4/fulltext Récher et al. 2011 (LNH03-2B)]
|style="background-color:#1a9851"|Phase III (E)
|[[#R-CHOP|R-CHOP]]
|style="background-color:#1a9850"|Superior OS
|style="background-color:#d73027"|Increased toxicity
|-
|[http://annonc.oxfordjournals.org/content/24/4/1032.long Ketterer et al. 2013 (LNH03-1B)]
|style="background-color:#1a9851"|Phase III (E)
|[[Diffuse_large_B-cell_lymphoma_-_historical#ACVBP|ACVBP]]
|style="background-color:#91cf60"|Seems to have superior PFS
|style="background-color:#91cf61"|Similar toxicity
|-
|}
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV once on day 1
*[[Vindesine (Eldisine)]] 2 mg/m<sup>2</sup> IV once per day on days 1 & 5
*[[Bleomycin (Blenoxane)]] 10 units IV once per day on days 1 & 5
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 5
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

====CNS prophylaxis====
*[[Methotrexate (MTX)]] 15 mg IT on day 1

====Supportive medications====
*[[Filgrastim (Neupogen)]] 300 mcg (for patients less than 75 kg) or 480 mcg (for patients greater than or equal to 75 kg) SC once per day on days 6 to 13

'''14-day cycle for 4 cycles''' 
====Subsequent treatment====
*[[#Methotrexate_monotherapy|Methotrexate consolidation]], in 4 weeks

===References===
# '''LNH03-2B:''' Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O, Thiéblemont C, Bosly A, Laurent G, Morschhauser F, Ghesquières H, Jardin F, Bologna S, Fruchart C, Corront B, Gabarre J, Bonnet C, Janvier M, Canioni D, Jais JP, Salles G, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011 Nov 26;378(9806):1858-67. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61040-4/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22118442 PubMed]
## '''Subgroup analysis:''' Molina TJ, Canioni D, Copie-Bergman C, Recher C, Brière J, Haioun C, Berger F, Fermé C, Copin MC, Casasnovas O, Thieblemont C, Petrella T, Leroy K, Salles G, Fabiani B, Morschauser F, Mounier N, Coiffier B, Jardin F, Gaulard P, Jais JP, Tilly H. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B. J Clin Oncol. 2014 Dec 10;32(35):3996-4003. Epub 2014 Nov 10. [http://ascopubs.org/doi/full/10.1200/JCO.2013.54.9493 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25385729 PubMed]
# '''LNH03-1B:''' Ketterer N, Coiffier B, Thieblemont C, Fermé C, Brière J, Casasnovas O, Bologna S, Christian B, Connerotte T, Récher C, Bordessoule D, Fruchart C, Delarue R, Bonnet C, Morschhauser F, Anglaret B, Soussain C, Fabiani B, Tilly H, Haioun C. Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). Ann Oncol. 2013 Apr;24(4):1032-7. Epub 2012 Dec 12. [http://annonc.oxfordjournals.org/content/24/4/1032.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23235801 PubMed]

==DA-R-EPOCH {{#subobject:ba36e5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DA-R-EPOCH: '''<u>D</u>'''ose '''<u>A</u>'''djusted '''<u>R</u>'''ituximab, '''<u>E</u>'''toposide, '''<u>P</u>'''rednisone, '''<u>O</u>'''ncovin (Vincristine), '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin)
<br>DA-EPOCH-R
===Regimen {{#subobject:6c5478|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2006.06438.x/full García-Suárez et al. 2007]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409217/ Wilson et al. 2008]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342980/ Wilson et al. 2012]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13273/full Purroy et al. 2014]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://ash.confex.com/ash/2016/webprogram/Paper97112.html Wilson et al. 2016 (CALGB 50303)]
|style="background-color:#1a9851"|Phase III (E)
|[[#R-CHOP|R-CHOP]]
|style="background-color:#ffffbf"|Seems not superior
|style="background-color:#d73027"|Increased toxicity
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per cycle or day 1 before the start of EPOCH (depending on reference)
*[[Etoposide (Vepesid)]] 50 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 200 mg/m<sup>2</sup>) 
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO twice per day on days 1 to 5
*[[Vincristine (Oncovin)]] 0.4 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 1.6 mg/m<sup>2</sup>) 
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV over 15 minutes once on day 5
*[[Doxorubicin (Adriamycin)]] 10 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 40 mg/m<sup>2</sup>)

====Supportive medications====
*Growth factor support with one of the following:
**[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting on day 6 and continuing until ANC greater than 5000/uL past nadir
**[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 6 (option per Purroy et al. 2014)
*PCP prophylaxis with any one of the following:
**[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] 160/800 mg PO twice per day 3 days per week 
***Alternative used only in García-Suárez et al. 2007: cotrimoxazole 480 mg PO twice per day 3 days per week
**[[Atovaquone (Mepron)]] 1500 mg PO once per day 
**[[Pentamidine (Nebupent)]] 300 mg nebulized every 28 days
*Only in García-Suárez et al. 2007: [[Darbepoetin alfa (Aranesp)]] 2.25 ug/kg SC when hemoglobin concentration was less than or equal to 10 g/dL.

'''21-day cycle for 6 to 8 cycles'''

====Dose modifications====
*Start cycle 1 as described above.
*Obtain CBCs twice per week for nadir measurements.
*If nadir ANC greater than 500/uL, increase etoposide, doxorubicin, and cyclophosphamide by 20% compared to previous cycle.
*If nadir ANC less than 500/uL on 1 or 2 measurements, use same doses as last cycle.
*If nadir ANC less than 500/uL on at least 3 measurements, decrease etoposide, doxorubicin, and cyclophosphamide by 20% compared to previous cycle.
*And/or if nadir platelet count less than 25 × 10<sup>9</sup>/L on at least 1 measurement, decrease etoposide, doxorubicin, and cyclophosphamide by 20% compared to previous cycle.
*'''Dose adjustments below the cycle 1 starting dose only applies to cyclophosphamide.''' The lowest etoposide and doxorubicin would be dosed at is the original cycle 1 dose.
*Can start new cycle every 21 days if ANC greater than 1000/uL and platelets greater than 100 × 10<sup>9</sup>/L. If counts are below those levels, check daily CBC and continue growth factor support until counts are adequate and next cycle can start.

===References===
# García-Suárez J, Bañas H, Arribas I, De Miguel D, Pascual T, Burgaleta C. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. Br J Haematol. 2007 Jan;136(2):276-85. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2006.06438.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17233819 PubMed]
# Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, Raffeld M, Gutierrez M, Chabner BA, Staudt L, Jaffe ES, Janik JE. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008 Jun 1;26(16):2717-24. [http://jco.ascopubs.org/content/26/16/2717.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409217/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18378569 PubMed]
# Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, Czuczman M, Lai R, Said J, Chadburn A, Jones D, Dunleavy K, Canellos G, Zelenetz AD, Cheson BD, Hsi ED; Cancer Leukemia Group B. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012 May;97(5):758-65. Epub 2011 Dec 1. [http://www.haematologica.org/content/97/5/758.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342980/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22133772 PubMed]
<!-- previously presented in part at the 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, December 5-8, 2009, and the 53rd Annual Meeting of the American Society of Hematology, San Diego, CA, December 10-13, 2011. -->
# Purroy N, Bergua J, Gallur L, Prieto J, Lopez LA, Sancho JM, García-Marco JA, Castellví J, Montes-Moreno S, Batlle A, de Villambrosia SG, Carnicero F, Ferrando-Lamana L, Piris MA, Lopez A. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma: a phase II study conducted by the Spanish PETHEMA group. Br J Haematol. 2015 Apr;169(2):188-98. Epub 2014 Dec 18. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13273/full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25521006 PubMed]
<!-- Prior publication: Poster presentation at the 2014 annual meeting of the American Society of Hematology (Howlett C, Landsburg DJ, Chong EA, Snedecor SJ, Schuster SJ, Green TM, Cohen JB, Svoboda J, Nasta SD, Feldman T, Rago R, Land D, Walsh KM, Goy A, Mato AR. Front-line, dose-escalated immunochemotherapy is associated with a significant PFS (but not OS) advantage in 401 patients (pts) with double-hit lymphomas (DHL): A systematic review and meta-analysis. Blood, 124, abst 3056). -->
# '''Retrospective:''' Howlett C, Snedecor SJ, Landsburg DJ, Svoboda J, Chong EA, Schuster SJ, Nasta SD, Feldman T, Rago A, Walsh KM, Weber S, Goy A, Mato A. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol. 2015 Aug;170(4):504-14. Epub 2015 Apr 24. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13463/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25907897 PubMed]
# '''Abstract:''' Wyndham H. Wilson, MD, PhD, Jung sin-Ho, Brandelyn Nicole Pitcher, MS, Eric D Hsi, MD, Jonathan Friedberg, MD, Bruce Cheson, MD, Nancy L Bartlett, MD, Scott Smith, Nina Wagner Johnston, MD, Brad S Kahl, Louis M. Staudt, MD, PhD, Kristie Blum, MD, Jeremy Abramson, Oliver W Press, MD, PhD, Richard I. Fisher, MD, Kristy L. Richards, PhD, MD, Heiko Schoder, MD, Julie E Chang, Andrew D. Zelenetz and John P. Leonard, MD. Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303. ASH 2016 Abstract 469 [https://ash.confex.com/ash/2016/webprogram/Paper97112.html link to abstract]

==R-CHOEP-14 {{#subobject:75c24e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-CHOEP-14: '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>E</u>'''toposide, '''<u>P</u>'''rednisone, '''<u>14</u>'''-day cycles

===Variant #1, flat-dose vincristine {{#subobject:b156e5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://link.springer.com/article/10.1385%2FMO%3A23%3A2%3A283 Adde et al. 2006]
|style="background-color:#91cf61"|Phase II
|
|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70481-3/fulltext Schmitz et al. 2012 (DSHNHL 2002-1)]
|style="background-color:#1a9851"|Phase III (C)
|R-MegaCHOEP
|style="background-color:#ffffbf"|Seems not superior
|style="background-color:#1a9851"|Decreased toxicity
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in a RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] as follows:
**Cycles 1 to 4, 6, 8: 375 mg/m<sup>2</sup> IV once on day 0
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 2 mg IV once on day 1
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5

'''14-day cycle for 8 cycles'''
====Subsequent treatment====
*"Mandatory" for patients with bulky disease (any mass greater than 7.5cm in diameter, or extranodal involvement): [[#Radiation_therapy|RT]] x 36 Gy

===Variant #2, capped vincristine, with CNS prophylaxis {{#subobject:0258f4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/24/5/1385.long Holte et al. 2013]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: Consolidative radiotherapy "given at the discretion of the individual centers (36 to 45 Gy). Indications for giving radiotherapy after the completion of chemotherapy included bulky disease (greater than or equal to 10 cm) at diagnosis, localized PET-positive residual lesions, and residual disease, not eligible for biopsy at a localized site, and potentially curable by radiotherapy."''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5

====Supportive medications====
*ONE of the following:
**[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day from day 4
**[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 4

'''14-day cycle for 8 cycles'''
====Subsequent treatment====
*CNS prophylaxis: [[CNS_lymphoma#Cytarabine_monotherapy|HiDAC]], then [[CNS_lymphoma#Methotrexate_monotherapy|HD-MTX]]

===References===
# Adde M, Enblad G, Hagberg H, Sundström C, Laurell A. Outcome for young high-risk aggressive B-cell lymphoma patients treated with CHOEP-14 and rituximab (R-CHOEP-14). Med Oncol. 2006;23(2):283-93. [https://link.springer.com/article/10.1385%2FMO%3A23%3A2%3A283 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16720929 PubMed]
# '''DSHNHL 2002-1:''' Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, Viardot A, Bentz M, Peter N, Ehninger G, Doelken G, Ruebe C, Truemper L, Rosenwald A, Pfreundschuh M, Loeffler M, Glass B; for the German High-Grade Lymphoma Study Group (DSHNHL). Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012 Dec;13(12):1250-1259. Epub 2012 Nov 16. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70481-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23168367 PubMed]
# Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, Sundström C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Fosså A, Ostenstad B, Löfvenberg E, Nordström M, Janes R, Pedersen LM, Anderson H, Jerkeman M, Eriksson M. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol. 2013 May;24(5):1385-92. Epub 2012 Dec 17. [http://annonc.oxfordjournals.org/content/24/5/1385.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23247661 PubMed]

==R-CHOP {{#subobject:240cc2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-CHOP: '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone
<br>R-CHOP-21: '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone given every '''<u>21</u>''' days
<br>CHOP-R: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone, '''<u>R</u>'''ituximab
<br>RCHOP: '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone
<br>CHOPR: '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone, '''<u>R</u>'''ituximab
===Example orders===
*[[Example orders for R-CHOP in lymphoma]]

''Note: most of the variation between regimen variants is in the dose or type of steroid.''
===Variant #1, prednisolone 40 mg/m<sup>2</sup> {{#subobject:74f424|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60313-X/fulltext Cunningham et al. 2013 (UK NCRI R-CHOP14v21)]
|style="background-color:#1a9851"|Phase III (C)
|[[#R-CHOP-14|R-CHOP-14]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ejcancer.com/article/S0959-8049(16)00088-5/fulltext Fridrik et al. 2016 (AGMT NHL-14)]
|style="background-color:#1a9851"|Phase III (C)
|R-COMP
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: Cunningham et al. 2013 states that the regimen is based on LNH 98-5, but notably it uses prednisolone instead of prednisone. AGMT NHL-14 states that R-CHOP was "given in standard doses" per LNH 98-5, but this regimen uses prednisone, whereas the title and text of Fridrik et al. 2016 implies that prednisolone was used. The authors have confirmed that prednisolone was used, due to prednisone not being available in Austria.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisolone (Millipred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 5

====CNS prophylaxis====
Per investigator discretion, but Cunningham et al. 2013 recommended that patients who had involvement of the "bone marrow, peripheral blood, nasal or paranasal sinuses, orbit, and testis" (they probably intended to say "or testis") receive:
*[[Methotrexate (MTX)]] 12.5 mg IT "for the first three cycles of treatment, administered as per local guidelines." No other details given.

====Supportive medications====
*Described in Cunningham et al. 2013
*[[Lenograstim (Granocyte)]] (dose/route not specified) given on days 4 to 12 at physician discretion
*[[Allopurinol (Zyloprim)]] 300 mg PO once per day during cycle 1
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Co-trimoxazole]] 80/400 mg PO twice per day on 3 days per week, taken throughout therapy, ending 2 weeks after chemotherapy is completed

'''21-day cycle for 8 cycles'''

===Variant #2, prednisone 40 mg/m<sup>2</sup> {{#subobject:a326e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa011795 Coiffier et al. 2002 (LNH 98-5)]
|style="background-color:#1a9851"|Phase III (E)
|[[Diffuse_large_B-cell_lymphoma_-_historical#CHOP|CHOP]]
|style="background-color:#1a9850"|Superior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70122-0/fulltext Delarue et al. 2013 (LNH03-6B)]
|style="background-color:#1a9851"|Phase III (C)
|[[#R-CHOP-14|R-CHOP-14]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 5

====CNS prophylaxis====
As described in Delarue et al. 2013 (LNH03-6B):
*[[Methotrexate (MTX)]] 15 mg IT once every 21 days x 4 total doses

====Supportive medications====
*[[Filgrastim (Neupogen)]] used for later cycles if patients developed grade 4 neutropenia or febrile neutropenia

'''21-day cycle for 8 cycles'''

===Variant #3, prednisone 60 mg/m<sup>2</sup> {{#subobject:18b582|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61040-4/fulltext Récher et al. 2011 (LNH03-2B)]
|style="background-color:#1a9851"|Phase III (C)
|[[#ACVBP-R|ACVBP-R]]
|style="background-color:#d73027"|Inferior OS
|style="background-color:#1a9851"|Decreased toxicity
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 5

'''21-day cycle for 8 cycles'''

===Variant #4, prednisone 100 mg, IV rituximab, BSA-based vincristine {{#subobject:13e254|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2001.19.2.389 Vose et al. 2001]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.tandfonline.com/doi/full/10.3109/10428194.2011.621565 Merli et al. 2012 (ANZINTER3)]
|style="background-color:#1a9851"|Phase III (C)
|[[#R-miniCEOP|R-miniCEOP]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://academic.oup.com/annonc/article/24/10/2618/177246 Herbrecht et al. 2013 (PIX203)]
|style="background-color:#1a9851"|Phase III (C)
|CPOP-R
|style="background-color:#ffffbf"|Inconclusive whether non-inferior (*)
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278952/ Oki et al. 2013 (MDACC 2005-0054)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[#R-HyperCVAD.2FR-MA|R-HCVAD/R-MA]]
|style="background-color:#fc8d59"|Seems to have inferior CRR
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4116833/ Seymour et al. 2014 (MAIN)]
|style="background-color:#1a9851"|Phase III (C)
|RA-CHOP-21
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.73.3402 Vitolo et al. 2017 (GOYA)]
|style="background-color:#1a9851"|Phase III (C)
|G-CHOP
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.73.2784 Leonard et al. 2017 (C05013)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[Diffuse_large_B-cell_lymphoma_-_historical#VR-CHOP|VR-CHOP]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: patients in Vose et al. 2001 received rituximab 2 days before CHOP, i.e., all CHOP days are moved forward by 2 days. Patients in GOYA received 8 doses of rituximab, regardless of the number of chemotherapy cycles given. While the primary endpoing in PIX203 was inconclusive (non-inferiority by CR/CRu rate), this arm seemed to have superior OS.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg IV or PO once per day on days 1 to 5

====Supportive medications====
*Varies per protocol
*Prophylactic [[:Category:Granulocyte colony-stimulating factors|G-CSF]] used for persisting grade 4 neutropenia or febrile neutropenia.
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Cotrimoxazole]] (dose/schedule not specified) prophylaxis.
*Erythropoietin use was allowed for hemoglobin less than 11 g/dL.

'''21-day cycle for 6 to 8 cycles (see note)'''
====Subsequent treatment====
*Some protocols: [[#Radiation_therapy|Radiation therapy]] was scheduled for sites of previous bulky disease or partially responding sites

===Variant #5, prednisone 100 mg, IV rituximab, flat-dose vincristine {{#subobject:bcb2bf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2806%2970664-7/fulltext Pfreundschuh et al. 2006 (NCIC CTG LY.9)]
|style="background-color:#1a9851"|Phase III (E)
|1. [[Diffuse_large_B-cell_lymphoma_-_historical#CHOP|CHOP]]<br> 2. [[Diffuse_large_B-cell_lymphoma_-_historical#CHOEP-21|CHOEP-21]]<br> 3. [[Diffuse_large_B-cell_lymphoma_-_historical#MACOP-B|MACOP-B]]<br> 4. [[Diffuse_large_B-cell_lymphoma_-_historical#PMitCEBO|PMitCEBO]]
|style="background-color:#1a9850"|Superior EFS
|style="background-color:#eeee01"|Similar toxicity
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 2 mg IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5

====Supportive medications====
*G-CSF with one of the following:
**[[Filgrastim (Neupogen)]] used at physician discretion for neutropenia
**[[Lenograstim (Granocyte)]] used at physician discretion for neutropenia

'''21-day cycle for 6 cycles'''

====Subsequent treatment====
*[[#Radiation_therapy|Radiation therapy]] 30 to 40 Gy given to sites of primary bulky disease; 30 to 40 Gy to primary extranodal disease at physician discretion

===Variant #6, prednisone 100 mg, SC rituximab {{#subobject:8a0576|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.haematologica.org/content/102/11/1913 Lugtenburg et al. 2017 (MabEase)]
|style="background-color:#1a9851"|Phase III (E)
|IV R-CHOP
|style="background-color:#d9ef8b"|Might have superior CR rate
|-
|}
''Note: the details for CHOP are not available in the manuscript or supplement; we have reproduced common CHOP dosing, here. For patients achieving CR after cycle 4, the CHOP could be omitted after cycle 6.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once on day 1
**Cycles 2 to 8: [[Rituximab and hyaluronidase human (Rituxan Hycela)]] 1400 mg SC once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 5

'''21-day cycle for 6 to 8 cycles'''

===Variant #7, prednisone 100 mg/m<sup>2</sup> {{#subobject:e3dfe2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616024/ Offner et al. 2015 (LYM-2034)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|VR-CAP
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''This regimen was used for non-germinal center B-cell (non-GCB) DLBCL.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 5

'''21-day cycle for 6 cycles'''

===Variant #8, rituximab lead-in {{#subobject:f05383|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/24/19/3121.long Habermann et al. 2006 (ECOG E4494/CALGB 9793)]
|style="background-color:#1a9851"|Phase III (E)
|[[Diffuse_large_B-cell_lymphoma_-_historical#CHOP|CHOP]]
|style="background-color:#91cf60"|Seems to have superior FFS
|-
|}
''Note: an advantage for maintenance was only seen in the group receiving [[Diffuse_large_B-cell_lymphoma_-_historical#CHOP|CHOP]] upfront, which is no longer standard of care.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once per day on days -7 & -3 
**Cycle 2 onwards: 375 mg/m<sup>2</sup> IV once on day -2
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose per cycle: 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 5

====Supportive medications====
*[[Filgrastim (Neupogen)]] "recommended according to guidelines"

'''21-day cycle for 6 to 8 cycles'''
====Subsequent treatment====
*[[#Rituximab_monotherapy|Rituximab maintenance]] versus [[#Observation|observation]]

===Variant #9, short-course for early stage DLBCL {{#subobject:caca45|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/26/14/2258.long Persky et al. 2008 (SWOG S0014)]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on days -7, 1, 22, 43 (4 doses total)
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5

'''21-day cycle for 3 cycles'''

====Subsequent treatment====
*[[#Radiation_therapy|IFRT]] to begin 3 weeks after last cycle of R-CHOP

===Variant #10, primary testicular DLBCL {{#subobject:7f4db5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/29/20/2766.long Vitolo et al. 2011 (IELSG-10)]
|style="background-color:#91cf61"|Phase II
|-
|}
''This regimen is for primary testicular lymphoma, and is a component of a sequential treatment protocol.''
====Preceding treatment====
*Diagnostic [[orchiectomy]] prior to starting chemotherapy
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 0 or 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5

====CNS prophylaxis====
*[[Methotrexate (MTX)]] 12 mg IT once per week x 4 total doses

'''21-day cycle for 6 cycles (up to 8 cycles for stage II patients)'''
====Subsequent treatent====
*[[#Radiation_therapy|RT]]

===Variant #11, 2 cycles with response adaptation {{#subobject:d56c17|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691189/ Witzig et al. 2015 (ECOG E3402)]
|style="background-color:#91cf61"|Phase II
|-
|}
''This regimen is intended for stage I-II DLBCL based on CT (not PET-CT) imaging.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 5

'''21-day cycle for 2 cycles'''
====Subsequent treatment====
*CR based on '''CT''' scan: R-CHOP x 2 (4 cycles total), then [[#Ibritumomab_tiuxetan_monotherapy|ibritumomab tiuxetan consolidation]]
*CRu or PR based on '''CT''' scan: R-CHOP x 4 (6 cycles total), then [[#Ibritumomab_tiuxetan_monotherapy|ibritumomab tiuxetan consolidation]]

===References===
# Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2001 Jan 15;19(2):389-97. [http://ascopubs.org/doi/full/10.1200/JCO.2001.19.2.389 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11208830 PubMed]
# '''LNH 98-5:''' Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jan 24;346(4):235-42. [https://www.nejm.org/doi/full/10.1056/NEJMoa011795 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11807147 PubMed]
## '''Update:''' Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005 Jun 20;23(18):4117-26. [http://jco.ascopubs.org/content/23/18/4117.full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15867204 PubMed]
## '''Update:''' Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Fermé C, Tilly H. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010 Sep 23;116(12):2040-5. [http://www.bloodjournal.org/content/116/12/2040.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951853/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20548096 PubMed] content property of [http://hemonc.org HemOnc.org]
## '''Update:''' Mounier N, Heutte N, Thieblemont C, Briere J, Gaulard P, Feugier P, Ghesquieres H, Van Den Neste E, Robu D, Tilly H, Bouabdallah R, Safar V, Coiffier B; Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ten-year relative survival and causes of death in elderly patients treated with R-CHOP or CHOP in the GELA LNH-985 trial. Clin Lymphoma Myeloma Leuk. 2012 Jun;12(3):151-4. Epub 2012 Feb 1. [http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(11)00607-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22301063 PubMed]
# '''NCIC CTG LY.9:''' Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M; MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006 May;7(5):379-91. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2806%2970664-7/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16648042 PubMed]
## '''Update:''' Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N; MabThera International Trial (MInT) Group. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011 Oct;12(11):1013-22. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2811%2970235-2/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21940214 PubMed]
# '''ECOG E4494/CALGB 9793:''' Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006 Jul 1;24(19):3121-7. Epub 2006 Jun 5. [http://jco.ascopubs.org/content/24/19/3121.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16754935 PubMed]
# '''SWOG S0014:''' Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, Miller TP; Southwest Oncology Group. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008 May 10;26(14):2258-63. Epub 2008 Apr 14. [http://jco.ascopubs.org/content/26/14/2258.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18413640 PubMed]
# '''IELSG-10:''' Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, Bottelli C, Conconi A, Gomez H, Lopez-Guillermo A, Martinelli G, Merli F, Novero D, Orsucci L, Pavone V, Ricardi U, Storti S, Gospodarowicz MK, Cavalli F, Sarris AH, Zucca E. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011 Jul 10;29(20):2766-72. Epub 2011 Jun 6. [http://jco.ascopubs.org/content/29/20/2766.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21646602 PubMed] 
# '''ANZINTER3:''' Merli F, Luminari S, Rossi G, Mammi C, Marcheselli L, Tucci A, Ilariucci F, Chiappella A, Musso M, Di Rocco A, Stelitano C, Alvarez I, Baldini L, Mazza P, Salvi F, Arcari A, Fragasso A, Gobbi PG, Liberati AM, Federico M. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. Leuk Lymphoma. 2012 Apr;53(4):581-8. Epub 2011 Nov 15. [https://www.tandfonline.com/doi/full/10.3109/10428194.2011.621565 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21895543 PubMed]
# '''LNH03-2B:''' Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O, Thiéblemont C, Bosly A, Laurent G, Morschhauser F, Ghesquières H, Jardin F, Bologna S, Fruchart C, Corront B, Gabarre J, Bonnet C, Janvier M, Canioni D, Jais JP, Salles G, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011 Nov 26;378(9806):1858-67. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61040-4/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22118442 PubMed]
## '''Subgroup analysis:''' Molina TJ, Canioni D, Copie-Bergman C, Recher C, Brière J, Haioun C, Berger F, Fermé C, Copin MC, Casasnovas O, Thieblemont C, Petrella T, Leroy K, Salles G, Fabiani B, Morschauser F, Mounier N, Coiffier B, Jardin F, Gaulard P, Jais JP, Tilly H. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B. J Clin Oncol. 2014 Dec 10;32(35):3996-4003. Epub 2014 Nov 10. [http://ascopubs.org/doi/full/10.1200/JCO.2013.54.9493 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25385729 PubMed]
# '''LNH03-6B:''' Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, Van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol. 2013 May;14(6):525-33. Epub 2013 Apr 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70122-0/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23578722 PubMed]
# '''UK NCRI R-CHOP14v21:''' Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013 May 25;381(9880):1817-26. Epub 2013 Apr 22. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60313-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23615461 PubMed]
# '''PIX203:''' Herbrecht R, Cernohous P, Engert A, Le Gouill S, Macdonald D, Machida C, Myint H, Saleh A, Singer J, Wilhelm M, van der Jagt R. Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma. Ann Oncol. 2013 Oct;24(10):2618-23. Epub 2013 Aug 14. [https://academic.oup.com/annonc/article/24/10/2618/177246 link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/23946328 PubMed]
# '''MDACC 2005-0054:''' Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol. 2013 Dec;163(5):611-20. Epub 2013 Oct 1. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.12585/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278952/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24117234 PubMed]
# '''SWOG S9704:''' Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Fisher RI. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med. 2013 Oct 31;369(18):1681-90. [https://www.nejm.org/doi/full/10.1056/NEJMoa1301077 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985418/ link to PMC article] '''does not contain protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24171516 PubMed]
## '''Subgroup analysis:''' Puvvada SD, Stiff PJ, Leblanc M, Cook JR, Couban S, Leonard JP, Kahl B, Marcellus D, Shea TC, Winter JN, Li H, Rimsza LM, Friedberg JW, Smith SM. Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. Br J Haematol. 2016 Sep;174(5):686-91. Epub 2016 Apr 13. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14100/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125530/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27072903 PubMed]
# '''MAIN:''' Seymour JF, Pfreundschuh M, Trnený M, Sehn LH, Catalano J, Csinady E, Moore N, Coiffier B; MAIN Study Investigators. R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. Haematologica. 2014 Aug;99(8):1343-9. Epub 2014 Jun 3. [http://www.haematologica.org/content/99/8/1343.abstract link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4116833/ link to PMC article] '''does not contain protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24895339 PubMed]
<!-- Prior publication: Poster presentation at the 2014 annual meeting of the American Society of Hematology (Howlett C, Landsburg DJ, Chong EA, Snedecor SJ, Schuster SJ, Green TM, Cohen JB, Svoboda J, Nasta SD, Feldman T, Rago R, Land D, Walsh KM, Goy A, Mato AR. Front-line, dose-escalated immunochemotherapy is associated with a significant PFS (but not OS) advantage in 401 patients (pts) with double-hit lymphomas (DHL): A systematic review and meta-analysis. Blood, 124, abst 3056). -->
# '''Retrospective:''' Howlett C, Snedecor SJ, Landsburg DJ, Svoboda J, Chong EA, Schuster SJ, Nasta SD, Feldman T, Rago A, Walsh KM, Weber S, Goy A, Mato A. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol. 2015 Aug;170(4):504-14. Epub 2015 Apr 24. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13463/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25907897 PubMed]
# '''ECOG E3402:''' Witzig TE, Hong F, Micallef IN, Gascoyne RD, Dogan A, Wagner H Jr, Kahl BS, Advani RH, Horning SJ. A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402. Br J Haematol. 2015 Sep;170(5):679-86. Epub 2015 May 14. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13493/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691189/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25974212 PubMed]
# '''LYM-2034:''' Offner F, Samoilova O, Osmanov E, Eom HS, Topp MS, Raposo J, Pavlov V, Ricci D, Chaturvedi S, Zhu E, van de Velde H, Enny C, Rizo A, Ferhanoglu B. Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood. 2015 Oct 15;126(16):1893-901. Epub 2015 Jul 31. [http://www.bloodjournal.org/content/126/16/1893.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616024/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26232170 PubMed]
# '''AGMT NHL-14:''' Fridrik MA, Jaeger U, Petzer A, Willenbacher W, Keil F, Lang A, Andel J, Burgstaller S, Krieger O, Oberaigner W, Sihorsch K, Greil R. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14). Eur J Cancer. 2016 May;58:112-21. Epub 2016 Mar 15. [https://www.ejcancer.com/article/S0959-8049(16)00088-5/fulltext link to original article] '''does not contain protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26990931 PubMed]
# '''Abstract:''' Wyndham H. Wilson, MD, PhD, Jung sin-Ho, Brandelyn Nicole Pitcher, MS, Eric D Hsi, MD, Jonathan Friedberg, MD, Bruce Cheson, MD, Nancy L Bartlett, MD, Scott Smith, Nina Wagner Johnston, MD, Brad S Kahl, Louis M. Staudt, MD, PhD, Kristie Blum, MD, Jeremy Abramson, Oliver W Press, MD, PhD, Richard I. Fisher, MD, Kristy L. Richards, PhD, MD, Heiko Schoder, MD, Julie E Chang, Andrew D. Zelenetz and John P. Leonard, MD. Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303. ASH 2016 Abstract 469 [https://ash.confex.com/ash/2016/webprogram/Paper97112.html link to abstract]
# '''CISL 12-09:''' Yoon DH, Sohn BS, Oh SY, Lee WS, Lee SM, Yang DH, Huh J, Suh C. Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09). Oncotarget. 2017 Feb 21;8(8):13367-13374. [http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=14531&path%5B%5D=46365 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355104/ link to PMC article] '''does not contain protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28076329 PubMed]
# '''MabEase:''' Lugtenburg P, Avivi I, Berenschot H, Ilhan O, Marolleau JP, Nagler A, Rueda A, Tani M, Turgut M, Osborne S, Smith R, Pfreundschuh M. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica. 2017 Nov;102(11):1913-1922. Epub 2017 Sep 21. [http://www.haematologica.org/content/102/11/1913 link to original article] '''contains partial protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28935843 PubMed]
# '''GOYA:''' Vitolo U, Trněný M, Belada D, Burke JM, Carella AM, Chua N, Abrisqueta P, Demeter J, Flinn I, Hong X, Kim WS, Pinto A, Shi YK, Tatsumi Y, Oestergaard MZ, Wenger M, Fingerle-Rowson G, Catalani O, Nielsen T, Martelli M, Sehn LH. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017 Nov 1;35(31):3529-3537. Epub 2017 Aug 10. [http://ascopubs.org/doi/full/10.1200/JCO.2017.73.3402 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28796588 PubMed]
# '''C05013:''' Leonard JP, Kolibaba KS, Reeves JA, Tulpule A, Flinn IW, Kolevska T, Robles R, Flowers CR, Collins R, DiBella NJ, Papish SW, Venugopal P, Horodner A, Tabatabai A, Hajdenberg J, Park J, Neuwirth R, Mulligan G, Suryanarayan K, Esseltine DL, de Vos S. Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol. 2017 Nov 1;35(31):3538-3546. Epub 2017 Sep 1. [http://ascopubs.org/doi/full/10.1200/JCO.2017.73.2784 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28862883 PubMed]
# Hara T, Yoshikawa T, Goto H, Sawada M, Yamada T, Fukuno K, Kasahara S, Shibata Y, Matsumoto T, Mabuchi R, Nakamura N, Nakamura H, Ninomiya S, Kitagawa J, Kanemura N, Nannya Y, Katsumura N, Takahashi T, Kito Y, Takami T, Miyazaki T, Takeuchi T, Shimizu M, Tsurumi H. R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial. Hematol Oncol. 2018 Oct;36(4):638-644. Epub 2018 Jun 8. [https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2524 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29882279 PubMed]

==R-CHOP-14 {{#subobject:fc3bde|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-CHOP-14: '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone every '''<u>14</u>''' days
===Synopsis===
To be completed. Note that most of the variation below is in the steroid dose.
===Variant #1, prednisone 40 mg/m<sup>2</sup>, 4 to 6 cycles {{#subobject:6ec36f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/131/2/174.long Lamy et al. 2017 (LYSA/GOELAMS 02-03)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 5

'''14-day cycle for 4 to 6 cycles'''
====Subsequent treatment====
*[[#Observation|Observation]] versus [[#Radiation_therapy|IFRT]] x 40 Gy

===Variant #2, prednisone 40 mg/m<sup>2</sup>, 8 cycles {{#subobject:6ec36f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70122-0/fulltext Delarue et al. 2013 (LNH03-6B)]
|style="background-color:#1a9851"|Phase III (E)
|[[#R-CHOP|R-CHOP21]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 5

====CNS prophylaxis====
*[[Methotrexate (MTX)]] 15 mg IT once every 14 days x 4 total doses

====Supportive medications====
*ONE of the following, "according to the treating doctor's decision, fulfilling existing guidelines and product labelling at that time."
**[[Filgrastim (Neupogen)|Granulocyte colony-stimulating factor]] 
**[[Pegfilgrastim (Neulasta)|Pegylated G-CSF]] 

'''14-day cycle for 8 cycles'''

===Variant #3, prednisone 100 mg, BSA-based vincristine, standard-dose IV rituximab {{#subobject:9cab31|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4116833/ Seymour et al. 2014 (MAIN)]
|style="background-color:#1a9851"|Phase III (C)
|RA-CHOP-14
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2016.67.2980 Cortelazzo et al. 2016]
|style="background-color:#1a9851"|Phase III (C)
|R-HDS
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=2|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30444-8/fulltext Chiappella et al. 2017 (DLCL04)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#R-MegaCHOP-14|R-MegaCHOP-14]]
|style="background-color:#d3d3d3"|Not reported
|-
|2. R-CHOP-14, then R-MAD, then BEAM, then auto HSCT<br> 3. R-MegaCHOP-14, then R-MAD, then BEAM, then auto HSCT
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: in MAIN, CHOP-14 was given for 6 cycles and rituximab for 8 cycles. In Cortelazzo et al. 2016, there is no cap on the vincristine dose, and there is also a discrepancy between the prednisone dose in the body of the manuscript and that in the appendix Figure A1; these discrepancies were clarified by the corresponding author in January 2017. In the abstract of DLCL04, there is no cap on vincristine.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5

====Supportive medications====
*ONE of the following:
**[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day on days 7 to 11
**[[Pegfilgrastim (Neulasta)]]

'''14-day cycle for 6 to 8 cycles (see note)'''

===Variant #4, prednisone 100 mg, BSA-based vincristine, high-dose IV rituximab {{#subobject:5fb2fa|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://meetinglibrary.asco.org/content/133133-144 Pfreundschuh et al. 2014 (SEXIE-R-CHOP-14)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|See below
|TBD
|-
|}
''Note: two arms were assessed; results are pending from this comparison. These higher doses were for males, only.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] by ONE of the following schedules:
**500 mg/m<sup>2</sup> IV once every two weeks
**500 mg/m<sup>2</sup> IV once on days -1, 0, 3, 7, 14, 21, 28, 42
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 2 mg IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5

'''14-day cycle for 6 cycles (8 doses of rituximab regardless of total number of CHOP-14 cycles)'''

===Variant #5, prednisone 100 mg, BSA-based vincristine, SC rituximab {{#subobject:dc3777|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.haematologica.org/content/102/11/1913 Lugtenburg et al. 2017 (MabEase)]
|style="background-color:#1a9851"|Phase III (E)
|IV R-CHOP
|style="background-color:#d9ef8b"|Might have superior CR rate
|-
|}
''Note: the details for CHOP-14 are not available in the manuscript or supplement; we have reproduced common CHOP-14 dosing, here. For patients achieving CR after cycle 4, the CHOP-14 could be omitted after cycle 6.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once on day 1
**Cycles 2 to 8: 1400 mg SC once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5

====Supportive medications====
*ONE of the following:
**[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day on days 7 to 11
**[[Pegfilgrastim (Neulasta)]]

'''14-day cycle for 6 to 8 cycles'''

===Variant #6, prednisone 100 mg, flat dose vincristine, 2 cycles, with response adaptation {{#subobject:a01893|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.76.8093 Dührsen et al. 2018 (PETAL)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#Vincristine_.26_Prednisone|Pre-phase vincristine & prednisone]]
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 2
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 2
*[[Vincristine (Oncovin)]] 2 mg IV once on day 2
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 2 to 6

'''14-day cycle for 2 cycles'''
====Subsequent treatment====
*PET-negative: R-CHOP x 4 (6 cycles total) versus R-CHOP x 4, then rituximab x 2
*PET-positive: R-CHOP x 6 (8 cycles total) versus intensive Burkitt lymphoma protocol

===Variant #7, prednisone 100 mg, flat dose vincristine, 6 cycles, extended rituximab exposure {{#subobject:aae4db|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/32/36/4127.full Pfreundschuh et al. 2014 (SMARTE-R-CHOP-14)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#Vincristine_.26_Prednisone|Pre-phase vincristine & prednisone]]
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days -4, 0, 10, 29, 57, 99, 155, and 239 (independent of CHOP cycles)
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 2 mg IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5

====Supportive medications====
*ONE of the following starting on day 4, to continue until count recovery:
**[[Filgrastim (Neupogen)]]
**[[Lenograstim (Granocyte)]]

'''14-day cycle for 6 cycles'''
====Subsequent treatment====
*Patients with initial bulky disease ("lymphoma masses or conglomerates with a diameter greater than or equal to 7.5 cm) or extranodal involvement"): [[#Radiation_therapy|RT]] x 36 Gy

===Variant #8, prednisone 100 mg, flat dose vincristine, 6-8 cycles {{#subobject:30c25c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=3 |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2808%2970002-0/fulltext Pfreundschuh et al. 2008 (RICOVER-60)]
|rowspan=3 style="background-color:#1a9851"|Phase III (E)
|1. [[Diffuse_large_B-cell_lymphoma_-_historical#CHOP-14|CHOP-14]] x 6
|style="background-color:#1a9850"|Superior OS
|-
|2. [[Diffuse_large_B-cell_lymphoma_-_historical#CHOP-14|CHOP-14]] x 8
|style="background-color:#d3d3d3"|Not reported
|-
|3. R-CHOP-14 x 8
|style="background-color:#d3d3d3"|Not reported
|-
|}
====Preceding treatment====
*[[#Vincristine_.26_Prednisone|Pre-phase vincristine & prednisone]]
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 2 mg IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5

====Supportive medications====
*ONE of the following starting on day 4, to continue until count recovery:
**[[Filgrastim (Neupogen)]]
**[[Lenograstim (Granocyte)]]

'''14-day cycle for 6 to 8 cycles (8 doses of rituximab regardless of total number of cycles)'''
====Subsequent treatment====
*Patients with initial bulky disease ("lymphoma masses or conglomerates with a diameter greater than or equal to 7.5 cm) or extranodal involvement"): [[#Radiation_therapy|RT]] x 36 Gy

===Variant #9, prednisolone 100 mg {{#subobject:8136b1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60313-X/fulltext Cunningham et al. 2013 (UK NCRI R-CHOP14v21)]
|style="background-color:#1a9851"|Phase III (E)
|[[#R-CHOP|R-CHOP-21]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1 (8 doses total)
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 2 mg IV once on day 1
*[[Prednisolone (Millipred)]] 100 mg PO once per day on days 1 to 5

====CNS prophylaxis====
Per investigator discretion, but Cunningham et al. 2013 recommended that patients who had involvement of the "bone marrow, peripheral blood, nasal or paranasal sinuses, orbit, and testis" (they probably intended to say "or testis") receive:
*[[Methotrexate (MTX)]] 12.5 mg IT "for the first three cycles of treatment, administered as per local guidelines." No other details given.

====Supportive medications====
*[[Lenograstim (Granocyte)]] (dose/route not specified) given on days 4 to 12
*[[Allopurinol (Zyloprim)]] 300 mg PO once per day during cycle 1
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Co-trimoxazole]] 480 mg (route not specified) twice per day on 3 days per week, taken throughout therapy, ending 2 weeks after treatment is completed

'''14-day cycle for 6 cycles (8 cycles of rituximab)'''

===References===
# '''RICOVER-60:''' Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008 Feb;9(2):105-16. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2808%2970002-0/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18226581 PubMed]
# '''Abstract:''' S. Le Gouill, N. J. Milpied, T. Lamy, V. Delwail, R. Gressin, D. Guyotat, G. L. Damaj, C. Foussard, G. Cartron, H. Maisonneuve, E. Deconinck, F. Dreyfus, E. Gyan, L. Sutton, N. Morineau, M. Alexis, F. Perry, M. Sauvezie. First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial. Journal of Clinical Oncology 29, no. 15_suppl (May 2011) 8003-8003. [http://ascopubs.org/doi/full/10.1200/jco.2011.29.15_suppl.8003 link to abstract]
# '''LNH03-6B:''' Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, Van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol. 2013 May;14(6):525-33. Epub 2013 Apr 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70122-0/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23578722 PubMed]
# '''UK NCRI R-CHOP14v21:''' Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013 May 25;381(9880):1817-26. Epub 2013 Apr 22. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60313-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23615461 PubMed]
# '''Abstract:''' Michael Pfreundschuh, Gerhard Held, Samira Zeynalova, Carsten Zwick, Mathias Haenel, Lorenz Truemper, Martin H. Dreyling, Judith Dierlamm, Markus Loeffler, Norbert Schmitz, Niels Murawski, German High-Grad Non-Hodgkin Lymphoma Study Group (DSHNHL). Increased rituximab (R) doses and effect on risk of elderly male patients with aggressive CD20+ B-cell lymphomas: Results from the SEXIE-R-CHOP-14 trial of the DSHNHL. J Clin Oncol 32:5s, 2014 (suppl; abstr 8501) [http://meetinglibrary.asco.org/content/133133-144 link to original abstract]
# '''MAIN:''' Seymour JF, Pfreundschuh M, Trnený M, Sehn LH, Catalano J, Csinady E, Moore N, Coiffier B; MAIN Study Investigators. R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. Haematologica. 2014 Aug;99(8):1343-9. Epub 2014 Jun 3. [http://www.haematologica.org/content/99/8/1343.abstract link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4116833/ link to PMC article] '''does not contain protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24895339 PubMed]
# '''SMARTE-R-CHOP-14:''' Pfreundschuh M, Poeschel V, Zeynalova S, Hänel M, Held G, Schmitz N, Viardot A, Dreyling MH, Hallek M, Mueller C, Wiesen MH, Witzens-Harig M, Truemper L, Keller U, Rixecker T, Zwick C, Murawski N. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group. J Clin Oncol. 2014 Dec 20;32(36):4127-33. Epub 2014 Nov 17. Erratum in: J Clin Oncol. 2015 Jun 10;33(17):1991. [http://jco.ascopubs.org/content/32/36/4127.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25403207 PubMed]
<!-- Presented in part at the 54th American Society of Hematology Annual Meeting, Atlanta, GA, December 8-11, 2012, and the 12th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 19-22, 2013 -->
# Cortelazzo S, Tarella C, Gianni AM, Ladetto M, Barbui AM, Rossi A, Gritti G, Corradini P, Di Nicola M, Patti C, Mulé A, Zanni M, Zoli V, Billio A, Piccin A, Negri G, Castellino C, Di Raimondo F, Ferreri AJ, Benedetti F, La Nasa G, Gini G, Trentin L, Frezzato M, Flenghi L, Falorio S, Chilosi M, Bruna R, Tabanelli V, Pileri S, Masciulli A, Delaini F, Boschini C, Rambaldi A. Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas. J Clin Oncol. 2016 Nov 20;34(33):4015-4022. Epub 2016 Oct 31. [http://ascopubs.org/doi/full/10.1200/JCO.2016.67.2980 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28199143 PubMed]
# '''DLCL04:''' Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2017 Aug;18(8):1076-1088. Epub 2017 Jun 28. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30444-8/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28668386 PubMed]
# '''MabEase:''' Lugtenburg P, Avivi I, Berenschot H, Ilhan O, Marolleau JP, Nagler A, Rueda A, Tani M, Turgut M, Osborne S, Smith R, Pfreundschuh M. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica. 2017 Nov;102(11):1913-1922. Epub 2017 Sep 21. [http://www.haematologica.org/content/102/11/1913 link to original article] '''contains partial protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28935843 PubMed]
# Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, Gressin R, Cornillon J, Banos A, Le Du K, Benchalal M, Moles MP, Le Gouill S, Fleury J, Godmer P, Maisonneuve H, Deconinck E, Houot R, Laribi K, Marolleau JP, Tournilhac O, Branger B, Devillers A, Vuillez JP, Fest T, Colombat P, Costes V, Szablewski V, Béné MC, Delwail V; LYSA Group. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood. 2018 Jan 11;131(2):174-181. Epub 2017 Oct 23. [http://www.bloodjournal.org/content/131/2/174.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29061568 PubMed]
# '''PETAL:''' Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, Berdel WE, Franzius C, Kroschinsky F, Weckesser M, Kofahl-Krause D, Bengel FM, Dürig J, Matschke J, Schmitz C, Pöppel T, Ose C, Brinkmann M, La Rosée P, Freesmeyer M, Hertel A, Höffkes HG, Behringer D, Prange-Krex G, Wilop S, Krohn T, Holzinger J, Griesshammer M, Giagounidis A, Raghavachar A, Maschmeyer G, Brink I, Bernhard H, Haberkorn U, Gaska T, Kurch L, van Assema DME, Klapper W, Hoelzer D, Geworski L, Jöckel KH, Scherag A, Bockisch A, Rekowski J, Hüttmann A; PETAL Trial Investigators. Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol. 2018 Jul 10;36(20):2024-2034. Epub 2018 May 11. [http://ascopubs.org/doi/full/10.1200/JCO.2017.76.8093 link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/29750632 PubMed]

==R-Hyper-CVAD/R-MA {{#subobject:432427|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-Hyper-CVAD/R-MA: '''<u>R</u>'''ituximab, '''<u>Hyper</u>'''fractionated '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''incristine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>D</u>'''examethasone alternating with '''<u>R</u>'''ituximab, '''<u>M</u>'''ethotrexate, '''<u>A</u>'''ra-C (Cytarabine)

===Regimen {{#subobject:b7ff27|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278952/ Oki et al. 2013 (MDACC 2005-0054)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#R-CHOP|R-CHOP]]
|style="background-color:#91cf60"|Seems to have increased CRR
|-
|}
''Intended for high-risk DLBCL (IPI greater than or equal to 3). The authors report "excellent outcome" in patients less than or equal to 45 years old, however patients greater than 45 years old had "unacceptable mortality."''
====Chemotherapy, part A (cycles 1, 3, 5)====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 300 mg/m<sup>2</sup> IV every 12 hours on days 1 to 3 (6 total doses)
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 5 & 12
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 5 
*[[Dexamethasone (Decadron)]] 40 mg IV or PO once per day on days 2 to 5

====Supportive medications====
*[[Mesna (Mesnex)]] 600 mg/m<sup>2</sup>/day IV continuous infusion over 72 hours, started on day 1
*[[Filgrastim (Neupogen)]] or [[Pegfilgrastim (Neulasta)]] starting 24 to 48 hours after completion of chemotherapy
*[[Ciprofloxacin (Cipro)]] 500 mg PO twice per day for 10 days after chemotherapy
*[[Fluconazole (Diflucan)]] 100 mg PO once per day for 10 days after chemotherapy
*[[Valacyclovir (Valtrex)]] 500 mg PO once per day for 10 days after chemotherapy

====Dose modifications====
*[[Vincristine (Oncovin)]] reduced once by 50% for NCI common toxicity criteria Grade 2+ peripheral neuropathy, omitted if Grade 2+ peripheral neuropathy persists
*[[Doxorubicin (Adriamycin)]] and [[Cyclophosphamide (Cytoxan)]] reduced by 20% in subsequent A cycles if neutropenic fever occurs, grade 3/4 non-hematological toxicity, or ANC less than 750/uL or platelet count less than 75 × 10<sup>9</sup>/L on day 21 

'''Next cycle to start once ANC is greater than or equal to 1000/uL and platelet count is greater than or equal to 100 × 10<sup>9</sup>/L.'''

''Although the protocol does not specify, it is assumed that if these thresholds are not met by day 21, the next cycle will start with the dose reductions as specified.''

====Chemotherapy, part B (cycles 2, 4, 6)====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Methotrexate (MTX)]] 200 mg/m<sup>2</sup> IV over 2 hours once on day 1, then 800 mg/m<sup>2</sup> IV over 22 hours (total dose per cycle: 1000 mg/m<sup>2</sup>)
*[[Cytarabine (Cytosar)]] 3000 mg/m<sup>2</sup> IV over 2 hours every 12 hours on days 3 & 4 (4 total doses)

====Supportive medications====
*[[Folinic acid (Leucovorin)]] (dose/timing not specified) until serum methotrexate level less than 100 nmol/L
*[[Sodium bicarbonate]] 1300 mg PO twice per day until methotrexate level less than 100 nmol/L
*[[Filgrastim (Neupogen)]] or [[Pegfilgrastim (Neulasta)]] starting 24 to 48 hours after completion of chemotherapy
*[[Ciprofloxacin (Cipro)]] 500 mg PO twice per day for 10 days after chemotherapy
*[[Fluconazole (Diflucan)]] 100 mg PO once per day for 10 days after chemotherapy
*[[Valacyclovir (Valtrex)]] 500 mg PO once per day for 10 days after chemotherapy

====Dose modifications====
*[[Methotrexate (MTX)]] reduced by 25% in subsequent B cycles if neutropenic fever occurs, grade 3/4 non-hematological toxicity, or ANC less than 750/uL or platelet count less than 75 × 10<sup>9</sup>/L on day 21
*[[Cytarabine (Cytosar)]] reduced by 33% in subsequent B cycles if neutropenic fever occurs, grade 3/4 non-hematological toxicity, or ANC less than 750/uL or platelet count less than 75 × 10<sup>9</sup>/L on day 21

'''21-day cycles'''

====CNS prophylaxis==== 
''"Recommended in patients with paraspinal disease, paranasal sinus disease, testicular disease, bone marrow disease, diffuse osseous disease or greater than or equal to 2 sites of extranodal disease. Actual administration of prophylactic intrathecal chemotherapy was at the treating physician's discretion."''

===References===
# Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol. 2013 Dec;163(5):611-20. Epub 2013 Oct 1. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.12585/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278952/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24117234 PubMed]
<!-- Prior publication: Poster presentation at the 2014 annual meeting of the American Society of Hematology (Howlett C, Landsburg DJ, Chong EA, Snedecor SJ, Schuster SJ, Green TM, Cohen JB, Svoboda J, Nasta SD, Feldman T, Rago R, Land D, Walsh KM, Goy A, Mato AR. Front-line, dose-escalated immunochemotherapy is associated with a significant PFS (but not OS) advantage in 401 patients (pts) with double-hit lymphomas (DHL): A systematic review and meta-analysis. Blood, 124, abst 3056). -->
# '''Retrospective:''' Howlett C, Snedecor SJ, Landsburg DJ, Svoboda J, Chong EA, Schuster SJ, Nasta SD, Feldman T, Rago A, Walsh KM, Weber S, Goy A, Mato A. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol. 2015 Aug;170(4):504-14. Epub 2015 Apr 24. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13463/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25907897 PubMed]

==R-MegaCHOP-14 {{#subobject:8e9669|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-MegaCHOP-14: '''<u>R</u>'''ituximab, "Mega" (high-dose) '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone every 14 days

===Regimen {{#subobject:6d7b6c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30444-8/fulltext Chiappella et al. 2017 (DLCL04)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#R-CHOP-14|R-CHOP-14]]
|style="background-color:#d3d3d3"|Not reported
|-
|2. R-CHOP-14, then R-MAD, then BEAM, then auto HSCT<br> 3. R-MegaCHOP-14, then R-MAD, then BEAM, then auto HSCT
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 70 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5

'''14-day cycle for 6 cycles'''

===References===
# Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2017 Aug;18(8):1076-1088. Epub 2017 Jun 28. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30444-8/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28668386 PubMed]

==R-miniCEOP {{#subobject:cd6200|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-miniCEOP: '''<u>R</u>'''ituximab, mini, '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''pirubicin, '''<u>O</u>'''?? (vinblastine), '''<u>P</u>'''rednisone

===Regimen {{#subobject:41cd4b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.tandfonline.com/doi/full/10.3109/10428194.2011.621565 Merli et al. 2012 (ANZINTER3)]
|style="background-color:#1a9851"|Phase III (E)
|[[#R-CHOP|R-CHOP]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vinblastine (Velban)]] 5 mg/m<sup>2</sup> IV once on day 1
*[[Prednisone (Sterapred)]] 50 mg/m<sup>2</sup> IV or PO once per day on days 1 to 5

====Supportive medications====
*Prophylactic [[:Category:Granulocyte colony-stimulating factors|G-CSF]] used for persisting grade 4 neutropenia or febrile neutropenia.
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)|Cotrimoxazole]] (dose/route/schedule not specified) prophylaxis.
*Erythropoietin use was allowed for hemoglobin less than 11 g/dL.

'''21-day cycle for 6 cycles'''
====Subsequent treatment====
*Patients with initial bulky disease and/or partially responding sites received [[#Radiation_therapy|radiothearpy]]

===References===
# '''ANZINTER3:''' Merli F, Luminari S, Rossi G, Mammi C, Marcheselli L, Tucci A, Ilariucci F, Chiappella A, Musso M, Di Rocco A, Stelitano C, Alvarez I, Baldini L, Mazza P, Salvi F, Arcari A, Fragasso A, Gobbi PG, Liberati AM, Federico M. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. Leuk Lymphoma. 2012 Apr;53(4):581-8. Epub 2011 Nov 15. [https://www.tandfonline.com/doi/full/10.3109/10428194.2011.621565 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21895543 PubMed]

=Untreated, non-randomized or retrospective data=

==BR {{#subobject:305d42|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BR: '''<u>B</u>'''endamustine, '''<u>R</u>'''ituximab
===Variant #1, 90 mg/m<sup>2</sup> {{#subobject:da8206|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063684/ Park et al. 2016]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: this dosing was intended for patients with [[Performance_status#ECOG_performance_status_.28WHO.2FGOG.2FZubrod_score.29|ECOG PS]] = 3 at baseline.''
====Chemotherapy====
*[[Bendamustine]] 90 mg/m<sup>2</sup> IV once per day on days 1 & 2, '''given first on day 1'''
**Dose increased to 120 mg/m<sup>2</sup> if ECOG PS improved to less than or equal to 2 after 3 cycles
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1, '''given second'''

'''21-day cycle for up to 8 cycles'''

===Variant #2, 120 mg/m<sup>2</sup> {{#subobject:2f4cc2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063684/ Park et al. 2016]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Bendamustine]] 120 mg/m<sup>2</sup> IV once per day on days 1 & 2, '''given first on day 1'''
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1, '''given second'''

'''21-day cycle for up to 8 cycles'''

===References===
# Park SI, Grover NS, Olajide O, Asch AS, Wall JG, Richards KL, Sobol AL, Deal AM, Ivanova A, Foster MC, Muss HB, Shea TC. A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma. Br J Haematol. 2016 Oct;175(2):281-289. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14232/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063684/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27448091 PubMed]

==Helicobacter pylori eradication therapy {{#subobject:be3ef5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:6a2469|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/119/21/4838.long Kuo et al. 2012]
| style="background-color:#91cf61" |Non-randomized
|-
|}
''Note: This regimen is intended for the treatment of gastric DLBCL only; H. pylori eradication would not be an appropriate treatment for systemic DLBCL.''
====Antibiotic therapy, before 1996====
*[[Amoxicillin]] 500mg PO every 6 hours x 28 days
*[[Metronidazole (Flagyl)]] 250mg PO every 6 hours x 28 days
*EITHER bismuth subcitrate 120mg PO every 6 hours x 28 days
*OR [[Omeprazole (Prilosec)]] 20mg PO twice per day x 28 days

====Antibiotic therapy, after 1996====
*[[Amoxicillin]] 500mg PO every 6 hours x 14 days
*[[Clarithromycin (Biaxin)]] 500mg PO twice per day x 14 days
*[[Omeprazole (Prilosec)]] 20mg PO twice per day x 14 days

===References===
# Kuo SH, Yeh KH, Wu MS, Lin CW, Hsu PN, Wang HP, Chen LT, Cheng AL. Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas. Blood. 2012 May 24;119(21):4838-44. Epub 2012 Mar 7. [http://www.bloodjournal.org/content/119/21/4838.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22403257 PubMed]

==O-miniCHOP {{#subobject:652b56|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
O-miniCHOP: '''<u>O</u>'''fatumumab, reduced-dose ('''mini''') '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone

===Regimen {{#subobject:6d1193|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30171-5/fulltext Peyrade et al. 2017 (LYSA LNH09-7B)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#Vincristine_.26_Prednisone|Pre-phase vincristine & prednisone]]
====Chemotherapy====
*[[Ofatumumab (Arzerra)]] 1000 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 400 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1 mg IV once on day 1
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 5

====Supportive medications====
*[[Acetaminophen (Tylenol)]] 1000 mg PO once prior to [[Ofatumumab (Arzerra)]]
*[[Diphenhydramine (Benadryl)]] 50 mg (route not specified) once prior to [[Ofatumumab (Arzerra)]]

'''21-day cycle for 6 cycles'''

===References===
# Peyrade F, Bologna S, Delwail V, Emile JF, Pascal L, Fermé C, Schiano JM, Coiffier B, Corront B, Farhat H, Fruchart C, Ghesquieres H, Macro M, Tilly H, Choufi B, Delarue R, Fitoussi O, Gabarre J, Haioun C, Jardin F. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. Lancet Haematol. 2017 Jan;4(1):e46-e55. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30171-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28041583 PubMed]

==R-BL {{#subobject:fe578a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-BL: '''<u>R</u>'''ituximab, '''<u>B</u>'''endamustine, '''<u>L</u>'''enalidomide

===Regimen {{#subobject:f063a7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.14049/abstract Hitz et al. 2016 (SAKK 38/08)]
|style="background-color:#91cf61"|Phase II, <20 pts in subgroup
|ORR: 61% (95% CI 45-76%)
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Bendamustine]] 70 mg/m<sup>2</sup> IV once per day on days 1 & 2
*[[Lenalidomide (Revlimid)]] 10 mg PO once per day on days 1 to 21

'''28-day cycle for 6 cycles'''

===References===
# Hitz F, Zucca E, Pabst T, Fischer N, Cairoli A, Samaras P, Caspar CB, Mach N, Krasniqi F, Schmidt A, Rothermundt C, Enoiu M, Eckhardt K, Berardi Vilei S, Rondeau S, Mey U. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08. Br J Haematol. 2016 Jul;174(2):255-63. Epub 2016 Mar 28. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14049/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27018242 PubMed]

==R-CDOP {{#subobject:bdf229|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-CDOP: '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>D</u>'''oxil (Pegylated liposomal doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone
<br>DRCOP: '''<u>D</u>'''oxil (Pegylated liposomal doxorubicin), '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone

===Variant #1 {{#subobject:7a864b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(14)00411-X/fulltext Oki et al. 2014]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Pegylated liposomal doxorubicin (Doxil)]] 40 mg/m<sup>2</sup> (maximum dose of 90 mg) IV over 60 minutes once on day 1
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 2 mg IV once on day 1
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 5

====Supportive medications====
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day from day 2 until ANC greater than 3000/μl
OR
*[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 2

====Dose modifications====
*Dose reduction level 1 (see paper for triggers):
**[[Pegylated liposomal doxorubicin (Doxil)]] reduced to 35 mg/m<sup>2</sup>
**[[Cyclophosphamide (Cytoxan)]] reduced to 600 mg/m<sup>2</sup>
*Dose reduction level 2 (see paper for triggers):
**[[Pegylated liposomal doxorubicin (Doxil)]] reduced to 30 mg/m<sup>2</sup>
**[[Cyclophosphamide (Cytoxan)]] reduced to 450 mg/m<sup>2</sup>

'''21-day cycle for 6 to 8 cycles'''

===Variant #2 {{#subobject:5fd9ca|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.tandfonline.com/doi/full/10.1080/10428190600799946 Zaja et al. 2006]
|style="background-color:#91cf61"|Phase II
|-
|}

''Only the dose of liposomal doxorubicin and number of cycles used was specified in the abstract. The doses of the other medications and schedule are provided based on the standard R-CHOP regimen, whose references can be found on this page.'' 
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Pegylated liposomal doxorubicin (Doxil)]] 30 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5

'''21-day cycle for 6 cycles'''

===References===
# Zaja F, Tomadini V, Zaccaria A, Lenoci M, Battista M, Molinari AL, Fabbri A, Battista R, Cabras MG, Gallamini A, Fanin R. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2006 Oct;47(10):2174-80. [https://www.tandfonline.com/doi/full/10.1080/10428190600799946 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17071492 PubMed]
# Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk. 2015 Mar;15(3):152-8. Epub 2014 Sep 28. [http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(14)00411-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344896/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25445468 PubMed]

==R-CEOP90 (Epirubicin) {{#subobject:ebcd7e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-CEOP90: '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''pirubicin ('''<u>90</u>''' mg/m<sup>2</sup> dosing), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone

===Variant #1, 4 cycles {{#subobject:d0b303|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.tandfonline.com/doi/full/10.3109/10428194.2013.876632 Cai et al. 2014]
|style="background-color:#91cf61"|Phase II
|-
|}
''This regimen is intended to reduce cardiotoxicity and was not just for patients with contraindicated doxorubicin. Note that the cycle length is not explicitly defined in the paper but was reported as a median of 21 days (range 21 to 33 days).'' 
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 2
*[[Epirubicin (Ellence)]] 90 mg/m<sup>2</sup> IV once on day 2
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 2
*[[Prednisolone (Millipred)]] 100 mg/day PO on days 2 to 6

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*Patients with stage IA or IIA disease with bulky disease and extranodal and residual masses: [[#Radiation_therapy|IFRT]], 30 to 45 Gy

===Variant #2, 6 cycles {{#subobject:d1cd34|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.tandfonline.com/doi/full/10.3109/10428194.2013.876632 Cai et al. 2014]
|style="background-color:#91cf61"|Phase II
|-
|}
''This regimen is intended to reduce cardiotoxicity and was not just for patients with contraindicated doxorubicin. Note that the cycle length is not explicitly defined in the paper but was reported as a median of 21 days (range 21 to 33 days).'' 
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 2
*[[Epirubicin (Ellence)]] 90 mg/m<sup>2</sup> IV once on day 2
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 2
*[[Prednisolone (Millipred)]] 100 mg/day PO on days 2 to 6

'''21-day cycle for 6 cycles''
===References===
# Cai QC, Gao Y, Wang XX, Cai QQ, Lin ZX, Bai B, Guo Y, Huang HQ. Long-term results of the R-CEOP90 in the treatment of young patients with chemotherapy-naïve diffuse large B cell lymphoma: a phase II study. Leuk Lymphoma. 2014 Oct;55(10):2387-8. [https://www.tandfonline.com/doi/full/10.3109/10428194.2013.876632 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24528221 PubMed]

==R-CEOP (Etoposide) {{#subobject:dfb13d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-CEOP: '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''toposide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone

===Regimen {{#subobject:d69b11|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://abstracts.hematologylibrary.org/cgi/content/abstract/114/22/408 Moccia et al. 2009]
|style="background-color:#ffffbe"|Retrospective
|-
|}

''This regimen is intended for patients with a contraindication to anthracyclines. Only the dose of etoposide and number of cycles used was specified in the abstract. The doses of the other medications and schedule are provided based on the standard R-CHOP regimen, whose references can be found on this page.'' 
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Etoposide (Vepesid)]] 50 mg/m<sup>2</sup> IV once on day 1; 100 mg/m<sup>2</sup> PO once per day on days 2 & 3
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5
**Alternate dosing used in the R-CHOP regimens described in Coiffier et al. 2002 & 2010; Feugier et al. 2005; Mounier et al. 2012 - LNH 98-5 is [[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 5

'''21-day cycle for 3 to 4 cycles +/- radiation therapy for patients with limited stage disease; 6 cycles for patients with advanced stage disease'''

===References===
# '''Retrospective:''' '''Abstract:''' Moccia, Alden A., Schaff, Kimberly, Hoskins, Paul, Klasa, Richard, Savage, Kerry J., Shenkier, Tamara, Gascoyne, Randy D., Connors, Joseph M., Sehn, Laurie H. R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines. ASH Annual Meeting Abstracts 2009 114: 408 [http://abstracts.hematologylibrary.org/cgi/content/abstract/114/22/408 link to abstract]

==R-CHMP {{#subobject:5510fa|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-CHMP: '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>M</u>'''arqibo (Vincristine liposomal), '''<u>P</u>'''rednisone
===Variant #1, 3 cycles {{#subobject:e77893|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.12446/full Hagemeister et al. 2013]
|style="background-color:#91cf61"|Phase II
|-
|}
''This regimen was intended for stage I patients with no LN greater than 5 cm.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Pegylated liposomal doxorubicin (Doxil)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine liposomal (Marqibo)]] 2 mg/m<sup>2</sup> IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[#Radiation_therapy|RT]]

===Variant #2, 6 cycles {{#subobject:a8501b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.12446/full Hagemeister et al. 2013]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Pegylated liposomal doxorubicin (Doxil)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine liposomal (Marqibo)]] 2 mg/m<sup>2</sup> IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg PO once per day on days 1 to 5

'''21-day cycle for 6 cycles'''

===References===
# Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A, Dang NH, Forman A, McLaughlin P, Medeiros LJ, Pro B, Romaguera J, Samaniego F, Silverman JA, Sarris A, Cabanillas F. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. Br J Haematol. 2013 Sep;162(5):631-8. Epub 2013 Jun 27. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.12446/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23802738 PubMed]

==R-GCVP {{#subobject:dff264|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-GCVP: '''<u>R</u>'''ituximab, '''<u>G</u>'''emcitabine, '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''incristine, '''<u>P</u>'''rednisolone

===Regimen {{#subobject:dad22|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/32/4/282.full Fields et al. 2013]
|style="background-color:#91cf61"|Phase II
|-
|}

''Intended for use in patients unlikely to tolerate anthracyclines due to cardiac comorbidity.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] as follows:
**Cycle 1: 750 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 8 
**Cycle 2: 875 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 8
**Cycles 3 to 6: 1000 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 8
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisolone (Millipred)]] 100 mg PO once per day on days 1 to 5

====Supportive medications====
*[[Acetaminophen (Tylenol)]] 1000 mg (route not specified) prior to [[Rituximab (Rituxan)]]
*[[Chlorpheniramine (Chlor-Trimeton)]] 10 mg IV prior to [[Rituximab (Rituxan)]]
*[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 9

====CNS prophylaxis====
*[[Methotrexate (MTX)]] 12.5 mg IT x 3 cycles (timing not specified) for patients at high risk of CNS relapse

'''21-day cycle for 6 cycles'''

===References===
<!-- Presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego, CA, December 10-13, 2011. -->
# Fields PA, Townsend W, Webb A, Counsell N, Pocock C, Smith P, Jack A, El-Mehidi N, Johnson PW, Radford J, Linch DC, Cunnningham D. De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United kingdom national cancer research institute trial. J Clin Oncol. 2014 Feb 1;32(4):282-7. Epub 2013 Nov 12. [http://jco.ascopubs.org/content/32/4/282.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24220559 PubMed]

==R-MegaCHOP {{#subobject:4e9b3e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-MegaCHOP: '''<u>R</u>'''ituximab, Mega, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone

===Regimen {{#subobject:c3f62c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13036/full Pardal et al. 2014 (GELTAMO-2006)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 1500 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 65 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> IV once on day 1
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 5

====Supportive medications====
*[[Pegfilgrastim (Neulasta)]] given after each cycle

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*Negative PET-CT after 3 cycles: another 3 cycles of R-MegaCHOP for a total of 6 cycles
*Positive PET-CT after 3 cycles: [[#R-IFE_2|R-IFE]]

===References===
# '''GELTAMO-2006:''' Pardal E, Coronado M, Martín A, Grande C, Marín-Niebla A, Panizo C, Bello JL, Conde E, Hernández MT, Arranz R, Bargay J, González-Barca E, Pérez-Ceballos E, Montes-Moreno S, Caballero MD. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial. Br J Haematol. 2014 Nov;167(3):327-36. Epub 2014 Jul 28. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13036/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25066542 PubMed]

==R-miniCHOP {{#subobject:17bb83|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-miniCHOP: '''<u>R</u>'''ituximab, reduced-dose ('''mini''') '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone

===Regimen {{#subobject:9fd3ee|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70069-9/fulltext Peyrade et al. 2011]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 400 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1 mg IV once on day 1
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 5
**No dose adjustments for hematologic toxicity. If needed, the subsequent R-miniCHOP cycle was postponed until ANC was greater than or equal to 1000/uL and platelet count was greater than or equal to 100 x 10<sup>9</sup>/L, with a maximum of 28 days between cycles. Treatment was stopped if patients' counts were not adequate within 28 days. 

====Supportive medications====
*"Prevention of tumour lysis syndrome by alkalinisation or hypouricaemic drugs was done if necessary."
*[[:Category:Serotonin_5-HT3_antagonists | Serotonin (5-HT3) antagonist]] given every cycle.
*Prophylactic [[Filgrastim (Neupogen) | G-CSF]] or erythropoietin was left to treating physician's discretion.
**Patients with severe neutropenia or neutropenic fever received [[Filgrastim (Neupogen) | G-CSF]] (dose not specified) SC on days 6 to 13 of the subsequent cycle until ANC is greater than or equal to 1000/uL.

'''21-day cycle for 6 cycles'''

===References===
# Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, André M, Fournier M, Gaulard P, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011 May;12(5):460-8. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70069-9/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21482186 PubMed]

==R2CHOP {{#subobject:2a4e31|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R2CHOP: '''<u>R</u>'''ituximab, '''<u>R</u>'''evlimid (Lenalidomide), '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone
<br>LR-CHOP-21: '''<u>L</u>'''enalidomide, '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone given every '''<u>21</u>''' days

===Variant #1, len 15 mg/day for 14 d/cycle {{#subobject:6fc8a3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70191-3/fulltext Vitolo et al. 2014 (REAL07)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#f7fcfd" |ORR: 92% (95% CI 81–97)
|-
|}
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 15 mg PO once per day on days 1 to 14
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 5

====CNS prophylaxis====
*For "at risk" patients:
*[[Methotrexate (MTX)]] 12 mg IT once on day 1 of first 4 cycles

====Supportive medications====
*[[:Category:Granulocyte_colony-stimulating_factors|Granulocyte colony-stimulating factors]] (dose/duration not specified)
*[[:Category:Low_molecular_weight_heparins|Low-molecular-weight heparins]] (dose/duration not specified)
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] or [[Pentamidine (Nebupent)]] (dose/duration not specified)
*[[Lamivudine (Epivir)]] (dose/duration not specified) for carriers of hepatitis B virus 

'''21-day cycle for 6 cycles'''

===Variant #2, len 25 mg/day for 10 d/cycle {{#subobject:ea91fc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/33/3/251.full Nowakowski et al. 2014 (Mayo Clinic MC078E)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#f7fcfd" |ORR: 98%
|-
|}
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 10
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once on day 1
*[[Prednisone (Sterapred)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 5

====Supportive medications====
*[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 2
*[[Aspirin]] 81 mg PO once per day unless on therapeutic dose [[Warfarin (Coumadin)]] or [[:Category:Low_molecular_weight_heparins|low molecular weight heparin]]

'''21-day cycle for up to 6 cycles'''

===References===
<!-- # '''Phase 1:''' Nowakowski GS, LaPlant B, Habermann TM, Rivera CE, Macon WR, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Klebig RR, Reeder CB, Witzig TE. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia. 2011 Dec;25(12):1877-81. Epub 2011 Jul 1. [https://www.nature.com/leu/journal/v25/n12/full/leu2011165a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21720383 PubMed]
# '''Phase 1:''' Chiappella A, Tucci A, Castellino A, Pavone V, Baldi I, Carella AM, Orsucci L, Zanni M, Salvi F, Liberati AM, Gaidano G, Bottelli C, Rossini B, Perticone S, De Masi P, Ladetto M, Ciccone G, Palumbo A, Rossi G, Vitolo U. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated elderly diffuse large B-cell lymphoma patients: phase I study by the Fondazione Italiana Linfomi. Haematologica. 2013 Nov;98(11):1732-8. Epub 2013 Jun 28. [http://www.haematologica.org/content/98/11/1732 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815174/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23812930 PubMed] -->
<!-- # '''Abstract:''' Chiappella A et al. Rituximab-CHOP21 plus lenalidomide (LR-CHOP21) is effective and feasible in elderly untreated diffuse large B-cell lymphoma (DLBCL): Results of Phase II REAL07 study of the Fondazione Italiana Linfomi (FIL). Proc ASH 2012; [http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/903?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=abstract+903&searchid=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT Abstract 903]. -->
# '''REAL07:''' Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G, Spina M, Pavone V, Ladetto M, Liberati AM, Molinari AL, Zinzani P, Salvi F, Fattori PP, Zaccaria A, Dreyling M, Botto B, Castellino A, Congiu A, Gaudiano M, Zanni M, Ciccone G, Gaidano G, Rossi G; on behalf of the Fondazione Italiana Linfomi. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol. 2014 Jun;15(7):730-7. Epub 2014 May 12. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70191-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24831981 PubMed] 
<!--# '''Abstract:''' Nowakowski GS et al. Combination of lenalidomide with R-CHOP (R2CHOP) is well-tolerated and effective as initial therapy for aggressive B-cell lymphomas — A Phase II study. Proc ASH 2012; [http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/689?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=abstract+689&searchid=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT Abstract 689].
# '''Abstract:''' Grzegorz S. Nowakowski, Betsy LaPlant, William R Macon, Craig B. Reeder, James M. Foran, Garth D. Nelson, Carrie A. Thompson, Candido Rivera, David James Inwards, Ivana N. M. Micallef, Patrick B. Johnston, Luis F. Porrata, Stephen Maxted Ansell, Thomas Matthew Habermann, Thomas E. Witzig. Effect of lenalidomide combined with R-CHOP (R2CHOP) on negative prognostic impact of nongerminal center (non-GCB) phenotype in newly diagnosed diffuse large B-cell lymphoma: A phase 2 study. J Clin Oncol 32:5s, 2014 (suppl; abstr 8520) [http://meetinglibrary.asco.org/content/134031-144 link to original abstract] -->
# '''Mayo Clinic MC078E:''' Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin Oncol. 2015 Jan 20;33(3):251-7. Epub 2014 Aug 18. [http://jco.ascopubs.org/content/33/3/251.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25135992 PubMed]

=Consolidation after upfront therapy=

==CBV, then auto HSCT {{#subobject:fccfc5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:00b635|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985418/ Stiff et al. 2013 (SWOG S9704)]
|style="background-color:#1a9851"|Phase III (E)
|[[#R-CHOP|R-CHOP x 8]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Preceding treatment====
*[[#R-CHOP|R-CHOP]] x 6
{{#lst:Autologous HSCT conditioning regimens|6fc278}}
===References===
# '''SWOG S9704:''' Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Fisher RI. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med. 2013 Oct 31;369(18):1681-90. [https://www.nejm.org/doi/full/10.1056/NEJMoa1301077 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985418/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24171516 PubMed]
## '''Subgroup analysis:''' Puvvada SD, Stiff PJ, Leblanc M, Cook JR, Couban S, Leonard JP, Kahl B, Marcellus D, Shea TC, Winter JN, Li H, Rimsza LM, Friedberg JW, Smith SM. Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. Br J Haematol. 2016 Sep;174(5):686-91. Epub 2016 Apr 13. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14100/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125530/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27072903 PubMed]

==CBVM, then auto HSCT {{#subobject:59bb2c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:bbedec|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/20/12/1985.long Haioun et al. 2009 (LNH 98-3)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[Diffuse_large_B-cell_lymphoma_-_historical#ACE|ACE]] versus [[Diffuse_large_B-cell_lymphoma_-_historical#ACVBP|ACVBP]]
====Chemotherapy====
*[[Carmustine (BiCNU)]]
*[[Etoposide (Vepesid)]]
*[[Cyclophosphamide (Cytoxan)]]
*[[Mitoxantrone (Novantrone)]]

'''Stem cells reinfused afterwards (unclear which day)'''
====Subsequent treatment====
*[[#Observation|Observation]] versus [[#Rituximab_monotherapy|rituximab maintenance]]

===References===
# '''LNH 98-3:''' Haioun C, Mounier N, Emile JF, Ranta D, Coiffier B, Tilly H, Récher C, Fermé C, Gabarre J, Herbrecht R, Morchhauser F, Gisselbrecht C. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Ann Oncol. 2009 Dec;20(12):1985-92. Epub 2009 Jun 30. [http://annonc.oxfordjournals.org/content/20/12/1985.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19567453 PubMed]

==Cytarabine monotherapy {{#subobject:fa5ce3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:4f9fa6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61040-4/fulltext Récher et al. 2011 (LNH03-2B)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|[http://annonc.oxfordjournals.org/content/24/4/1032.long Ketterer et al. 2013 (LNH03-1B)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#R-IFE|REI consolidation]] x 4
====Chemotherapy====
*[[Cytarabine (Cytosar)]] 100 mg/m<sup>2</sup> SC once per day on days 1 to 4

'''14-day cycle for 2 cycles'''

===References===
# '''LNH03-2B:''' Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O, Thiéblemont C, Bosly A, Laurent G, Morschhauser F, Ghesquières H, Jardin F, Bologna S, Fruchart C, Corront B, Gabarre J, Bonnet C, Janvier M, Canioni D, Jais JP, Salles G, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011 Nov 26;378(9806):1858-67. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61040-4/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22118442 PubMed]
## '''Subgroup analysis:''' Molina TJ, Canioni D, Copie-Bergman C, Recher C, Brière J, Haioun C, Berger F, Fermé C, Copin MC, Casasnovas O, Thieblemont C, Petrella T, Leroy K, Salles G, Fabiani B, Morschauser F, Mounier N, Coiffier B, Jardin F, Gaulard P, Jais JP, Tilly H. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B. J Clin Oncol. 2014 Dec 10;32(35):3996-4003. Epub 2014 Nov 10. [http://ascopubs.org/doi/full/10.1200/JCO.2013.54.9493 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25385729 PubMed]
# '''LNH03-1B:''' Ketterer N, Coiffier B, Thieblemont C, Fermé C, Brière J, Casasnovas O, Bologna S, Christian B, Connerotte T, Récher C, Bordessoule D, Fruchart C, Delarue R, Bonnet C, Morschhauser F, Anglaret B, Soussain C, Fabiani B, Tilly H, Haioun C. Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). Ann Oncol. 2013 Apr;24(4):1032-7. Epub 2012 Dec 12. [http://annonc.oxfordjournals.org/content/24/4/1032.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23235801 PubMed]

==Ibritumomab tiuxetan monotherapy {{#subobject:85625d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, no cap {{#subobject:a989fb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691189/ Witzig et al. 2015 (ECOG E3402)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#R-CHOP|R-CHOP]] x 4 to 6
====Radioimmunotherapy====
*[[Rituximab (Rituxan)]] 250 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Ibritumomab tiuxetan (Zevalin)|Ibritumomab tiuxetan & Yttrium-90 (Zevalin) ]] 14.8 MBq/kg IV once on day 8

'''One course'''
====Subsequent treatment====
*Patients with CT or PET positive disease 12 weeks after radioimmunotherapy: [[#Radiation_therapy|30 Gy of IFRT]]

===Variant #2, capped dose {{#subobject:dfc019|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287635/ Persky et al. 2014 (SWOG S0313)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[Diffuse_large_B-cell_lymphoma_-_historical#CHOP|CHOP]] x 3, then [[#Radiation_therapy|IFRT]]
====Radioimmunotherapy====
*[[Rituximab (Rituxan)]] 250 mg/m<sup>2</sup> IV once on day 1, then another single dose on day 7, 8, or 9, '''given first on day 7, 8, or 9'''
*[[Ibritumomab tiuxetan (Zevalin)|Ibritumomab tiuxetan & Yttrium-90 (Zevalin) ]] 0.4 mCi/kg (maximum dose of 32 mCi) IV once, '''given second, within 4 hours'''

===References===
# '''SWOG S0313:''' Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea BD, Press OW, Constine LS, Barton KP, Friedberg JW, LeBlanc M, Fisher RI. Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood. 2015 Jan 8;125(2):236-41. Epub 2014 Nov 13. [http://www.bloodjournal.org/content/125/2/236.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287635/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25395425 PubMed]
# '''ECOG E3402:''' Witzig TE, Hong F, Micallef IN, Gascoyne RD, Dogan A, Wagner H Jr, Kahl BS, Advani RH, Horning SJ. A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402. Br J Haematol. 2015 Sep;170(5):679-86. Epub 2015 May 14. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13493/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691189/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25974212 PubMed]

==Methotrexate monotherapy {{#subobject:d77e3a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:b1d075|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61040-4/fulltext Récher et al. 2011 (LNH03-2B)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|[http://annonc.oxfordjournals.org/content/24/4/1032.long Ketterer et al. 2013 (LNH03-1B)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#ACVBP-R|ACVBP-R induction]] x 4
====Chemotherapy====
*[[Methotrexate (MTX)]] 3000 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Folinic acid (Leucovorin)|Calcium folinate - Folinic acid (Leucovorin)]] rescue

'''14-day cycle for 2 cycles'''
====Subsequent treatment====
*[[#R-IFE|REI consolidation]], in 2 weeks

===References===
# '''LNH03-2B:''' Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O, Thiéblemont C, Bosly A, Laurent G, Morschhauser F, Ghesquières H, Jardin F, Bologna S, Fruchart C, Corront B, Gabarre J, Bonnet C, Janvier M, Canioni D, Jais JP, Salles G, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011 Nov 26;378(9806):1858-67. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61040-4/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22118442 PubMed]
## '''Subgroup analysis:''' Molina TJ, Canioni D, Copie-Bergman C, Recher C, Brière J, Haioun C, Berger F, Fermé C, Copin MC, Casasnovas O, Thieblemont C, Petrella T, Leroy K, Salles G, Fabiani B, Morschauser F, Mounier N, Coiffier B, Jardin F, Gaulard P, Jais JP, Tilly H. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B. J Clin Oncol. 2014 Dec 10;32(35):3996-4003. Epub 2014 Nov 10. [http://ascopubs.org/doi/full/10.1200/JCO.2013.54.9493 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25385729 PubMed]
# '''LNH03-1B:''' Ketterer N, Coiffier B, Thieblemont C, Fermé C, Brière J, Casasnovas O, Bologna S, Christian B, Connerotte T, Récher C, Bordessoule D, Fruchart C, Delarue R, Bonnet C, Morschhauser F, Anglaret B, Soussain C, Fabiani B, Tilly H, Haioun C. Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). Ann Oncol. 2013 Apr;24(4):1032-7. Epub 2012 Dec 12. [http://annonc.oxfordjournals.org/content/24/4/1032.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23235801 PubMed]

==Observation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/22/15/3032.long Horning et al. 2004 (ECOG E1484)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Radiation_therapy|IFRT]]
|style="background-color:#fc8d59"|Seems to have inferior DFS
|-
|[http://jco.ascopubs.org/content/24/19/3121.long Habermann et al. 2006 (ECOG E4494/CALGB 9793)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Rituximab_monotherapy|Rituximab]]
|style="background-color:#d3d3d3"|See note
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2006.07.0722 Bonnet et al. 2007]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy|IFRT]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://annonc.oxfordjournals.org/content/20/12/1985.long Haioun et al. 2009 (LNH 98-3)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Rituximab_monotherapy|Rituximab]]
|style="background-color:#fee08b"|Might have inferior EFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486230/ Jaeger et al. 2015 (NHL13)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Rituximab_monotherapy|Rituximab]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13652/full Witzens-Harig et al. 2015 (HD2002)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Rituximab_monotherapy|Rituximab]]
|style="background-color:#d73027"|Inferior OS in males
|-
|[http://www.bloodjournal.org/content/131/2/174.long Lamy et al. 2017 (LYSA/GOELAMS 02-03)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Radiation_therapy|IFRT]]
|style="background-color:#eeee00"|Non-inferior EFS
|-
|}
''No further treatment, also variously termed "observation" and "watchful waiting". Note: in '''ECOG E4494/CALGB 9793''', a disadvantage to observation was only seen in the group receiving [[Diffuse_large_B-cell_lymphoma_-_historical#CHOP|CHOP induction]], which is no longer standard of care.''
====Preceding treatment====
*ECOG E1484: [[Diffuse_large_B-cell_lymphoma_-_historical#CHOP|CHOP]] x 8, with CR
*ECOG E4494/CALGB 9793: [[#R-CHOP|R-CHOP]] versus [[Diffuse_large_B-cell_lymphoma_-_historical#CHOP|CHOP]] induction
*Bonnet et al. 2007: [[Diffuse_large_B-cell_lymphoma_-_historical#CHOP|CHOP]] x 4
*LNH 98-3: [[#CBVM.2C_then_auto_HSCT|CBVM, then auto HSCT consolidation]] 
*HD2002: "Standard treatment" 
*LYSA/GOELAMS 02-03: [[#R-CHOP-14|R-CHOP-14]] x 4 to 6

===References===
# '''ECOG E1484:''' Horning SJ, Weller E, Kim K, Earle JD, O'Connell MJ, Habermann TM, Glick JH. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol. 2004 Aug 1;22(15):3032-8. Epub 2004 Jun 21. [http://jco.ascopubs.org/content/22/15/3032.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15210738 PubMed]
# '''ECOG E4494/CALGB 9793:''' Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006 Jul 1;24(19):3121-7. Epub 2006 Jun 5. [http://jco.ascopubs.org/content/24/19/3121.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16754935 PubMed]
# Bonnet C, Fillet G, Mounier N, Ganem G, Molina TJ, Thiéblemont C, Fermé C, Quesnel B, Martin C, Gisselbrecht C, Tilly H, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007 Mar 1;25(7):787-92. Epub 2007 Jan 16. [http://ascopubs.org/doi/full/10.1200/JCO.2006.07.0722 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17228021 PubMed]
# '''LNH 98-3:''' Haioun C, Mounier N, Emile JF, Ranta D, Coiffier B, Tilly H, Récher C, Fermé C, Gabarre J, Herbrecht R, Morchhauser F, Gisselbrecht C. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Ann Oncol. 2009 Dec;20(12):1985-92. Epub 2009 Jun 30. [http://annonc.oxfordjournals.org/content/20/12/1985.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19567453 PubMed]
<!-- These data have been presented in part at the 55th Annual Meeting of the American Society of Hematology, New Orleans 2013, the 12th International Conference on Malignant Lymphoma 2013, Lugano, and the 18th Congress of the European Hematology Association, Stockholm 2013. -->
# '''NHL13:''' Jaeger U, Trneny M, Melzer H, Praxmarer M, Nawarawong W, Ben Yehuda D, Goldstein D, Mihaljevic B, Ilhan O, Ballova V, Hedenus M, Hsiao LT, Au WY, Burgstaller S, Weidinger G, Keil F, Dittrich C, Skrabs C, Klingler A, Chott A, Fridrik MA, Greil R. Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. Haematologica. 2015 Jul;100(7):955-63. Epub 2015 Apr 24. [http://www.haematologica.org/content/100/7/955 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486230/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25911553 PubMed]
# '''HD2002:''' Witzens-Harig M, Benner A, McClanahan F, Klemmer J, Brandt J, Brants E, Rieger M, Meissner J, Hensel M, Neben K, Dreger P, Lengfelder E, Schmidt-Wolf I, Krämer A, Ho AD. Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma: results of the HD2002 prospective multicentre randomized phase III trial. Br J Haematol. 2015 Dec;171(5):710-9. Epub 2015 Oct 9. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13652/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26449739 PubMed]
# '''LYSA/GOELAMS 02-03:''' Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, Gressin R, Cornillon J, Banos A, Le Du K, Benchalal M, Moles MP, Le Gouill S, Fleury J, Godmer P, Maisonneuve H, Deconinck E, Houot R, Laribi K, Marolleau JP, Tournilhac O, Branger B, Devillers A, Vuillez JP, Fest T, Colombat P, Costes V, Szablewski V, Béné MC, Delwail V; LYSA Group. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood. 2018 Jan 11;131(2):174-181. Epub 2017 Oct 23. [http://www.bloodjournal.org/content/131/2/174.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29061568 PubMed]

==Placebo==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/34/21/2484.full Crump et al. 2016 (PRELUDE)]
|style="background-color:#1a9851"|Phase III (C)
|Enzastaurin
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.72.6984 Thieblemont et al. 2017 (REMARC)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Lenalidomide_monotherapy|Lenalidomide]]
|style="background-color:#fc8d59"|Seems to have inferior PFS
|-
|[https://academic.oup.com/annonc/article-abstract/29/3/707/4748817 Witzig et al. 2018 (PILLAR-2)]
|style="background-color:#1a9851"|Phase III (C)
|Everolimus
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''No further antineoplastic treatment.''
====Preceding treatment====
*PRELUDE: [[#R-CHOP|R-CHOP induction]] 
*REMARC: [[#R-CHOP|R-CHOP21]] or [[#R-CHOP-14|R-CHOP-14]] induction
===References===
<!-- Presented in part at the Annual Meeting of the American Society of Hematology, New Orleans, LA, December 8, 2013, and at the Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, April 22, 2015. -->
# '''PRELUDE:''' Crump M, Leppä S, Fayad L, Lee JJ, Di Rocco A, Ogura M, Hagberg H, Schnell F, Rifkin R, Mackensen A, Offner F, Pinter-Brown L, Smith S, Tobinai K, Yeh SP, Hsi ED, Nguyen T, Shi P, Hahka-Kemppinen M, Thornton D, Lin B, Kahl B, Schmitz N, Savage KJ, Habermann T. Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma. J Clin Oncol. 2016 Jul 20;34(21):2484-92. Epub 2016 May 23. [http://jco.ascopubs.org/content/34/21/2484.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27217449 PubMed]
<!-- # '''Abstract:''' Catherine Thieblemont, Hervé Tilly, Maria Gomez da Silva, Rene-Olivier Casasnovas, Christophe Fruchart, Franck Morschhauser, Corinne Haioun, Julien Lazarovici, Sebastian Grosicki, Aurore Perrot, Judith Trotman, Catherine Sebban, Dolores Caballero, Richard Greil, Koen Van Eygen, Josette Briere, Jose Cabecadas, Gilles Andre Salles, Philippe Gaulard, Andre Bosly and Bertrand Coiffier. First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysa. Blood 2016 128:471 [http://www.bloodjournal.org/content/128/22/471 link to abstract] -->
# '''REMARC:''' Thieblemont C, Tilly H, Gomes da Silva M, Casasnovas RO, Fruchart C, Morschhauser F, Haioun C, Lazarovici J, Grosicka A, Perrot A, Trotman J, Sebban C, Caballero D, Greil R, van Eygen K, Cohen AM, Gonzalez H, Bouabdallah R, Oberic L, Corront B, Choufi B, Lopez-Guillermo A, Catalano J, Van Hoof A, Briere J, Cabeçadas J, Salles G, Gaulard P, Bosly A, Coiffier B. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2017 Aug 1;35(22):2473-2481. Epub 2017 Apr 20. [http://ascopubs.org/doi/full/10.1200/JCO.2017.72.6984 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28426350 PubMed]
<!-- # '''Abstract:''' Thomas E. Witzig, Kensei Tobinai, Luigi Rigacci, Tongyu Lin, Takashi Ikeda, Anna Vanazzi, Masayuki Hino, Yuankai Shi, Jiri Mayer, Luciano J Costa, Carlos Daniel Bermudez, Jun Zhu, David Belada, Kamal Bouabdallah, Joseph Gergi Kattan, Cassandra Wu, Jenna Fan, Anne-Laure Louveau, Maurizio Voi, and Franco Cavalli. PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL). Journal of Clinical Oncology 2016 34:15_suppl, 7506-7506 [http://ascopubs.org/doi/full/10.1200/JCO.2016.34.15_suppl.7506 link to abstract] -->
# '''PILLAR-2:''' Witzig TE, Tobinai K, Rigacci L, Ikeda T, Vanazzi A, Hino M, Shi Y, Mayer J, Costa LJ, Bermudez Silva CD, Zhu J, Belada D, Bouabdallah K, Kattan JG, Kuruvilla J, Kim WS, Larouche JF, Ogura M, Ozcan M, Fayad L, Wu C, Fan J, Louveau AL, Voi M, Cavalli F. Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial. Ann Oncol. 2018 Mar 1;29(3):707-714. [https://academic.oup.com/annonc/article-abstract/29/3/707/4748817 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29253068 PubMed]

==Radiation therapy {{#subobject:98e441|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, testicular irradiation {{#subobject:a72fd1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/29/20/2766.long Vitolo et al. 2011 (IELSG-10)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#R-CHOP|R-CHOP]] x 6 to 8 cycles
====Radiotherapy====
*[[External beam radiotherapy]] 25 to 30 Gy to the contralateral testis. For patients with stage II disease, involved-field radiation therapy was added; see paper for details.

===Variant #2, IFRT x 30 Gy {{#subobject:54f3d9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/22/15/3032.long Horning et al. 2004 (ECOG E1484)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Observation]]
| style="background-color:#91cf60" |Seems to have superior DFS
|-
|}
====Preceding treatment====
*ECOG E1484: [[Diffuse_large_B-cell_lymphoma_-_historical#CHOP|CHOP]] x 8, with CR
====Radiotherapy====
*[[External beam radiotherapy|IFRT]] 30 Gy

===Variant #3, 36 Gy {{#subobject:214e87|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/104/3/634.long Pfreundschuh et al. 2004 (NHL-B2)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2808%2970002-0/fulltext Pfreundschuh et al. 2008 (RICOVER-60)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70481-3/fulltext Schmitz et al. 2012 (DSHNHL 2002-1)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|[http://jco.ascopubs.org/content/32/36/4127.full Pfreundschuh et al. 2014 (SMARTE-R-CHOP-14)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*NHL-B2: [[Diffuse_large_B-cell_lymphoma_-_historical#CHOEP-14|CHOEP-14]] x 6 versus [[Diffuse_large_B-cell_lymphoma_-_historical#CHOEP-21|CHOEP-21]] x 6 versus [[Diffuse_large_B-cell_lymphoma_-_historical#CHOP-14|CHOP-14]] x 6 versus [[Diffuse_large_B-cell_lymphoma_-_historical#CHOP|CHOP-21]] x 6
*RICOVER-60: [[Diffuse_large_B-cell_lymphoma_-_historical#CHOP-14|CHOP-14]] x 6 versus [[Diffuse_large_B-cell_lymphoma_-_historical#CHOP-14|CHOP-14]] x 8 versus [[#R-CHOP-14|R-CHOP-14]] x 6 versus [[#R-CHOP-14|R-CHOP-14]] x 8
*DSHNHL 2002-1: [[#R-CHOEP-14|R-CHOEP-14]] x 8 versus R-MegaCHOEP
*SMARTE-R-CHOP-14: [[#R-CHOP-14|R-CHOP-14]] x 6
====Radiotherapy====
*[[External beam radiotherapy]] 36 Gy in daily fractions

===Variant #4, IFRT x 40 Gy {{#subobject:54f3d9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/22/15/3032.long Horning et al. 2004 (ECOG E1484)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2006.07.0722 Bonnet et al. 2007]
|style="background-color:#1a9851"|Phase III (C)
|[[#Observation|Observation]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287635/ Persky et al. 2014 (SWOG S0313)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://www.bloodjournal.org/content/131/2/174.long Lamy et al. 2017 (LYSA/GOELAMS 02-03)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Observation|Observation]]
|style="background-color:#eeee00"|Non-inferior EFS
|-
|}
====Preceding treatment====
*ECOG E1484: [[Diffuse_large_B-cell_lymphoma_-_historical#CHOP|CHOP]] x 8, with PR
*SWOG S0313: [[Diffuse_large_B-cell_lymphoma_-_historical#CHOP|CHOP]] x 3, with CR
*Bonnet et al. 2007: [[Diffuse_large_B-cell_lymphoma_-_historical#CHOP|CHOP]] x 4
*LYSA/GOELAMS 02-03: [[#R-CHOP-14|R-CHOP-14]] x 4 to 6
====Radiotherapy====
*[[External beam radiotherapy]] 40 Gy in daily fractions of 1.80 to 2.00 Gy
====Subsequent treatment====
*SWOG S0313: [[#Ibritumomab_tiuxetan_monotherapy|Ibritumomab tiuxetan consolidation]]

===Variant #5, IFRT x 40 to 55 Gy {{#subobject:0cd919|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199807023390104 Miller et al. 1998 (SWOG S8736)]
|style="background-color:#1a9851"|Phase III (E)
|[[Complex_multipart_regimens#SWOG_S8736|See link]]
|[[Complex_multipart_regimens#SWOG_S8736|See link]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2806%2970664-7/fulltext Pfreundschuh et al. 2006 (NCIC CTG LY.9)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://jco.ascopubs.org/content/26/14/2258.long Persky et al. 2008 (SWOG S0014)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287635/ Persky et al. 2014 (SWOG S0313)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|}
''Note: these studies did not specify an exact dose; see papers for details.''
====Preceding treatment====
*SWOG S8736 and SWOG S0014: [[Diffuse_large_B-cell_lymphoma_-_historical#CHOP|CHOP]] x 3
*NCIC CTG LY.9: CHOP-like therapy x 6 versus R-CHOP-like therapy x 6
*SWOG S0313: [[Diffuse_large_B-cell_lymphoma_-_historical#CHOP|CHOP]] x 3, with PR
====Radiotherapy====
*[[External beam radiotherapy]] 46 to 50 Gy in daily fractions of 1.80 to 2.00 Gy
====Subsequent treatment====
*SWOG S0313: [[#Ibritumomab_tiuxetan_monotherapy|Ibritumumoab tiuxetan consolidation]]

===References===
# '''SWOG S8736:''' Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998 Jul 2;339(1):21-6. [https://www.nejm.org/doi/full/10.1056/NEJM199807023390104 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9647875 PubMed]
## '''Update:''' Stephens DM, Li H, LeBlanc ML, Puvvada SD, Persky D, Friedberg JW, Smith SM. Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: Final and long-term analysis of Southwest Oncology Group study S8736. J Clin Oncol. 2016 Sep 1;34(25):2997-3004. Epub 2016 Jul 5. [http://jco.ascopubs.org/content/34/25/2997.full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012710/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27382104 PubMed]
# '''NHL-B2:''' Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004 Aug 1;104(3):634-41. Epub 2004 Mar 11. [http://www.bloodjournal.org/content/104/3/634.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15016643 PubMed]
# '''ECOG E1484:''' Horning SJ, Weller E, Kim K, Earle JD, O'Connell MJ, Habermann TM, Glick JH. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol. 2004 Aug 1;22(15):3032-8. Epub 2004 Jun 21. [http://jco.ascopubs.org/content/22/15/3032.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15210738 PubMed]
# '''LNH 93-01:''' Reyes F, Lepage E, Ganem G, Molina TJ, Brice P, Coiffier B, Morel P, Ferme C, Bosly A, Lederlin P, Laurent G, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte (GELA). ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005 Mar 24;352(12):1197-205. [https://www.nejm.org/doi/full/10.1056/NEJMoa042040 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15788496 PubMed]
# '''NCIC CTG LY.9:''' Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M; MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006 May;7(5):379-91. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2806%2970664-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16648042 PubMed]
## '''Update:''' Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N; MabThera International Trial (MInT) Group. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011 Oct;12(11):1013-22. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2811%2970235-2/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21940214 PubMed]
# Bonnet C, Fillet G, Mounier N, Ganem G, Molina TJ, Thiéblemont C, Fermé C, Quesnel B, Martin C, Gisselbrecht C, Tilly H, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007 Mar 1;25(7):787-92. Epub 2007 Jan 16. [http://ascopubs.org/doi/full/10.1200/JCO.2006.07.0722 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17228021 PubMed]
# '''RICOVER-60:''' Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008 Feb;9(2):105-16. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2808%2970002-0/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18226581 PubMed]
# '''SWOG S0014:''' Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, Miller TP; Southwest Oncology Group. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008 May 10;26(14):2258-63. Epub 2008 Apr 14. [http://jco.ascopubs.org/content/26/14/2258.long link to original article] '''does not contain protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18413640 PubMed]
# '''IELSG-10:''' Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, Bottelli C, Conconi A, Gomez H, Lopez-Guillermo A, Martinelli G, Merli F, Novero D, Orsucci L, Pavone V, Ricardi U, Storti S, Gospodarowicz MK, Cavalli F, Sarris AH, Zucca E. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011 Jul 10;29(20):2766-72. Epub 2011 Jun 6. [http://jco.ascopubs.org/content/29/20/2766.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21646602 PubMed]
# '''DSHNHL 2002-1:''' Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, Viardot A, Bentz M, Peter N, Ehninger G, Doelken G, Ruebe C, Truemper L, Rosenwald A, Pfreundschuh M, Loeffler M, Glass B; for the German High-Grade Lymphoma Study Group (DSHNHL). Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012 Dec;13(12):1250-1259. Epub 2012 Nov 16. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70481-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23168367 PubMed]
# '''SWOG S0313:''' Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea BD, Press OW, Constine LS, Barton KP, Friedberg JW, LeBlanc M, Fisher RI. Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood. 2015 Jan 8;125(2):236-41. Epub 2014 Nov 13. [http://www.bloodjournal.org/content/125/2/236.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287635/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25395425 PubMed]
# '''SMARTE-R-CHOP-14:''' Pfreundschuh M, Poeschel V, Zeynalova S, Hänel M, Held G, Schmitz N, Viardot A, Dreyling MH, Hallek M, Mueller C, Wiesen MH, Witzens-Harig M, Truemper L, Keller U, Rixecker T, Zwick C, Murawski N. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group. J Clin Oncol. 2014 Dec 20;32(36):4127-33. Epub 2014 Nov 17. Erratum in: J Clin Oncol. 2015 Jun 10;33(17):1991. [http://jco.ascopubs.org/content/32/36/4127.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25403207 PubMed]
# '''LYSA/GOELAMS 02-03:''' Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, Gressin R, Cornillon J, Banos A, Le Du K, Benchalal M, Moles MP, Le Gouill S, Fleury J, Godmer P, Maisonneuve H, Deconinck E, Houot R, Laribi K, Marolleau JP, Tournilhac O, Branger B, Devillers A, Vuillez JP, Fest T, Colombat P, Costes V, Szablewski V, Béné MC, Delwail V; LYSA Group. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood. 2018 Jan 11;131(2):174-181. Epub 2017 Oct 23. [http://www.bloodjournal.org/content/131/2/174.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29061568 PubMed]

==R-IFE {{#subobject:62de3a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-IFE: '''<u>R</u>'''ituximab, '''<u>IF</u>'''osfamide, '''<u>E</u>'''toposide
<br>REI: '''<u>R</u>'''ituximab, '''<u>E</u>'''toposide, '''<u>I</u>'''fosfamide
===Regimen {{#subobject:6de486|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61040-4/fulltext Récher et al. 2011 (LNH03-2B)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|[http://annonc.oxfordjournals.org/content/24/4/1032.long Ketterer et al. 2013 (LNH03-1B)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#Methotrexate_monotherapy|Methotrexate consolidation]] x 2
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Etoposide (Vepesid)]] 300 mg/m<sup>2</sup> IV once on day 1
*[[Ifosfamide (Ifex)]] 1500 mg/m<sup>2</sup> IV once on day 1

'''14-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Cytarabine_monotherapy|Cytarabine consolidation]], in 2 weeks

===References===
# '''LNH03-2B:''' Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O, Thiéblemont C, Bosly A, Laurent G, Morschhauser F, Ghesquières H, Jardin F, Bologna S, Fruchart C, Corront B, Gabarre J, Bonnet C, Janvier M, Canioni D, Jais JP, Salles G, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011 Nov 26;378(9806):1858-67. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61040-4/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22118442 PubMed]
## '''Subgroup analysis:''' Molina TJ, Canioni D, Copie-Bergman C, Recher C, Brière J, Haioun C, Berger F, Fermé C, Copin MC, Casasnovas O, Thieblemont C, Petrella T, Leroy K, Salles G, Fabiani B, Morschauser F, Mounier N, Coiffier B, Jardin F, Gaulard P, Jais JP, Tilly H. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B. J Clin Oncol. 2014 Dec 10;32(35):3996-4003. Epub 2014 Nov 10. [http://ascopubs.org/doi/full/10.1200/JCO.2013.54.9493 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25385729 PubMed]
# '''LNH03-1B:''' Ketterer N, Coiffier B, Thieblemont C, Fermé C, Brière J, Casasnovas O, Bologna S, Christian B, Connerotte T, Récher C, Bordessoule D, Fruchart C, Delarue R, Bonnet C, Morschhauser F, Anglaret B, Soussain C, Fabiani B, Tilly H, Haioun C. Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). Ann Oncol. 2013 Apr;24(4):1032-7. Epub 2012 Dec 12. [http://annonc.oxfordjournals.org/content/24/4/1032.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23235801 PubMed]

==TBI, then auto HSCT {{#subobject:37bf17|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:619e49|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985418/ Stiff et al. 2013 (SWOG S9704)]
|style="background-color:#1a9851"|Phase III (E)
|[[#R-CHOP|R-CHOP x 8]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Preceding treatment====
*[[#R-CHOP|R-CHOP]] x 6
{{#lst:Autologous HSCT conditioning regimens|635694}}
'''Stem cells reinfused on day 0'''

===References===
# '''SWOG S9704:''' Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Fisher RI. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med. 2013 Oct 31;369(18):1681-90. [https://www.nejm.org/doi/full/10.1056/NEJMoa1301077 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985418/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24171516 PubMed]
## '''Subgroup analysis:''' Puvvada SD, Stiff PJ, Leblanc M, Cook JR, Couban S, Leonard JP, Kahl B, Marcellus D, Shea TC, Winter JN, Li H, Rimsza LM, Friedberg JW, Smith SM. Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. Br J Haematol. 2016 Sep;174(5):686-91. Epub 2016 Apr 13. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14100/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125530/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27072903 PubMed]

==Z-BEAM, then auto HSCT {{#subobject:19f0d0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Z-BEAM: '''<u>Z</u>'''evalin (Ibritumomab tiuxetan), '''<u>B</u>'''iCNU (Carmustine), '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan
===Variant #1 {{#subobject:9aeafe|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.27418/full Shimoni et al. 2012]
| style="background-color:#1a9851" |Randomized Phase II (E)
|[[#BEAM|BEAM]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943314/ Briones et al. 2013]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
{{#lst:Autologous HSCT|9aeafe}}
===Variant #2 {{#subobject:e7f161|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bbmt.org/article/S1083-8791(14)00473-X/fulltext Fruchart et al. 2014]
| style="background-color:#91cf61" |Phase II
|-
|}
====Preceding treatment====
*[[#ACVBP-R|R-ACVBP]] or [[#R-CHOP|R-CHOP]]
{{#lst:Autologous HSCT|e7f161}}
===References===
# Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Exp Hematol. 2007 Apr;35(4):534-40. [http://www.exphem.org/article/S0301-472X(07)00050-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17379063 PubMed]
# Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R, Patachenko P, Avigdor A, Zwas T, Nagler A. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer. 2012 Oct 1;118(19):4706-14. Epub 2012 Jan 17. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.27418/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22252613 PubMed]
# Briones J, Novelli S, García-Marco JA, Tomás JF, Bernal T, Grande C, Canales MA, Torres A, Moraleda JM, Panizo C, Jarque I, Palmero F, Hernández M, González-Barca E, López D, Caballero D. Autologous stem cell transplantation after conditioning with Yttrium-90 ibritumomab tiuxetan plus beam in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica. 2014 Mar;99(3):505-10. Epub 2013 Oct 25. [http://www.haematologica.org/content/99/3/505.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943314/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24162789 PubMed]
# Fruchart C, Tilly H, Morschhauser F, Ghesquières H, Bouteloup M, Fermé C, Van Den Neste E, Bordessoule D, Bouabdallah R, Delmer A, Casasnovas RO, Ysebaert L, Ciappuccini R, Briere J, Gisselbrecht C. Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2014 Dec;20(12):1905-11. Epub 2014 Jul 26. [http://www.bbmt.org/article/S1083-8791(14)00473-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25072780 PubMed]

=Maintenance after upfront therapy=
==Lenalidomide monotherapy {{#subobject:45aeb1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 1 year {{#subobject:085502|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214342/ Reddy et al. 2016]
|style="background-color:#1a9851"|Randomized Phase II (E)
|Lenalidomide & Rituximab
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Preceding treatment====
*[[#R-CHOP|R-CHOP]] with or without radiation
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21

'''28-day cycle for 12 cycles'''

===Variant #2, 2 years {{#subobject:9e4448|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.72.6984 Thieblemont et al. 2017 (REMARC)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Observation]]
|style="background-color:#91cf60"|Seems to have superior PFS
|-
|}
====Preceding treatment====
*[[#R-CHOP|R-CHOP-21]] or [[#R-CHOP-14|R-CHOP14]]
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21

'''28-day cycle for up to 2 years'''

===References===
# Reddy NM, Greer JP, Morgan DS, Chen H, Park SI, Richards KL. A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma. Leukemia. 2017 Jan;31(1):241-244. Epub 2016 Sep 22. [https://www.nature.com/leu/journal/v31/n1/full/leu2016255a.html link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214342/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27654851 PubMed]
<!-- # '''Abstract:''' Catherine Thieblemont, Hervé Tilly, Maria Gomez da Silva, Rene-Olivier Casasnovas, Christophe Fruchart, Franck Morschhauser, Corinne Haioun, Julien Lazarovici, Sebastian Grosicki, Aurore Perrot, Judith Trotman, Catherine Sebban, Dolores Caballero, Richard Greil, Koen Van Eygen, Josette Briere, Jose Cabecadas, Gilles Andre Salles, Philippe Gaulard, Andre Bosly and Bertrand Coiffier. First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysa. Blood 2016 128:471 [http://www.bloodjournal.org/content/128/22/471 link to abstract] -->
# '''REMARC:''' Thieblemont C, Tilly H, Gomes da Silva M, Casasnovas RO, Fruchart C, Morschhauser F, Haioun C, Lazarovici J, Grosicka A, Perrot A, Trotman J, Sebban C, Caballero D, Greil R, van Eygen K, Cohen AM, Gonzalez H, Bouabdallah R, Oberic L, Corront B, Choufi B, Lopez-Guillermo A, Catalano J, Van Hoof A, Briere J, Cabeçadas J, Salles G, Gaulard P, Bosly A, Coiffier B. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2017 Aug 1;35(22):2473-2481. Epub 2017 Apr 20. [http://ascopubs.org/doi/full/10.1200/JCO.2017.72.6984 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28426350 PubMed]

==Rituximab monotherapy {{#subobject:c28fe4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Variant #1 {{#subobject:da32ff|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486230/ Jaeger et al. 2015 (NHL13)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Observation]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Patients required to be in CR or CRu prior to enrollment. The protocol was amended after the first 69 patients enrolled to increase length of treatment from 1 to 2 years.''
====Preceding treatment====
*Rituximab (375 mg/m<sup>2</sup>) x 8 and 4 to 8 cycles of CHOP-like chemotherapy
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once every 2 months

'''1 to 2 year course (6 to 12 doses total)'''

===Variant #2 {{#subobject:6c6458|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13652/full Witzens-Harig et al. 2015 (HD2002)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Observation]]
|style="background-color:#1a9850"|Superior OS in males
|-
|}
====Preceding treatment====
*"Standard treatment" which was not further described in the paper, beyond that a majority of patient received R-CHOP (see Tables)
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once every 3 months

'''2 year course (8 doses total)'''

===Variant #3 {{#subobject:7c3ba2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/20/12/1985.long Haioun et al. 2009 (LNH 98-3)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Observation]]
|style="background-color:#d9ef8b"|Might have superior EFS
|-
|}
====Preceding treatment====
*[[#CBVM.2C_then_auto_HSCT|CBVM, then auto HSCT]]
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per week

'''4-week course (4 doses total)'''

===Variant #4 {{#subobject:8afe47|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/24/19/3121.long Habermann et al. 2006 (ECOG E4494/CALGB 9793)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation|Observation]]
|style="background-color:#d3d3d3"|See note
|-
|}
''Note: in '''ECOG E4494/CALGB 9793''', an advantage to rituximab was only seen in the group receiving [[Diffuse_large_B-cell_lymphoma_-_historical#CHOP|CHOP]] upfront, which is no longer standard of care.''
====Preceding treatment====
*[[#R-CHOP|R-CHOP]] versus [[Diffuse_large_B-cell_lymphoma_-_historical#CHOP|CHOP]]
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per week for 4 weeks

'''6-month cycle for 4 cycles (16 doses total)'''

===References===
# '''ECOG E4494/CALGB 9793:''' Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006 Jul 1;24(19):3121-7. Epub 2006 Jun 5. [http://jco.ascopubs.org/content/24/19/3121.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16754935 PubMed]
# '''LNH 98-3:''' Haioun C, Mounier N, Emile JF, Ranta D, Coiffier B, Tilly H, Récher C, Fermé C, Gabarre J, Herbrecht R, Morchhauser F, Gisselbrecht C. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Ann Oncol. 2009 Dec;20(12):1985-92. Epub 2009 Jun 30. [http://annonc.oxfordjournals.org/content/20/12/1985.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19567453 PubMed]
<!-- These data have been presented in part at the 55th Annual Meeting of the American Society of Hematology, New Orleans 2013, the 12th International Conference on Malignant Lymphoma 2013, Lugano, and the 18th Congress of the European Hematology Association, Stockholm 2013. -->
# '''NHL13:''' Jaeger U, Trneny M, Melzer H, Praxmarer M, Nawarawong W, Ben Yehuda D, Goldstein D, Mihaljevic B, Ilhan O, Ballova V, Hedenus M, Hsiao LT, Au WY, Burgstaller S, Weidinger G, Keil F, Dittrich C, Skrabs C, Klingler A, Chott A, Fridrik MA, Greil R. Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. Haematologica. 2015 Jul;100(7):955-63. Epub 2015 Apr 24. [http://www.haematologica.org/content/100/7/955 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486230/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25911553 PubMed]
# '''HD2002:''' Witzens-Harig M, Benner A, McClanahan F, Klemmer J, Brandt J, Brants E, Rieger M, Meissner J, Hensel M, Neben K, Dreger P, Lengfelder E, Schmidt-Wolf I, Krämer A, Ho AD. Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma: results of the HD2002 prospective multicentre randomized phase III trial. Br J Haematol. 2015 Dec;171(5):710-9. Epub 2015 Oct 9. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13652/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26449739 PubMed]

=Relapsed or refractory, salvage therapy=

==O-DHAP {{#subobject:49372b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
O-DHAP: '''<u>O</u>'''fatumumab, '''<u>D</u>'''examethasone, '''<u>H</u>'''igh-dose '''<u>A</u>'''ra-C (Cytarabine), '''<u>P</u>'''latinol (Cisplatin)

===Regimen {{#subobject:294f6d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724189/ Matasar et al. 2013]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://ascopubs.org/doi/suppl/10.1200/JCO.2016.69.0198 van Imhoff et al. 2016 (ORCHARRD)]
|style="background-color:#1a9851"|Phase III (E)
|[[#R-DHAP|R-DHAP]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Ofatumumab (Arzerra)]] as follows:
**Cycle 1: 1000 mg IV once per day on days 1 & 8
**Cycles 2 & 3: 1000 mg IV once on day 1
*[[Dexamethasone (Decadron)]] 40 mg IV or PO once per day on days 1 to 4
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV every 12 hours x 2 doses on day 2 (total of 2 doses)
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1

====Supportive medications====
*Matasar et al. 2013: [[Filgrastim (Neupogen) | G-CSF]] or [[Pegfilgrastim (Neulasta) | Neulasta]] was recommended (no details given).

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*Matasar et al. 2013, responders: Stem-cell mobilization and autologous hematopoietic stem cell transplant (regimen not specified) 
*ORCHARRD, responders: [[#BEAM.2C_then_auto_HSCT|BEAM with autologous hematopoietic stem cell transplant]] except those in Japan who received [[#LEED.2C_then_auto_HSCT|LEED with autologous hematopoietic stem cell transplant]]

===References===
<!-- Presented at the 2011 American Society of Hematology Annual Meeting, San Diego, CA, December 10-13, 2011. -->
# Matasar MJ, Czuczman MS, Rodriguez MA, Fennessy M, Shea TC, Spitzer G, Lossos IS, Kharfan-Dabaja MA, Joyce R, Fayad L, Henkel K, Liao Q, Edvardsen K, Jewell RC, Fecteau D, Singh RP, Lisby S, Moskowitz CH. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood. 2013 Jul 25;122(4):499-506. Epub 2013 May 21. [http://www.bloodjournal.org/content/122/4/499.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724189/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23692856 PubMed]
# van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, Kim W, Hong X, Goerloev JS, Davies A, Barrigón MD, Ogura M, Leppä S, Fennessy M, Liao Q, van der Holt B, Lisby S, Hagenbeek A. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: The ORCHARRD study. J Clin Oncol. 2017 Feb 10;35(5):544-51. Epub 2016 Dec 28. [http://ascopubs.org/doi/suppl/10.1200/JCO.2016.69.0198 link to original article] [http://ascopubs.org/doi/suppl/10.1200/JCO.2016.69.0198/suppl_file/ds_2016.690198.pdf link to data supplement] '''verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/28029326 PubMed]

==O-ICE {{#subobject:f3f288|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
O-ICE: '''<u>O</u>'''fatumumab, '''<u>I</u>'''fosfamide, '''<u>C</u>'''arboplatin, '''<u>E</u>'''toposide

===Regimen {{#subobject:abb23b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724189/ Matasar et al. 2013]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Ofatumumab (Arzerra)]] as follows:
**Cycle 1: 1000 mg IV once per day on days 1 & 8
**Cycles 2 & 3: 1000 mg IV once on day 1
*[[Ifosfamide (Ifex)]] 5000 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 2, '''mixed with [[Mesna (Mesnex)]]'''
*[[Carboplatin (Paraplatin)]] AUC 5 (maximum dose of 800 mg) IV once on day 1 OR 2 (1 dose, total)
**Carboplatin AUC calculated based on a 12-hour creatinine clearance
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3

====Supportive medications====
*[[Mesna (Mesnex)]] 5000 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 2, '''mixed with [[Ifosfamide (Ifex)]]'''
*[[Filgrastim (Neupogen) | G-CSF]] or [[Pegfilgrastim (Neulasta) | Neulasta]] was recommended (no details given).

'''21-day cycle for 3 cycles'''

''Subsequent consolidation therapy was not specified.''

===References===
<!-- Presented at the 2011 American Society of Hematology Annual Meeting, San Diego, CA, December 10-13, 2011. -->
# Matasar MJ, Czuczman MS, Rodriguez MA, Fennessy M, Shea TC, Spitzer G, Lossos IS, Kharfan-Dabaja MA, Joyce R, Fayad L, Henkel K, Liao Q, Edvardsen K, Jewell RC, Fecteau D, Singh RP, Lisby S, Moskowitz CH. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood. 2013 Jul 25;122(4):499-506. Epub 2013 May 21. [http://www.bloodjournal.org/content/122/4/499.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724189/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23692856 PubMed]

==R-DexaBEAM {{#subobject:81a0a4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-DexaBEAM: '''<u>R</u>'''ituximab, '''<u>Dexa</u>'''methasone, '''<u>B</u>'''iCNU (Carmustine), '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan

===Regimen {{#subobject:801417|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13234/full Kirschey et al. 2014]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: the dosing in the manuscript is different than below. The below are the correct doses as verified by the authors.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Dexamethasone (Decadron)]] 8 mg PO three times per day on days 1 to 10
*[[Carmustine (BiCNU)]] 60 mg/m<sup>2</sup> IV once on day 3
*[[Etoposide (Vepesid)]] 75 mg/m<sup>2</sup> IV once per day on days 4 to 7
*[[Cytarabine (Cytosar)]] 100 mg/m<sup>2</sup> IV twice per day on days 4 to 7
*[[Melphalan (Alkeran)]] 20 mg/m<sup>2</sup> IV once on day 2

'''3- to 4-week cycle for 2 cycles'''
====Subsequent treatment====
*[[#R-BEAM.2C_then_auto_HSCT|R-BEAM with autologous hematopoietic stem cell transplant]] or [[#R-TBI.2FCy.2C_then_auto_HSCT|R-TBI/Cy with autologous hematopoietic stem cell transplant]]

===References===
# Kirschey S, Flohr T, Wolf HH, Frickhofen N, Gramatzki M, Link H, Basara N, Peter N, Meyer RG, Schmitz N, Weidmann E, Banat A, Schulz A, Kolbe K, Derigs G, Theobald M, Hess G. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study. Br J Haematol. 2015 Mar;168(6):824-34. Epub 2014 Dec 28. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13234/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25546611 PubMed]

==R-DHAOx {{#subobject:0d0c67|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-DHAOx: '''<u>R</u>'''ituximab, '''<u>D</u>'''examethasone, '''<u>H</u>'''igh-dose '''<u>A</u>'''ra-C (Cytarabine), '''<u>O</u>'''xaliplatin
<br>ROAD: '''<u>R</u>'''ituximab, '''<u>O</u>'''xaliplatin, '''<u>A</u>'''ra-C (Cytarabine), '''<u>D</u>'''examethasone
===Regimen {{#subobject:962cf0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/ajh.24824/full Witzig et al. 2017 (MCCRC MC0485)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#bfd3e6" |ORR: 71% (95% CI, 56–84)
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1 only: 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22
*[[Dexamethasone (Decadron)]] 40 mg IV or PO once per day on days 2 to 5
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV over 3 hours once per day on days 2 & 3
**Second dose to be given no sooner than 12 hours and no later than 24 hours after '''end''' of first dose
*[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV over 2 hours once on day 2

====Supportive medications====
*[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 4

'''21-day cycles'''
====Subsequent treatment====
*Most responders proceeded to high-dose chemotherapy with autologous hematopoietic stem cell transplant after 2 cycles, although this was not mandated in the protocol

===References===
# '''MCCRC MC0485:''' Witzig TE, Johnston PB, LaPlant BR, Kurtin PJ, Pederson LD, Moore DF Jr, Nabbout NH, Nikcevich DA, Rowland KM, Grothey A. Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU). Am J Hematol. 2017 Oct;92(10):1004-1010. Epub 2017 Aug 17. [https://onlinelibrary.wiley.com/doi/10.1002/ajh.24824/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28614905 PubMed]

==R-DHAP {{#subobject:18c266|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-DHAP: '''<u>R</u>'''ituximab, '''<u>D</u>'''examethasone, '''<u>H</u>'''igh-dose '''<u>A</u>'''ra-C (Cytarabine), '''<u>P</u>'''latinol (Cisplatin)

===Variant #1 {{#subobject:af0858|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664033/ Gisselbrecht et al. 2010 (CORAL)]
|style="background-color:#1a9851"|Phase III (E)
|[[#R-ICE|R-ICE]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/suppl/10.1200/JCO.2016.69.0198 van Imhoff et al. 2016 (ORCHARRD)]
|style="background-color:#1a9851"|Phase III (C)
|[[#O-DHAP|O-DHAP]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: '''CORAL''' makes reference to Velasquez et al. 1988 to describe this regimen, although this reference is for DHAP, not R-DHAP. The paper also contains the following regimen information:''
====Chemotherapy====
*[[Rituximab (Rituxan)]] as follows, '''given first''':
**Cycle 1: 375 mg/m<sup>2</sup> IV once per day on days -1 & 1 ('''CORAL''') or days 1 & 8 ('''ORCHARRD''')
**Cycle 2: 375 mg/m<sup>2</sup> IV once on day 1 
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV over 3 hours every 12 hours x 2 doses on day 2 (total of 2 doses)
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1

====Supportive medications====
*'''CORAL''': [[Filgrastim (Neupogen) | G-CSF]] "depending on site policy, with R-DHAP, but always after the third cycle until the end of leukaphereses"

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*CORAL, responders: [[#BEAM.2C_then_auto_HSCT|BEAM with autologous hematopoietic stem cell transplant]]
*ORCHARRD, responders: [[#BEAM.2C_then_auto_HSCT|BEAM with autologous hematopoietic stem cell transplant]] except those in Japan who received [[#LEED.2C_then_auto_HSCT|LEED with autologous hematopoietic stem cell transplant]]

===Variant #2 {{#subobject:ac829f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/32/31/3490.full Crump et al. 2014 (NCIC-CTG LY.12)]
|style="background-color:#1a9851"|Phase III (C)
|[[#R-GDP|R-GDP]]
|style="background-color:#eeee01"|Seems non-inferior
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV over 3 hours every 12 hours x 2 doses on day 2 (total of 2 doses)
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1

'''21-day cycle for up to 3 cycles'''
====Subsequent treatment====
*Responders: Stem-cell mobilization and high-dose chemotherapy with autologous hematopoietic stem cell transplant (regimen not specified)

===Variant #3 {{#subobject:65859a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.tandfonline.com/doi/full/10.1080/07357900600814490 Mey et al. 2006]
|style="background-color:#91cf61"|Phase II
|-
|}
''The doses here were used after a mid-protocol amendment pertaining to the first cycle.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Dexamethasone (Decadron)]] as follows:
**Cycle 1: 40 mg PO once per day on days 3 to 5
**Cycles 2 to 4: 40 mg PO once per day on days 3 to 6
*[[Cytarabine (Cytosar)]] as follows:
**Cycle 1 as follows:
***Younger than 60 years: 1000 mg/m<sup>2</sup> IV over 2 hours every 12 hours x 2 doses on day 4 (total of 2 doses)
***Older than 60 years: 500 mg/m<sup>2</sup> IV over 2 hours every 12 hours x 2 doses on day 4 (total of 2 doses)
**Cycles 2 to 4 as follows:
***Younger than 60 years: 2000 mg/m<sup>2</sup> IV over 2 hours every 12 hours x 2 doses on day 4 (total of 2 doses) 
***Older than 60 years: 1000 mg/m<sup>2</sup> IV over 2 hours every 12 hours x 2 doses on day 4 (total of 2 doses)
*[[Cisplatin (Platinol)]] as follows:
**Cycle 1: 25 mg/m<sup>2</sup>/day IV continuous infusion over 72 hours, started on day 3 (total dose: 75 mg/m<sup>2</sup>)
**Cycles 2 to 4: 25 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 3 (total dose per cycle: 100 mg/m<sup>2</sup>)

'''21-day cycle for up to 4 cycles'''
====Subsequent treatment====
*Patients with at least PR were allowed to undergo high-dose chemotherapy with autologous stem-cell transplant (regimen not specified)

===References===
# Mey UJ, Orlopp KS, Flieger D, Strehl JW, Ho AD, Hensel M, Bopp C, Gorschlüter M, Wilhelm M, Birkmann J, Kaiser U, Neubauer A, Florschütz A, Rabe C, Hahn C, Glasmacher AG, Schmidt-Wolf IG. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest. 2006 Oct;24(6):593-600. [https://www.tandfonline.com/doi/full/10.1080/07357900600814490 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16982464 PubMed]
<!-- # Hagberg H, Gisselbrecht C; CORAL study group. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol. 2006 May;17 Suppl 4:iv31-2. [http://annonc.oxfordjournals.org/content/17/suppl_4/iv31.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16702182 PubMed]
# Presented at the 45th Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2009, Orlando, FL, and at the 51st Annual Meeting of the American Society of Hematology, December 5-8, 2009, New Orleans, LA. -->
# '''CORAL:''' Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH, Schmitz N. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010 Sep 20;28(27):4184-90. Epub 2010 Jul 26. Erratum in: J Clin Oncol. 2012 May 20;30(15):1896. [http://jco.ascopubs.org/content/28/27/4184.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664033/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20660832 PubMed]
<!-- Presented in part at the Annual Meeting of the American Society of Hematology, Atlanta, GA, December 7-10, 2013, and the International Conference on Malignant Lymphoma, Lugano, Switzerland, June 19-22, 2013. -->
# '''NCIC-CTG LY.12:''' Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, Di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner AR, Sussman J, Hay AE, Djurfeldt MS, Meyer RM, Chen BE, Shepherd LE. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014 Nov 1;32(31):3490-6. Epub 2014 Sep 29. [http://jco.ascopubs.org/content/32/31/3490.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25267740 PubMed]
# '''ORCHARRD:''' van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, Kim W, Hong X, Goerloev JS, Davies A, Barrigón MD, Ogura M, Leppä S, Fennessy M, Liao Q, van der Holt B, Lisby S, Hagenbeek A. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: The ORCHARRD study. J Clin Oncol. 2017 Feb 10;35(5):544-51. Epub 2016 Dec 28. [http://ascopubs.org/doi/suppl/10.1200/JCO.2016.69.0198 link to original article] [http://ascopubs.org/doi/suppl/10.1200/JCO.2016.69.0198/suppl_file/ds_2016.690198.pdf link to data supplement] '''verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/28029326 PubMed]

==R-DHAP/R-VIM {{#subobject:e57948|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-DHAP/R-VIM: '''<u>R</u>'''ituximab, '''<u>D</u>'''examethasone, '''<u>H</u>'''igh-dose '''<u>A</u>'''ra-C (Cytarabine), '''<u>P</u>'''latinol (Cisplatin) alternating with '''<u>R</u>'''ituximab, '''<u>V</u>'''P-16 (Etoposide), '''<u>I</u>'''fosfamide, '''<u>M</u>'''ethotrexate
===Regimen {{#subobject:f46b7f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/111/2/537.long Vellenga et al. 2008 (HOVON-44)]
|style="background-color:#1a9851"|Phase III (E)
|DHAP/VIM
|style="background-color:#1a9850"|Superior PFS
|-
|}
''Note: per the paper, "in case patients were non-responsive to R-DHAP but responsive to R-VIM, it was allowed to repeat the R-VIM regimen as the third cycle of reinduction chemotherapy." No statement is made as to whether Mesna is used in the VIM protocol.''
====Chemotherapy, R-DHAP portion====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 5
*[[Dexamethasone (Decadron)]] 40 mg IV or PO once per day on days 1 to 4
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV over 3 hours every 12 hours x 2 doses on day 2 (total of 2 doses)
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1

'''28-day cycle for 2 cycles, with VIM interposed'''

====Chemotherapy, R-VIM portion====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 6
*[[Etoposide (Vepesid)]] 90 mg/m<sup>2</sup> IV once per day on days 1, 3, 5
*[[Ifosfamide (Ifex)]] 1200 mg/m<sup>2</sup> IV once per day on days 1 to 5
*[[Methotrexate (MTX)]] 30 mg/m<sup>2</sup> IV once per day on days 1 & 5

'''28-day cycle for 1 cycle, given in-between R-DHAP cycles'''
====Subsequent treatment====
*Responders: Stem-cell mobilization, then [[#BEAM.2C_then_auto_HSCT|BEAM with autologous hematopoietic stem cell transplant]]

===References===
# Vellenga E, van Putten WL, van 't Veer MB, Zijlstra JM, Fibbe WE, van Oers MH, Verdonck LF, Wijermans PW, van Imhoff GW, Lugtenburg PJ, Huijgens PC. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood. 2008 Jan 15;111(2):537-43. [http://www.bloodjournal.org/content/111/2/537.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17971487 PubMed]

==R-EPOCH {{#subobject:ddfe7d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-EPOCH: '''<u>R</u>'''ituximab, '''<u>E</u>'''toposide, '''<u>P</u>'''rednisone, '''<u>O</u>'''ncovin (Vincristine), '''<u>C</u>'''yclophosphamide, '''<u>H</u>'''ydroxydaunorubicin (Doxorubicin)

===Regimen {{#subobject:a10d44|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/15/3/511.long Jermann et al. 2004]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: this is not the dose-adjusted R-EPOCH regimen''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV on day 1
*[[Etoposide (Vepesid)]] 65 mg/m<sup>2</sup>/day IV continuous infusion over 72 hours, started on day 2 (total dose per cycle: 195 mg/m<sup>2</sup>) 
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup>/day PO on days 1 to 14
*[[Vincristine (Oncovin)]] 0.5 mg/m<sup>2</sup>/day IV continuous infusion over 72 hours, started on day 2 (total dose per cycle: 1.5 mg/m<sup>2</sup>) 
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 5
*[[Doxorubicin (Adriamycin)]] 15 mg/m<sup>2</sup>/day IV continuous infusion over 72 hours, started on day 2 (total dose per cycle: 45 mg/m<sup>2</sup>)

'''21-day cycle for 4 to 6 cycles'''
====Subsequent treatment====
*Patients younger than 60 who achieved at least PR: High-dose chemotherapy with autologous hematopoietic stem-cell transplantation (regimen not specified)
===References===
# Jermann M, Jost LM, Taverna Ch, Jacky E, Honegger HP, Betticher DC, Egli F, Kroner T, Stahel RA. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol. 2004 Mar;15(3):511-6. [http://annonc.oxfordjournals.org/content/15/3/511.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14998858 PubMed]

==R-ESHAP {{#subobject:7794d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-ESHAP: '''<u>R</u>'''ituximab, '''<u>E</u>'''toposide, '''<u>S</u>'''olumedrol (Methylprednisolone) '''<u>H</u>'''igh-dose '''<u>A</u>'''ra-C (Cytarabine), '''<u>P</u>'''latinol (Cisplatin)

===Regimen {{#subobject:b6038c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.haematologica.org/content/93/12/1829.long Martín et al. 2008]
|style="background-color:#ffffbe"|Retrospective
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(11)70097-0/fulltext Avilés et al. 2010]
|style="background-color:#1a9851"|Phase III (E)
|[[#ESHAP|ESHAP]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Regimen details are based on ESHAP paper from 1994. Per retrospective review (Martin et al. 2008), 90% of patients given R-ESHAP received rituximab on day 1, 10% on day 5.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1 (or day 5)
*[[Etoposide (Vepesid)]] 40 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 to 4
*[[Methylprednisolone (Solumedrol)]] 250 to 500 mg IV over 15 minutes once per day on days 1 to 5
**In Martín et al. 2008, could either be given on days 1 to 4 or days 1 to 5, with patients receiving total doses of anywhere from 1000 mg per cycle to 2500 mg per cycle
*[[Cytarabine (Cytosar)]] 2000 mg/m<sup>2</sup> IV over 2 hours once on day 5
*[[Cisplatin (Platinol)]] 25 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 100 mg/m<sup>2</sup>)

====Supportive medications====
*At least 1 liter normal saline with 25 to 50 g [[Mannitol]] once per day throughout chemotherapy
*[[Metoclopramide (Reglan)]] 0.5 to 1 mg/kg (route not specified) "given regularly"

'''21 to 28 day cycles ("after recovery of the toxic effects") for 6 to 8 cycles'''

===References===
# '''Retrospective:''' Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, García-Sanchez P, Vázquez L, Nistal S, Requena MJ, Donato EM, González JA, León A, Ruiz C, Grande C, González-Barca E, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO Cooperative Group). R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica. 2008 Dec;93(12):1829-36. Epub 2008 Oct 22. [http://www.haematologica.org/content/93/12/1829.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18945747 PubMed]
# Avilés A, Neri N, Huerta-Guzmán J, de Jesús Nambo M. ESHAP versus rituximab-ESHAP in frail patients with refractory diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2010 Apr;10(2):125-8. [http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(11)70097-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20371445 PubMed]

==R-GDP {{#subobject:a5d411|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-GDP: '''<u>R</u>'''ituximab, '''<u>G</u>'''emcitabine, '''<u>D</u>'''examethasone, '''<u>P</u>'''latinol (Cisplatin)

===Variant #1, 1 day of cisplatin/cycle {{#subobject:c6480d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/32/31/3490.full Crump et al. 2014 (NCIC-CTG LY.12)]
|style="background-color:#1a9851"|Phase III (E)
|[[#R-DHAP|R-DHAP]]
|style="background-color:#eeee01"|Seems non-inferior
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 3 cycles'''
====Subsequent treatment====
*Responders: Stem-cell mobilization and high-dose chemotherapy with autologous hematopoietic stem cell transplant (regimen not specified)

===Variant #2, 3 days of cisplatin/cycle {{#subobject:325d38|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://link.springer.com/article/10.1007%2Fs12032-012-0211-2 Hou et al. 2012]
|style="background-color:#91cf61"|Non-randomized
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Dexamethasone (Decadron)]] 40 mg IV once per day on days 1 to 4
*[[Cisplatin (Platinol)]] 25 mg/m<sup>2</sup> IV once per day on days 1 to 3

'''21-day cycle for up to 6 cycles'''

===References===
# Hou Y, Wang HQ, Ba Y. Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma. Med Oncol. 2012 Dec;29(4):2409-16. Epub 2012 Apr 3. [http://link.springer.com/article/10.1007%2Fs12032-012-0211-2 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22476761 PubMed]
# '''NCIC-CTG LY.12:''' Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, Di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner AR, Sussman J, Hay AE, Djurfeldt MS, Meyer RM, Chen BE, Shepherd LE. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014 Nov 1;32(31):3490-6. Epub 2014 Sep 29. [http://jco.ascopubs.org/content/32/31/3490.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25267740 PubMed]

==R-ICE {{#subobject:117cd8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-ICE: '''<u>R</u>'''ituximab, '''<u>I</u>'''fosfamide, '''<u>C</u>'''arboplatin, '''<u>E</u>'''toposide
<br>ICE-R: '''<u>I</u>'''fosfamide, '''<u>C</u>'''arboplatin, '''<u>E</u>'''toposide, '''<u>R</u>'''ituximab
===Variant #1 {{#subobject:35e1ac|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664033/ Gisselbrecht et al. 2010 (CORAL)]
|style="background-color:#1a9851"|Phase III (E)
|[[#R-DHAP|R-DHAP]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://www.tandfonline.com/doi/full/10.3109/10428194.2015.1007504 Fayad et al. 2015]
|style="background-color:#1a9851"|Randomized Phase IIb (C)
|R-ICE + Dacetuzumab
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: '''Gisselbrecht et al. 2010''' refers to the non-randomized regimen described in variant #3 below, although it has slightly different day numbering. Doses are the same.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] as follows (given first before other chemotherapy):
**Cycle 1: 375 mg/m<sup>2</sup> IV once per day on days -1 & 1
**Cycles 2 & 3: 375 mg/m<sup>2</sup> IV once on day 1 
*[[Ifosfamide (Ifex)]] 5000 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 2
*[[Carboplatin (Paraplatin)]] AUC 5 (maximum dose of 800 mg) IV once on day 2
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3

====Supportive medications====
*[[Mesna (Mesnex)]] given with [[Ifosfamide (Ifex)]] (dose & schedule not specified)
*"[[Filgrastim (Neupogen) | Granulocyte colony-stimulating factor]] was administered after R-ICE"

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*CORAL with complete or partial response: [[#BEAM.2C_then_auto_HSCT|BEAM with autologous hematopoietic stem cell transplant]]

===Variant #2 {{#subobject:871cdf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://zhxyxzz.yiigle.com/zhxyxzz20143504/395338.htm Guo et al. 2014]
|style="background-color:#91cf61"|Phase II
| style="background-color:#e0ecf4" |ORR: 78%
|-
|}
''Note: original article is in Chinese; this information is from the English abstract.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Ifosfamide (Ifex)]] 1600 mg/m<sup>2</sup> IV once per day on days 2 to 4
*[[Carboplatin (Paraplatin)]] AUC 5 (maximum dose of 800 mg) IV once on day 3
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 2 to 4

'''3 cycles; duration of cycles not specified in the abstract'''

===Variant #3 {{#subobject:820b17|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/14/suppl_1/i5.long Zelenetz et al. 2003]
|style="background-color:#91cf61"|Phase II
| style="background-color:#e0ecf4" |ORR: 81% (*)
|-
|[http://www.bloodjournal.org/content/103/10/3684.long Kewalramani et al. 2004]
|style="background-color:#91cf61"|Phase II
| style="background-color:#e0ecf4" |ORR: 78% (*)
|-
|}
''Third cycle intended to be followed by peripheral blood hematopoietic stem cell collection. ORR reported in Zelenetz et al. 2003 is for the subset of DLBCL patients who received R-ICE; it is unclear if these patients were exposed to rituximab previously. None of the patients in Kewalaramani et al. 2004 had previously received rituximab.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
**An additional one-time dose of 375 mg/m<sup>2</sup> IV was given 48 hours before the beginning of cycle 1
*[[Ifosfamide (Ifex)]] 5000 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 4, '''mixed with [[Mesna (Mesnex)]]'''
*[[Carboplatin (Paraplatin)]] AUC 5 (maximum dose of 800 mg) IV bolus once on day 4
**Carboplatin AUC calculated based on a 12-hour creatinine clearance
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV bolus once per day on days 3 to 5

====Supportive medications====
*(as described by Kewalramani et al. 2004):
*[[Mesna (Mesnex)]] 5000 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 4, '''mixed with [[Ifosfamide (Ifex)]]'''
*[[Acetaminophen (Tylenol)]] 650 mg PO once as premedication for [[Rituximab (Rituxan)]]
*[[Diphenhydramine (Benadryl)]] 50 mg IV once as premedication for [[Rituximab (Rituxan)]]
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day on days 7 to 14 (10 mcg/kg with cycle 3, given until collection of peripheral blood hematopoietic stem cells)

'''14-day cycle for 3 cycles'''

===References===
# Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol. 2003;14 Suppl 1:i5-10. [http://annonc.oxfordjournals.org/content/14/suppl_1/i5.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12736224 PubMed]
# Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, O'Connor O, Filippa DA, Teruya-Feldstein J, Gencarelli A, Qin J, Waxman A, Yahalom J, Moskowitz CH. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004 May 15;103(10):3684-8. Epub 2004 Jan 22. [http://www.bloodjournal.org/content/103/10/3684.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14739217 PubMed]
<!-- # Hagberg H, Gisselbrecht C; CORAL study group. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol. 2006 May;17 Suppl 4:iv31-2. [http://annonc.oxfordjournals.org/content/17/suppl_4/iv31.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16702182 PubMed]
Presented at the 45th Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2009, Orlando, FL, and at the 51st Annual Meeting of the American Society of Hematology, December 5-8, 2009, New Orleans, LA. -->
# Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH, Schmitz N. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010 Sep 20;28(27):4184-90. Epub 2010 Jul 26. Erratum in: J Clin Oncol. 2012 May 20;30(15):1896. [http://jco.ascopubs.org/content/28/27/4184.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664033/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20660832 PubMed]
# Guo Y, Chen Y, Hong X, Yu L, Ma J, Shi Y, Liu T, Jiang W, Zhu J, Jin J, Zou P, Wu D, Shen Z. [A phase II multicenter study to investigate R-ICE as a salvage therapy for relapsed diffuse large B-cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2014 Apr;35(4):314-7. Chinese. [http://zhxyxzz.yiigle.com/zhxyxzz20143504/395338.htm link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24759019 PubMed]
# Fayad L, Ansell SM, Advani R, Coiffier B, Stuart R, Bartlett NL, Forero-Torres A, Kuliczkowski K, Belada D, Ng E, Drachman JG. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leuk Lymphoma. 2015;56(9):2569-78. Epub 2015 Feb 26. [http://www.tandfonline.com/doi/full/10.3109/10428194.2015.1007504 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25651427 PubMed]

==RICER {{#subobject:28fda|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RICER: '''<u>R</u>'''ituximab, '''<u>I</u>'''fosfamide, '''<u>C</u>'''arboplatin, '''<u>E</u>'''toposide, '''<u>R</u>'''evlimid (Lenalidomide)

===Regimen {{#subobject:f8dffd|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283736/ Feldman et al. 2014]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Ifosfamide (Ifex)]] 5000 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 2, '''mixed with [[Mesna (Mesnex)]]'''
*[[Carboplatin (Paraplatin)]] AUC 5 (maximum dose of 800 mg) IV once on day 2
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV bolus once per day on days 2 to 4
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 7

====Supportive medications====
*[[Mesna (Mesnex)]] 5000 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 2, '''mixed with [[Ifosfamide (Ifex)]]'''
*[[Aspirin]] 81 mg PO once per day from day 1 until platelets less than 50 × 10<sup>9</sup>/L
*Low dose LMWH for patients intolerant of [[Aspirin]]
*"[[Filgrastim (Neupogen) | Granulocyte colony-stimulating factor]] was administered after R-ICE"

'''14-day cycle for 2 cycles'''
====Subsequent treatment====
*Responders received a 3rd cycle with hematopoietic stem cell collection 10 to 14 days afterwards, then [[#BEAM.2C_then_auto_HSCT|BEAM with autologous hematopoietic stem cell transplant (details not described)]]

===References===
# Feldman T, Mato AR, Chow KF, Protomastro EA, Yannotti KM, Bhattacharyya P, Yang X, Donato ML, Rowley SD, Carini C, Valentinetti M, Smith J, Gadaleta G, Bejot C, Stives S, Timberg M, Kdiry S, Pecora AL, Beaven AW, Goy A. Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma. Br J Haematol. 2014 Jul;166(1):77-83. Epub 2014 Mar 25. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.12846/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283736/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24661044 PubMed]

==R-IFE {{#subobject:19b4ea|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-IFE: '''<u>R</u>'''ituximab, '''<u>IF</u>'''osfamide, '''<u>E</u>'''toposide
===Regimen {{#subobject:116aa7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13036/full Pardal et al. 2014 (GELTAMO-2006)]
|style="background-color:#91cf61"|Phase II
|-
|}
''These were patients with PET-positive disease at interim assessment.''
====Preceding treatment====
*[[#R-MegaCHOP|R-MegaCHOP]] x 3
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Ifosfamide (Ifex)]] 3,333 mg/m<sup>2</sup>/day IV continuous infusion over 72 hours, started on day 1 (total dose per cycle: 10,000 mg/m<sup>2</sup>)
*[[Etoposide (Vepesid)]] 150 mg/m<sup>2</sup> IV over 12 hours once per day on days 1 to 3

====Supportive medications====
*[[Mesna (Mesnex)]] given after R-IFE; details not supplied in manuscript
*[[Pegfilgrastim (Neulasta)]] given after each cycle

'''2 cycles (duration not specified)'''
====Subsequent treatment====
*Responders: [[#BEAM.2C_then_auto_HSCT|BEAM with autologous hematopoietic stem cell transplant]]

===References===
# '''GELTAMO-2006:''' Pardal E, Coronado M, Martín A, Grande C, Marín-Niebla A, Panizo C, Bello JL, Conde E, Hernández MT, Arranz R, Bargay J, González-Barca E, Pérez-Ceballos E, Montes-Moreno S, Caballero MD. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial. Br J Haematol. 2014 Nov;167(3):327-36. Epub 2014 Jul 28. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13036/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25066542 PubMed]

==R-NIMP {{#subobject:fb6d8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-NIMP: '''<u>R</u>'''ituximab, '''<u>N</u>'''avelbine (Vinorelbine), '''<u>I</u>'''fosfamide, '''<u>M</u>'''itoxantrone, '''<u>P</u>'''rednisone

===Regimen {{#subobject:8fecee|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.12379/full Gyan et al. 2013]
|style="background-color:#91cf61"|Phase II
|68% (95%CI: 53–79)
|-
|}
''BSA was capped at 2 for all dose calculations.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Vinorelbine (Navelbine)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15
*[[Ifosfamide (Ifex)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 5000 mg/m<sup>2</sup>)
*[[Mitoxantrone (Novantrone)]] 10 mg/m<sup>2</sup> IV once on day 1
*[[Prednisone (Sterapred)]] 1 mg/kg (route not specified) once per day on days 1 to 5

====Supportive medications====
*[[Mesna (Mesnex)]] given with [[Ifosfamide (Ifex)]] "at the same dose"; schedule not specified in the paper
*[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 7 was recommended
*Epoietin alpha support was recommended for hemoglobin less than 10 g/dL

'''28-day cycle for 3 cycles'''

''Responders were recommended to undergo 3 additional cycles of R-NIMP (if transplant ineligible) or high-dose chemotherapy with autologous hematopoietic stem cell transplant (regimen not specified).''

===References===
# Gyan E, Damotte D, Courby S, Sénécal D, Quittet P, Schmidt-Tanguy A, Banos A, Le Gouill S, Lamy T, Fontan J, Maisonneuve H, Alexis M, Dreyfus F, Tournilhac O, Laribi K, Solal-Céligny P, Arakelyan N, Cartron G, Gressin R; GOELAMS Group. High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study. Br J Haematol. 2013 Jul;162(2):240-9. Epub 2013 May 21. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.12379/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23692641 PubMed]

=Consolidation after salvage therapy=

==BEAC, then auto HSCT {{#subobject:0341c3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BEAC: '''<u>R</u>'''ituximab, '''<u>B</u>'''iCNU (Carmustine), '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>C</u>'''yclophosphamide
===Regimen {{#subobject:61a3cd|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/77/7/1587.long Philip et al. 1991 (Parma)]
| style="background-color:#91cf61" |Prospective pilot
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199512073332305 Philip et al. 1995 (PARMA)]
|style="background-color:#1a9851"|Phase III (E)
|[[#DHAP|DHAP x4]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Preceding treatment====
[[Diffuse_large_B-cell_lymphoma_-_historical#DHAP|DHAP x 2]]; radiation was also given to sites of bulky disease (>5cm)
{{#lst:Autologous HSCT conditioning regimens|728b1c}}
===References===
# Philip T, Chauvin F, Armitage J, Bron D, Hagenbeek A, Biron P, Spitzer G, Velasquez W, Weisenburger DD, Fernandez-Ranada J, Somers R, Rizzoli V, Harousseau JL, Sotto JJ, Cahn JY, Guilhot F, Biggs J, Sonneveld P, Misset JL, Manna A, Jagannath S, Guglielmi C, Chevreau C, Delmer A, Santini G, Coiffier B. Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood. 1991 Apr 1;77(7):1587-92. [http://www.bloodjournal.org/content/77/7/1587.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2009374 PubMed]
# '''PARMA:''' Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, Coiffier B, Biron P, Mandelli F, Chauvin F. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995 Dec 7;333(23):1540-5. [https://www.nejm.org/doi/full/10.1056/NEJM199512073332305 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7477169 PubMed]

==BEAM, then allo HSCT {{#subobject:bda306|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BEAM: '''<u>B</u>'''iCNU (Carmustine), '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan
===Regimen {{#subobject:a8d4a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/10/5/527.long Przepiorka et al. 1999]
| style="background-color:#91cf61" |Phase II
|-
|}
{{#lst:Allogeneic HSCT|a8d4a}}
===References===
# Przepiorka D, van Besien K, Khouri I, Hagemeister F, Samuels B, Folloder J, Ueno NT, Molldrem J, Mehra R, Körbling M, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, Andersson B, Anderlini P, Champlin R. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999 May;10(5):527-32. [http://annonc.oxfordjournals.org/content/10/5/527.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10416001 PubMed]

==BEAM, then auto HSCT {{#subobject:0304c6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BEAM: '''<u>R</u>'''ituximab, '''<u>B</u>'''iCNU (Carmustine), '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan

===Variant #1 {{#subobject:445dc0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.27418/full Shimoni et al. 2012]
| style="background-color:#1a9851" |Randomized Phase II (C)
|[[#Z-BEAM.2C_then_auto_HSCT_2|Z-BEAM]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13036/full Pardal et al. 2014 (GELTAMO-2006)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/suppl/10.1200/JCO.2016.69.0198 van Imhoff et al. 2016 (ORCHARRD)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
====Preceding treatment====
*GELTAMO-2006: [[#R-MegaCHOP|R-MegaCHOP]] x 3, then [[#R-IFE_2|R-IFE]] x 2
*ORCHARRD: [[#O-DHAP|O-DHAP]] x 3 versus [[#R-DHAP|R-DHAP]] x 3
{{#lst:Autologous HSCT|fa5ca4}}
'''Stem cells reinfused on day 0'''

===Variant #2 {{#subobject:445dc0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/111/2/537.long Vellenga et al. 2008 (HOVON-44)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664033/ Gisselbrecht et al. 2010 (CORAL)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*HOVON-44: DHAP/VIM versus [[#R-DHAP.2FR-VIM|R-DHAP/R-VIM]]
*CORAL: [[#R-ICE|R-ICE]] x 3 versus [[#R-DHAP|R-DHAP]] x 3
{{#lst:Autologous HSCT|c92668}}
'''Stem cells reinfused on day 0'''

====Subsequent treatment==== 
*CORAL: [[#Rituximab_monotherapy_2|Rituximab maintenance]] versus [[#Observation_2|observation]]

===Variant #3, 300/100q12/200/140 {{#subobject:76416d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM198706113162401 Philip et al. 1987]
|style="background-color:#91cf61"|Non-randomized
|-
|}
{{#lst:Autologous HSCT|76416d}}
===References===
# Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, Colombat P, Goldstone AH, Gorin NC, Flesh M, Laporte JP, Maraninchi D, Pico J, Bosly A, Anderson C, Schots R, Biron P, Cabanillas F, Dicke K. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med. 1987 Jun 11;316(24):1493-8. [https://www.nejm.org/doi/full/10.1056/NEJM198706113162401 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/3295541 PubMed]
# '''HOVON-44:''' Vellenga E, van Putten WL, van 't Veer MB, Zijlstra JM, Fibbe WE, van Oers MH, Verdonck LF, Wijermans PW, van Imhoff GW, Lugtenburg PJ, Huijgens PC. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood. 2008 Jan 15;111(2):537-43. [http://www.bloodjournal.org/content/111/2/537.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17971487 PubMed]
<!--
Presented at the 45th Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2009, Orlando, FL, and at the 51st Annual Meeting of the American Society of Hematology, December 5-8, 2009, New Orleans, LA. -->
# '''CORAL:''' Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH, Schmitz N. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010 Sep 20;28(27):4184-90. Epub 2010 Jul 26. Erratum in: J Clin Oncol. 2012 May 20;30(15):1896. [http://jco.ascopubs.org/content/28/27/4184.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664033/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20660832 PubMed]
# Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R, Patachenko P, Avigdor A, Zwas T, Nagler A. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer. 2012 Oct 1;118(19):4706-14. Epub 2012 Jan 17. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.27418/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22252613 PubMed]
# '''GELTAMO-2006:''' Pardal E, Coronado M, Martín A, Grande C, Marín-Niebla A, Panizo C, Bello JL, Conde E, Hernández MT, Arranz R, Bargay J, González-Barca E, Pérez-Ceballos E, Montes-Moreno S, Caballero MD. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial. Br J Haematol. 2014 Nov;167(3):327-36. Epub 2014 Jul 28. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13036/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25066542 PubMed]
# '''ORCHARRD:''' van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, Kim W, Hong X, Goerloev JS, Davies A, Barrigón MD, Ogura M, Leppä S, Fennessy M, Liao Q, van der Holt B, Lisby S, Hagenbeek A. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J Clin Oncol. 2017 Feb 10;35(5):544-51. Epub 2016 Dec 28. [http://ascopubs.org/doi/suppl/10.1200/JCO.2016.69.0198 link to original article] [http://ascopubs.org/doi/suppl/10.1200/JCO.2016.69.0198/suppl_file/ds_2016.690198.pdf link to data supplement] '''verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/28029326 PubMed]

==BeEAM, then auto HSCT {{#subobject:dee72f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BeEAM: '''<u>Be</u>'''ndamustine, '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan
===Regimen {{#subobject:81ff2e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/118/12/3419.long Visani et al. 2011]
| style="background-color:#ffffbe" |Phase I/II, <20 pts in this subgroup
|-
|}
{{#lst:Autologous HSCT|81ff2e}}
===References===
# Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Giardini C, Falcioni S, Cuberli F, Gobbi M, Sarina B, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Isidori A. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011 Sep 22;118(12):3419-25. Epub 2011 Aug 3. [http://www.bloodjournal.org/content/118/12/3419.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21816830 PubMed]

==CBV, then auto HSCT {{#subobject:935235|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CBV: '''<u>C</u>'''yclophosphamide, '''<u>B</u>'''iCNU (Carmustine), '''<u>V</u>'''P-16 (Etoposide)
===Regimen {{#subobject:35a696|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/16/1/48.long Stiff et al. 1998]
| style="background-color:#91cf61" |Phase II
|-
|}
{{#lst:Autologous HSCT|35a696}}
===References===
# Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, Blume KG, LeBlanc M, Fisher RI. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial. J Clin Oncol. 1998 Jan;16(1):48-55. [http://jco.ascopubs.org/content/16/1/48.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9440722 PubMed]

==Cyclophosphamide & TBI, then auto HSCT {{#subobject:0a4915|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Cy/TBI: '''<u>Cy</u>'''clophosphamide & '''<u>T</u>'''otal '''<u>B</u>'''ody '''<u>I</u>'''rradiation
===Regimen {{#subobject:a2b2d3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM198406143102403 Phillips et al. 1984]
| style="background-color:#91cf61" |Non-randomized
|-
|}
{{#lst:Autologous HSCT|a2b2d3}}
===References===
# Phillips GL, Herzig RH, Lazarus HM, Fay JW, Wolff SN, Mill WB, Lin H, Thomas PR, Glasgow GP, Shina DC, Herzig GP. Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation, and transplantation of cryopreserved autologous marrow. N Engl J Med. 1984 Jun 14;310(24):1557-61. [https://www.nejm.org/doi/full/10.1056/NEJM198406143102403 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/6374452 PubMed]

==FEAM, then auto HSCT {{#subobject:0aac6f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FEAM: '''<u>F</u>'''otemustine, '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan
===Regimen {{#subobject:74d43c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nature.com/bmt/journal/v45/n7/full/bmt2009318a.html Musso et al. 2009]
| style="background-color:#91cf61" |Phase II
|-
|}
{{#lst:Autologous HSCT|74d43c}}
===References===
# Musso M, Scalone R, Marcacci G, Lanza F, Di Renzo N, Cascavilla N, Di Bartolomeo P, Crescimanno A, Perrone T, Pinto A. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant. 2010 Jul;45(7):1147-53. Epub 2009 Nov 9. [https://www.nature.com/bmt/journal/v45/n7/full/bmt2009318a.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19898504 PubMed]

==FluBuCy, then allo HSCT {{#subobject:84acb0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FluBuCy: '''<u>Flu</u>'''darabine, '''<u>Bu</u>'''sulfan, '''<u>Cy</u>'''clophosphamide
===Regimen {{#subobject:bfe434|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70161-5/fulltext Glass et al. 2014 (DSHNHL R3)]
| style="background-color:#91cf61" |Phase II
|-
|}
{{#lst:Allogeneic HSCT|bfe434}}
===References===
<!-- # Glass B, rabbits Kamp J, Wulf G, Dreger P, Pfreundschuh M, Gramatzki M Silling G, Wilhelm C, Zeis M, Görlitz A, Pfeiffer S, Hilgers R, Truemper L, Schmitz N. High-dose chemotherapy Followed by allogeneic stem cell transplantation in relapsed and refractory high-risk aggressive non-Hodgkin's lymphoma: Results of a prospective study of the German high-grade non-Hodgkin's lymphoma study group. J Clin Oncol 30, 2012 (suppl; abstr 8004) -->
# '''DSHNHL R3:''' Glass B, Hasenkamp J, Wulf G, Dreger P, Pfreundschuh M, Gramatzki M, Silling G, Wilhelm C, Zeis M, Görlitz A, Pfeiffer S, Hilgers R, Truemper L, Schmitz N; on behalf of the German High-Grade Lymphoma Study Group. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol. 2014 Jun;15(7):757-66. Epub 2014 May 11. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70161-5/fulltext link to original article] [http://www.dshnhl.org/app/download/9495510598/Studienprotokoll+DSHNHL+alloFBC+final+vollst.pdf link to original protocol (in German)] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24827808 PubMed]

==Fludarabine, Busulfan, ATG, Ibritumomab tiuxetan, then allo HSCT {{#subobject:68bee2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:822e5a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/26/1/193.full Bouabdallah et al. 2015]
| style="background-color:#91cf61" |Phase II
|-
|}
{{#lst:Allogeneic HSCT|822e5a}}
===References===
# Bouabdallah K, Furst S, Asselineau J, Chevalier P, Tournilhac O, Ceballos P, Vigouroux S, Tabrizi R, Doussau A, Bouabdallah R, Mohty M, Le Gouill S, Blaise D, Milpied N. 90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas. Ann Oncol. 2015 Jan;26(1):193-8. Epub 2014 Oct 30. [http://annonc.oxfordjournals.org/content/26/1/193.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25361987 PubMed]

==LEED, then auto HSCT {{#subobject:bf49e4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
LEED: '''<u>L</u>'''-PAM (Melphalan), '''<u>E</u>'''ndoxan (Cyclophosphamide), '''<u>E</u>'''toposide, '''<u>D</u>'''examethasone
===Regimen {{#subobject:a8ec2f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/suppl/10.1200/JCO.2016.69.0198 van Imhoff et al. 2016 (ORCHARRD)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#O-DHAP|O-DHAP]] x 3 versus [[#R-DHAP|R-DHAP]] x 3
{{#lst:Autologous HSCT conditioning regimens|47e3df}}
'''Stem cells reinfused on day 0'''

===References===
# '''ORCHARRD:''' van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, Kim W, Hong X, Goerloev JS, Davies A, Barrigón MD, Ogura M, Leppä S, Fennessy M, Liao Q, van der Holt B, Lisby S, Hagenbeek A. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: The ORCHARRD study. J Clin Oncol. 2017 Feb 10;35(5):544-51. Epub 2016 Dec 28. [http://ascopubs.org/doi/suppl/10.1200/JCO.2016.69.0198 link to original article] [http://ascopubs.org/doi/suppl/10.1200/JCO.2016.69.0198/suppl_file/ds_2016.690198.pdf link to data supplement] '''verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/28029326 PubMed]

==R-BEAM, then auto HSCT {{#subobject:8b88db|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-BEAM: '''<u>R</u>'''ituximab, '''<u>B</u>'''iCNU (Carmustine), '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan
===Variant #1, 750/300/800/800/140 {{#subobject:9131e1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2012.45.9453 Vose et al. 2013 (BMT CTN 0401)]
| style="background-color:#1a9851" |Phase III (C)
|B-BEAM
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
{{#lst:Autologous HSCT|9131e1}}

===Variant #2, 750/300/1600/3200/140 {{#subobject:77f5a0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13234/full Kirschey et al. 2014]
| style="background-color:#91cf61" |Phase II
|-
|}
''A minimum number of 2 × 10<sup>6</sup>/kg bw CD34-positive cells were required to proceed.''
====Preceding treatment====
*[[#R-DexaBEAM|R-DexaBEAM]] x 2
{{#lst:Autologous HSCT conditioning regimens|77f5a0}}
===References===
# '''BMT CTN 0401:''' Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, Stadtmauer EA, Mineshi S, Ambinder R, Fenske T, Horowitz M, Fisher R, Tomblyn M. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol. 2013 May 1;31(13):1662-8. Epub 2013 Mar 11. [http://ascopubs.org/doi/full/10.1200/JCO.2012.45.9453 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3635682/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23478060 PubMed]
# Kirschey S, Flohr T, Wolf HH, Frickhofen N, Gramatzki M, Link H, Basara N, Peter N, Meyer RG, Schmitz N, Weidmann E, Banat A, Schulz A, Kolbe K, Derigs G, Theobald M, Hess G. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study. Br J Haematol. 2015 Mar;168(6):824-34. Epub 2014 Dec 28. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13234/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25546611 PubMed]

==R-TBI/Cy, then auto HSCT {{#subobject:38a16a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-TBI/Cy: '''<u>R</u>'''ituximab, '''<u>T</u>'''otal, '''<u>B</u>'''ody, '''<u>I</u>'''rradiation, '''<u>Cy</u>'''clophosphamide
===Regimen {{#subobject:1b28ce|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13234/full Kirschey et al. 2014]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#R-DexaBEAM|R-DexaBEAM]] x 2
{{#lst:Autologous HSCT conditioning regimens|785614}}
'''Stem cells reinfused on day 0'''
===References===
# Kirschey S, Flohr T, Wolf HH, Frickhofen N, Gramatzki M, Link H, Basara N, Peter N, Meyer RG, Schmitz N, Weidmann E, Banat A, Schulz A, Kolbe K, Derigs G, Theobald M, Hess G. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study. Br J Haematol. 2015 Mar;168(6):824-34. Epub 2014 Dec 28. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13234/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25546611 PubMed]

==Z-BEAM, then auto HSCT {{#subobject:a6ae5d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Z-BEAM: '''<u>Z</u>'''evalin (Ibritumomab tiuxetan), '''<u>B</u>'''iCNU (Carmustine), '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan
===Regimen {{#subobject:df0b80|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.exphem.org/article/S0301-472X(07)00050-1/fulltext Shimoni et al. 2007]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.27418/full Shimoni et al. 2012]
| style="background-color:#1a9851" |Randomized Phase II (E)
|[[#BEAM.2C_then_auto_HSCT|BEAM]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943314/ Briones et al. 2013]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
''Patients in Shimoni et al. 2012 had primary induction failure or were chemosensitive to salvage therapy. Patients in Briones et al. 2013 had primary induction failure or were refractory to salvage therapy.''
{{#lst:Autologous HSCT|9aeafe}}

===References===
# Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Exp Hematol. 2007 Apr;35(4):534-40. [http://www.exphem.org/article/S0301-472X(07)00050-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17379063 PubMed]
# Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R, Patachenko P, Avigdor A, Zwas T, Nagler A. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer. 2012 Oct 1;118(19):4706-14. Epub 2012 Jan 17. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.27418/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22252613 PubMed]
# Briones J, Novelli S, García-Marco JA, Tomás JF, Bernal T, Grande C, Canales MA, Torres A, Moraleda JM, Panizo C, Jarque I, Palmero F, Hernsández M, González-Barca E, López D, Caballero D. Autologous stem cell transplantation after conditioning with Yttrium-90 ibritumomab tiuxetan plus beam in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica. 2014 Mar;99(3):505-10. Epub 2013 Oct 25. [http://www.haematologica.org/content/99/3/505.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943314/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24162789 PubMed]

=Maintenance after salvage therapy=
==Lenalidomide monotherapy {{#subobject:e4284f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 25 mg 21/28, indefinite {{#subobject:ac6517|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30016-9/fulltext Ferreri et al. 2017]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*Rituximab-containing salvage chemotherapy
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21

'''28-day cycles'''

===Variant #2, 25 mg 21/28 for 12 months {{#subobject:baf27c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283736/ Feldman et al. 2014]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#BEAM.2C_then_auto_HSCT|BEAM with autologous hematopoietic stem cell transplant (details not described)]]
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21

'''28-day cycles for up to 12 months'''

===References===
# Feldman T, Mato AR, Chow KF, Protomastro EA, Yannotti KM, Bhattacharyya P, Yang X, Donato ML, Rowley SD, Carini C, Valentinetti M, Smith J, Gadaleta G, Bejot C, Stives S, Timberg M, Kdiry S, Pecora AL, Beaven AW, Goy A. Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma. Br J Haematol. 2014 Jul;166(1):77-83. Epub 2014 Mar 25. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.12846/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283736/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24661044 PubMed]
# Ferreri AJ, Sassone M, Zaja F, Re A, Spina M, di Rocco A, Fabbri A, Stelitano C, Frezzato M, Rusconi C, Zambello R, Couto S, Ren Y, Arcari A, Bertoldero G, Nonis A, Scarfò L, Calimeri T, Cecchetti C, Chiozzotto M, Govi S, Ponzoni M. Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. Lancet Haematol. 2017 Mar;4(3):e137-e146. Epub 2017 Feb 17. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30016-9/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28219694 PubMed]

==Observation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2288718/ Thompson et al. 2008 (SWOG 9438)]
|style="background-color:#1a9851"|Phase III (C)
|IL-2
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682835/ Furman et al. 2011 (CALGB 9254)]
|style="background-color:#1a9851"|Phase III (C)
|Anti-B4-bR
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664033/ Gisselbrecht et al. 2010 (CORAL)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Rituximab_monotherapy_2|Rituximab]]
|style="background-color:#ffffbf"|Seems not superior (*)
|-
|}
''No further treatment. Reported efficacy for CORAL is based on the 2012 update.''
====Preceding treatment====
*SWOG 9438: Cyclophosphamide, Etoposide, TBI with autologous hematopoietic stem cell transplant
*CORAL: [[#BEAM.2C_then_auto_HSCT|BEAM with autologous hematopoietic stem cell transplant]]

===References===
# '''SWOG 9438:''' Thompson JA, Fisher RI, Leblanc M, Forman SJ, Press OW, Unger JM, Nademanee AP, Stiff PJ, Petersdorf SH, Fefer A. Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). Blood. 2008 Apr 15;111(8):4048-54. Epub 2008 Feb 6. [http://www.bloodjournal.org/content/111/8/4048.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2288718/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18256325 PubMed]
# '''CALGB 9254:''' Furman RR, Grossbard ML, Johnson JL, Pecora AL, Cassileth PA, Jung SH, Peterson BA, Nadler LM, Freedman A, Bayer RL, Bartlett NL, Hurd DD, Cheson BD; Cancer Leukemia Group B; Eastern Cooperative Oncology Group. A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leuk Lymphoma. 2011 Apr;52(4):587-96. Epub 2011 Jan 28. [https://www.tandfonline.com/doi/abs/10.3109/10428194.2010.543714 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682835/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21275630 PubMed]
<!-- Presented at the 45th Annual Meeting of the American Society of Clinical Oncology, June 4-6, 2011, Chicago, IL. -->
# '''CORAL:''' Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH, Schmitz N. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010 Sep 20;28(27):4184-90. Epub 2010 Jul 26. Erratum in: J Clin Oncol. 2012 May 20;30(15):1896. [http://jco.ascopubs.org/content/28/27/4184.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664033/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20660832 PubMed]
## '''Update:''' Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Milpied NJ, Radford J, Ketterer N, Shpilberg O, Dührsen U, Hagberg H, Ma DD, Viardot A, Lowenthal R, Brière J, Salles G, Moskowitz CH, Glass B. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol. 2012 Dec 20;30(36):4462-9. Epub 2012 Oct 22. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.12846/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646314/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23091101 PubMed]

==Rituximab monotherapy {{#subobject:4a4553|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:7bef48|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664033/ Gisselbrecht et al. 2010 (CORAL)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Observation_2|Observation]]
|style="background-color:#ffffbf"|Seems not superior (*)
|-
|}
''Treatment begins on day +28. Reported efficacy is based on the 2012 update.''
====Preceding treatment====
*[[#BEAM.2C_then_auto_HSCT|BEAM with autologous hematopoietic stem cell transplant]]
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once every 8 weeks

'''1 year course'''

===References===
<!-- Presented at the 45th Annual Meeting of the American Society of Clinical Oncology, June 4-6, 2011, Chicago, IL. -->
# '''CORAL:''' Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH, Schmitz N. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010 Sep 20;28(27):4184-90. Epub 2010 Jul 26. Erratum in: J Clin Oncol. 2012 May 20;30(15):1896. [http://jco.ascopubs.org/content/28/27/4184.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664033/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20660832 PubMed]
## '''Update:''' Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Milpied NJ, Radford J, Ketterer N, Shpilberg O, Dührsen U, Hagberg H, Ma DD, Viardot A, Lowenthal R, Brière J, Salles G, Moskowitz CH, Glass B. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol. 2012 Dec 20;30(36):4462-9. Epub 2012 Oct 22. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.12846/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646314/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23091101 PubMed]

=Relapsed or refractory, further lines of therapy=
''Note: these are regimens that are generally given with non-curative intent. However, some of these regimens, such as CAR-T therapy, can function as a bridge to consolidation with one of the salvage consolidation regimens, above.''
==Axicabtagene ciloleucel monotherapy {{#subobject:78231d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e3e516|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363293/ Locke et al. 2017 (ZUMA-1)]
| style="background-color:#ffffbe" |Phase 1
|
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1707447 Nellapu et al. 2017 (ZUMA-1)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#e0ecf4" |ORR: 82%
|-
|}
{{#lst:Autologous HSCT conditioning regimens|b295a4}}
'''Treatment followed by:'''
====Cellular therapy====
*[[Axicabtagene ciloleucel (Yescarta)]] target dose of 2 × 10<sup>6</sup> CAR T cells/kg IV once on day 0

====Supportive medications====
*[[Acetaminophen (Tylenol)]] 650 mg PO once approximately 60 minutes prior to infusion
*[[Diphenhydramine (Benadryl)]] 12.5 mg IV or PO once approximately 60 minutes prior to infusion
 
'''One course; patients with initial response and disease progression at least 3 months later could be retreated'''

===References===
# '''Phase 1:''' Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go WY. Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017 Jan 4;25(1):285-295. Epub 2017 Jan 4. [http://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)45375-X link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363293/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28129122 PubMed]
# '''ZUMA-1:''' Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017 Dec 28;377(26):2531-2544. Epub 2017 Dec 10. [https://www.nejm.org/doi/full/10.1056/NEJMoa1707447 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29226797 PubMed]

==Bendamustine monotherapy {{#subobject:78231d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:e3e516|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/13/8/1285/143237 Weidmann et al. 2002]
|style="background-color:#ffffbe"|Phase II, <20 pts
|44%
|-
|}
====Chemotherapy====
*[[Bendamustine]] 120 mg/m<sup>2</sup> IV once per day on days 1 & 2

'''21-day cycle for up to 6 cycles'''

===References===
# Weidmann E, Kim SZ, Rost A, Schuppert H, Seipelt G, Hoelzer D, Mitrou PS. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002 Aug;13(8):1285-9. [https://academic.oup.com/annonc/article/13/8/1285/143237 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12181253 PubMed]

==Blinatumomab monotherapy {{#subobject:4c5004|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:94f800|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4797019/ Viardot et al. 2016]
|style="background-color:#91cf61"|Phase II
|-
|}

''Two dosing schemas were evaluated; this is the preferred dosing regimen, per the authors.''
====Chemotherapy====
*[[Blinatumomab (Blincyto)]] as follows:
**9 mcg/day IV continuous infusion during week 1, then
**28 mcg/day IV continuous infusion during week 2, then
**112 mcg/day IV continuous infusion for remainder of the 8-week course

====Supportive medications====
*[[Dexamethasone (Decadron)]] 20 mg PO 6 to 12 hours before infusion start and dose increases, 20 mg PO 1 hour before infusion start and dose increases, and 8 mg PO three times per day for 2 days following infusion start and dose increases
**Patients with neurologic symptoms or cytokine release syndrome received 8 mg IV or PO Q8H for up to 3 days, with a subsequent taper over 4 days

'''8-week course'''

''Responders could receive a 4-week consolidation cycle after a 4-week treatment-free period. Patients relapsing within 2 years of treatment could receive another 8-week course.''

===References===
<!--Presented in abstract form at the 55th annual meeting (New Orleans, LA, December 2013) and the 56th annual meeting (San Francisco, CA, December 2014) of the American Society of Hematology; the 2015 annual meeting of the American Society of Clinical Oncology (Chicago, IL, June 2015); and the 13th International Conference on Malignant Lymphoma (Lugano, Switzerland, June 2015). -->
# Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N, Zettl F, Libicher M, Sayehli C, Stieglmaier J, Zhang A, Nagorsen D, Bargou RC. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016 Mar 17;127(11):1410-6. Epub 2016 Jan 11. [http://www.bloodjournal.org/content/127/11/1410.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4797019/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26755709 PubMed]

==BR {{#subobject:1bb486|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
BR: '''<u>B</u>'''endamustine, '''<u>R</u>'''ituximab

===Regimen {{#subobject:87e6f7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/31/17/2103.full Ohmachi et al. 2013]
|style="background-color:#91cf61"|Phase II
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918114/ Vacirca et al. 2013]
|style="background-color:#91cf61"|Phase II
|-
|}
''Note: Bendamustine was given on days 2 & 3 by Ohmachi et al. and on days 1 & 2 by Vacirca et al.''
====Chemotherapy====
*[[Bendamustine]] 120 mg/m<sup>2</sup> IV once per day on days 1 & 2 OR on days 2 & 3
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]] was recommended
*[[Acyclovir (Zovirax)]] was recommended

'''21-day cycle for up to 6 cycles'''

===References===
<!-- Presented at the 48th Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2012, Chicago, IL. -->
# Ohmachi K, Niitsu N, Uchida T, Kim SJ, Ando K, Takahashi N, Takahashi N, Uike N, Eom HS, Chae YS, Terauchi T, Tateishi U, Tatsumi M, Kim WS, Tobinai K, Suh C, Ogura M. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2013 Jun 10;31(17):2103-9. Epub 2013 May 6. [http://jco.ascopubs.org/content/31/17/2103.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23650408 PubMed]
# Vacirca JL, Acs PI, Tabbara IA, Rosen PJ, Lee P, Lynam E. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Ann Hematol. 2014 Mar;93(3):403-9. Epub 2013 Aug 17. [http://link.springer.com/article/10.1007%2Fs00277-013-1879-x/fulltext.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918114/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23955074 PubMed]

==Brentuximab vedotin monotherapy {{#subobject:d4dff2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:965d6b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/125/9/1394 Jacobsen et al. 2015]
|style="background-color:#91cf61"|Phase II
|-
|[https://www.tandfonline.com/doi/full/10.1080/10428194.2016.1256481 Bartlett et al. 2016]
|style="background-color:#91cf61"|Phase II
|-
|}
''Bartlett et al. treated patients with undetectable CD30 by visual assessment using routine IHC. Jacobsen et al. treated patients with CD30+ non-Hodgkin lymphoma, as determined by IHC.''
====Chemotherapy====
*[[Brentuximab vedotin (Adcetris)]] 1.8 mg/kg IV over 30 minutes once on day 1

'''21-day cycles'''

===References===
<!-- '''Abstract:''' Nancy L. Bartlett, MD, Jeff P. Sharman, MD, Yasuhiro Oki, MD, Ranjana H. Advani, MD, Celeste M. Bello, MD, Jane N. Winter, MD, Yin Yang, MS, Dana A. Kennedy, PharmD and Eric D. Jacobsen, MD. A Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results In Patients With DLBCL and Other B-Cell Lymphomas. ASH Abstract 848. [https://ash.confex.com/ash/2013/webprogram/Paper59695.html link to abstract] -->
# Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, Spitzer G, Palanca-Wessels MC, Kennedy DA, Levine P, Yang J, Bartlett NL. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015 Feb 26;125(9):1394-402. Epub 2015 Jan 8. [http://www.bloodjournal.org/content/125/9/1394 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25573987 PubMed]
<!-- # '''Abstract:''' Nancy L. Bartlett, MD, Mitchell R. Smith, MD, Ranjana Advani, MD, Tatyana Feldman, MD, Kerry J. Savage, MD MSc, Maria Corinna Palanca-Wessels, MD, PhD and Tanya Siddiqi, MD. Brentuximab Vedotin Monotherapy in DLBCL Patients with Undetectable CD30: Preliminary Results from a Phase 2 Study. ASH Annual Meeting 2014 Abstract 629 [https://ash.confex.com/ash/2014/webprogram/Paper67042.html link to abstract] -->
# Bartlett NL, Smith MR, Siddiqi T, Advani RH, O'Connor OA, Sharman JP, Feldman T, Savage KJ, Shustov AR, Diefenbach CS, Oki Y, Palanca-Wessels MC, Uttarwar M, Li M, Yang J, Jacobsen ED. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Leuk Lymphoma. 2017 Jul;58(7):1607-1616. Epub 2016 Nov 20. [https://www.tandfonline.com/doi/full/10.1080/10428194.2016.1256481 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27868471 PubMed]

==Etoposide monotherapy {{#subobject:1ed00b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, IV (3 days/cycle) {{#subobject:7a80fc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://clincancerres.aacrjournals.org/content/23/15/4127.long Czuczman et al. 2017 (DLC-001)]
| style="background-color:#1a9851" |Phase II/III (C)
|[[#Lenalidomide_monotherapy_3|Lenalidomide]]
| style="background-color:#fee08b" |Might have inferior ORR
|-
|}
====Chemotherapy====
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 3

'''28-day cycle for up to 6 cycles'''

===Variant #2, IV (5 days/cycle) {{#subobject:1bece4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70212-7/fulltext Pettengell et al. 2012 (PIX301)]
|style="background-color:#91cf61"|Phase III, <20 pts in this arm (C)
|[[#Pixantrone_monotherapy|Pixantrone]]
|style="background-color:#fc8d59"|Seems to have inferior CR/CRu rate
|-
|[http://clincancerres.aacrjournals.org/content/23/15/4127.long Czuczman et al. 2017 (DLC-001)]
| style="background-color:#1a9851" |Phase II/III (C)
|[[#Lenalidomide_monotherapy_3|Lenalidomide]]
| style="background-color:#fee08b" |Might have inferior ORR
|-
|}
====Chemotherapy====
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 5

'''28-day cycle for up to 6 cycles'''

===Variant #3, PO (10 days/cycle) {{#subobject:c6531a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://clincancerres.aacrjournals.org/content/23/15/4127.long Czuczman et al. 2017 (DLC-001)]
| style="background-color:#1a9851" |Phase II/III (C)
|[[#Lenalidomide_monotherapy_3|Lenalidomide]]
| style="background-color:#fee08b" |Might have inferior ORR
|-
|}
====Chemotherapy====
*[[Etoposide (Vepesid)]] 50 mg/m<sup>2</sup> PO once per day on days 1 to 10

'''28-day cycle for up to 6 cycles'''

===Variant #4, PO (14 days/cycle) {{#subobject:f3bee1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://clincancerres.aacrjournals.org/content/23/15/4127.long Czuczman et al. 2017 (DLC-001)]
| style="background-color:#1a9851" |Phase II/III (C)
|[[#Lenalidomide_monotherapy_3|Lenalidomide]]
| style="background-color:#fee08b" |Might have inferior ORR
|-
|}
====Chemotherapy====
*[[Etoposide (Vepesid)]] 50 mg/m<sup>2</sup> PO once per day on days 1 to 14

'''28-day cycle for up to 6 cycles'''

===Variant #5, PO (21 days/cycle) {{#subobject:929913|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://link.springer.com/chapter/10.1007/978-3-642-78350-0_29 Hainsworth et al. 1992]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70212-7/fulltext Pettengell et al. 2012 (PIX301)]
|style="background-color:#91cf61"|Phase III, <20 pts in this arm (C)
|[[#Pixantrone_monotherapy|Pixantrone]]
|style="background-color:#fc8d59"|Seems to have inferior CR/CRu rate
|-
|[http://clincancerres.aacrjournals.org/content/23/15/4127.long Czuczman et al. 2017 (DLC-001)]
| style="background-color:#1a9851" |Phase II/III (C)
|[[#Lenalidomide_monotherapy_3|Lenalidomide]]
| style="background-color:#fee08b" |Might have inferior ORR
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Etoposide (Vepesid)]] 50 mg/m<sup>2</sup> PO once per day on days 1 to 21

'''28-day cycle for up to 6 cycles'''

===References===
# Hainsworth JD, Johnson DH, Greco FA. Chronic etoposide schedules in the treatment of non-Hodgkin's lymphoma. Semin Oncol. 1992 Dec;19(6 Suppl 14):13-8. [https://link.springer.com/chapter/10.1007/978-3-642-78350-0_29 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/1488651 PubMed]
# '''PIX301:''' Pettengell R, Coiffier B, Narayanan G, de Mendoza FH, Digumarti R, Gomez H, Zinzani PL, Schiller G, Rizzieri D, Boland G, Cernohous P, Wang L, Kuepfer C, Gorbatchevsky I, Singer JW. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2012 Jul;13(7):696-706. Epub 2012 May 30. Erratum in: Lancet Oncol. 2012 Jul;13(7):e285. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70212-7/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22652183 PubMed]
# '''DLC-001:''' Czuczman MS, Trněný M, Davies A, Rule S, Linton KM, Wagner-Johnston N, Gascoyne RD, Slack GW, Brousset P, Eberhard DA, Hernandez-Ilizaliturri FJ, Salles G, Witzig TE, Zinzani PL, Wright GW, Staudt LM, Yang Y, Williams PM, Lih CJ, Russo J, Thakurta A, Hagner P, Fustier P, Song D, Lewis ID. A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator's choice in patients with relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res. 2017 Aug 1;23(15):4127-4137. Epub 2017 Apr 5. [http://clincancerres.aacrjournals.org/content/23/15/4127.long link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/28381416 PubMed]

==Everolimus monotherapy {{#subobject:fb3cbd|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:9aafa|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049870/ Witzig et al. 2011]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Everolimus (Afinitor)]] 10 mg PO once per day on an empty stomach

====Supportive medications====
*"Patients could receive white blood cell growth factors, if neutropenia developed at physician's discretion. Erythropoietin treatment for anemia was permitted per standard guidelines."

'''28-day cycles'''

===References===
# Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN, Porrata LF, Ansell SM, Colgan JP, Jacobsen ED, Ghobrial IM, Habermann TM. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011 Feb;25(2):341-7. Epub 2010 Dec 7. [https://www.nature.com/leu/journal/v25/n2/full/leu2010226a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049870/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21135857 PubMed]

==Everolimus & Rituximab {{#subobject:bae86f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:9621eb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659994/ Barnes et al. 2013]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Everolimus (Afinitor)]] 5 mg PO once per day on days 1 to 14, increased to 10 mg PO once per day for the remainder of cycle 1 and thereafter, if tolerated
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per week x 4 weeks, then once on day 1 of cycle 2 onwards

'''28-day cycle for 6 cycles''' 
''Responders had the option of continuing everolimus for another 6 months.''

===References===
# Barnes JA, Jacobsen E, Feng Y, Freedman A, Hochberg EP, LaCasce AS, Armand P, Joyce R, Sohani AR, Rodig SJ, Neuberg D, Fisher DC, Abramson JS. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica. 2013 Apr;98(4):615-9. Epub 2012 Nov 9. [http://www.haematologica.org/content/98/4/615.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659994/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23144193 PubMed]

==Gemcitabine monotherapy {{#subobject:df3421|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, bi-weekly {{#subobject:5776e8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://clincancerres.aacrjournals.org/content/23/15/4127.long Czuczman et al. 2017 (DLC-001)]
| style="background-color:#1a9851" |Phase II/III (C)
|[[#Lenalidomide_monotherapy_3|Lenalidomide]]
| style="background-color:#fee08b" |Might have inferior ORR
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1 & 15

'''28-day cycle for up to 6 cycles'''

===Variant #2, 3 out of 4 weeks x 6 {{#subobject:853906|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://clincancerres.aacrjournals.org/content/23/15/4127.long Czuczman et al. 2017 (DLC-001)]
| style="background-color:#1a9851" |Phase II/III (C)
|[[#Lenalidomide_monotherapy_3|Lenalidomide]]
| style="background-color:#fee08b" |Might have inferior ORR
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycle for up to 6 cycles'''

===Variant #3, indefinite 3 out of 4 weeks {{#subobject:4d3a21|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/17/12/3786.long Fosså et al. 1999]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70212-7/fulltext Pettengell et al. 2012 (PIX301)]
|style="background-color:#91cf61"|Phase III, <20 pts in this arm (C)
|[[#Pixantrone_monotherapy|Pixantrone]]
|style="background-color:#fc8d59"|Seems to have inferior CR/CRu rate
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] as follows:
**Cycle 1: 1250 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15
**Fosså et al. 1999, subsequent cycles (if no hematologic or nonhematologic toxicities): Optional increase to 1500 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15

'''28-day cycle for up to 6 cycles (PIX301) or indefinitely (Fosså et al. 1999)'''

===References===
# Fosså A, Santoro A, Hiddemann W, Truemper L, Niederle N, Buksmaui S, Bonadonna G, Seeber S, Nowrousian MR. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1999 Dec;17(12):3786-92. [http://jco.ascopubs.org/content/17/12/3786.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10577850 PubMed]
# '''PIX301:''' Pettengell R, Coiffier B, Narayanan G, de Mendoza FH, Digumarti R, Gomez H, Zinzani PL, Schiller G, Rizzieri D, Boland G, Cernohous P, Wang L, Kuepfer C, Gorbatchevsky I, Singer JW. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2012 Jul;13(7):696-706. Epub 2012 May 30. Erratum in: Lancet Oncol. 2012 Jul;13(7):e285. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70212-7/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22652183 PubMed]
# '''DLC-001:''' Czuczman MS, Trněný M, Davies A, Rule S, Linton KM, Wagner-Johnston N, Gascoyne RD, Slack GW, Brousset P, Eberhard DA, Hernandez-Ilizaliturri FJ, Salles G, Witzig TE, Zinzani PL, Wright GW, Staudt LM, Yang Y, Williams PM, Lih CJ, Russo J, Thakurta A, Hagner P, Fustier P, Song D, Lewis ID. A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator's choice in patients with relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res. 2017 Aug 1;23(15):4127-4137. Epub 2017 Apr 5. [http://clincancerres.aacrjournals.org/content/23/15/4127.long link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/28381416 PubMed]

==GVD {{#subobject:7102c5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
GVD: '''<u>G</u>'''emcitabine, '''<u>V</u>'''inorelbine, '''<u>D</u>'''oxil (Doxorubicin liposomal)

===Regimen {{#subobject:b6f37c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://link.springer.com/article/10.1007%2Fs12032-012-0350-5 Bai et al. 2013]
|style="background-color:#ffffbe"|Retrospective
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 800 mg/m<sup>2</sup> IV once on day 1
*[[Vinorelbine (Navelbine)]] 15 mg/m<sup>2</sup> IV once on day 1
*[[Pegylated liposomal doxorubicin (Doxil)]] 20 mg/m<sup>2</sup> IV once on day 1

'''14-day cycles'''

===References===
# '''Retrospective:''' Bai B, Huang HQ, Cai QQ, Wang XX, Cai QC, Lin ZX, Gao Y, Xia Y, Bu Q, Guo Y. Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma. Med Oncol. 2013 Mar;30(1):350. Epub 2013 Jan 18. [http://link.springer.com/article/10.1007%2Fs12032-012-0350-5 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23329307 PubMed]

==Ibritumomab tiuxetan monotherapy {{#subobject:0b97a2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:5fd5b6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/110/1/54.long Morschhauser et al. 2007]
| style="background-color:#91cf61" |Phase II
|-
|}
''To be completed''
====Radioimmunotherapy====
*[[Ibritumomab tiuxetan (Zevalin)|Ibritumomab tiuxetan & Yttrium-90 (Zevalin) ]]
===References===
# Morschhauser F, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani PL, Rule S, Liberati AM, Milpied N, Hess G, Stein H, Kalmus J, Marcus R. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood. 2007 Jul 1;110(1):54-8. Epub 2007 Mar 26. [http://www.bloodjournal.org/content/110/1/54.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17387223 PubMed]

==Ibrutinib monotherapy {{#subobject:ba5ba9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:f4ee96|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nature.com/articles/nm.3884 Wilson et al. 2015 (PCYC-1106-CA)]
|style="background-color:#91cf61"|Phase II
|-
|}
''Clinically meaningful responses were observed in the ABC subtype, only. Further clinical trials are currently underway.''
====Chemotherapy====
*[[Ibrutinib (Imbruvica)]] 560 mg PO once per day

'''Continued indefinitely'''

===References===
<!-- # '''Abstract:''' Wyndham H. Wilson, MD, PhD, John F. Gerecitano, MD, PhD, Andre Goy, MD, Sven de Vos, MD, PhD, Vaishalee P. Kenkre, MD, Paul M. Barr, MD, Kristie A. Blum, MD, Andrei R. Shustov, MD, Ranjana H. Advani, MD, Jason Lih, PhD, Mickey Williams, PhD, Roland Schmitz, PhD, Yandan Yang, PhD, Stefania Pittaluga, MD, PhD, George Wright, PhD, Lori A. Kunkel, MD, Jesse McGreivy, MD, Sriram Balasubramanian, PhD, Mei Cheng, PhD, Davina Moussa, Joseph J. Buggy, PhD and Louis M. Staudt, MD, PhD. The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study. Blood 120, a686 (2012). [https://ash.confex.com/ash/2012/webprogram/Paper48270.html link to abstract] -->
# '''PCYC-1106-CA:''' Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015 Aug;21(8):922-6. Epub 2015 Jul 20. [https://www.nature.com/articles/nm.3884 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26193343 PubMed]

==Ifosfamide monotherapy {{#subobject:b9a669|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:cd9499|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/1743622 Case et al. 1991 (CALGB 8552)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70212-7/fulltext Pettengell et al. 2012 (PIX301)]
|style="background-color:#91cf61"|Phase III, <20 pts in this arm (C)
|[[#Pixantrone_monotherapy|Pixantrone]]
|style="background-color:#fc8d59"|Seems to have inferior CR/CRu rate
|-
|}
''Dose & schedule is as given in Pettengell et al. 2012. CALGB 8552 used a different dose & schedule. To our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Ifosfamide (Ifex)]] 3000 mg/m<sup>2</sup> IV once per day on days 1 & 2

====Supportive medications====
*[[Mesna (Mesnex)]] dose not specified

'''28-day cycle for up to 6 cycles'''

===References===
# '''CALGB 8552:''' Case DC Jr, Anderson J, Ervin TJ, Gottlieb A. Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B study 8552. Hematol Oncol. 1991 Jul-Oct;9(4-5):189-96. [https://www.ncbi.nlm.nih.gov/pubmed/1743622 PubMed]
# '''Review:''' Webb MS, Saltman DL, Connors JM, Goldie JH. A literature review of single agent treatment of multiply relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2002 May;43(5):975-82. Review. [https://www.tandfonline.com/doi/full/10.1080/10428190290021632 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12148908 PubMed]
# '''PIX301:''' Pettengell R, Coiffier B, Narayanan G, de Mendoza FH, Digumarti R, Gomez H, Zinzani PL, Schiller G, Rizzieri D, Boland G, Cernohous P, Wang L, Kuepfer C, Gorbatchevsky I, Singer JW. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2012 Jul;13(7):696-706. Epub 2012 May 30. Erratum in: Lancet Oncol. 2012 Jul;13(7):e285. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70212-7/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22652183 PubMed]

==Lenalidomide monotherapy {{#subobject:f5ca0d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, low dose {{#subobject:64ba17|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://clincancerres.aacrjournals.org/content/23/15/4127.long Czuczman et al. 2017 (DLC-001)]
| style="background-color:#1a9851" |Phase II/III (E)
|Investigator's choice of:<br> 1. [[#Etoposide_monotherapy|Etoposide]]<br> 2. [[#Gemcitabine_monotherapy|Gemcitabine]]<br> 3. [[#Oxaliplatin_monotherapy|Oxaliplatin]]<br> 4. [[#Rituximab_monotherapy_3|Rituximab]]
| style="background-color:#d9ef8b" |Might have superior ORR
|-
|}
''This dose was intended for patients with CrCl at least 30 but less than 60 mL/min/1.73m<sup>2</sup>.''
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 10 mg PO once per day on days 1 to 21

'''28-day cycles'''

===Variant #2, normal dose {{#subobject:7d5704|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/26/30/4952.long Wiernik et al. 2008 (NHL-002)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#8c6bb1" |ORR: 35%
|-
|[http://annonc.oxfordjournals.org/content/22/7/1622.long Witzig et al. 2011 (NHL-003)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#8c6bb1" |ORR: 28%
|-
|[http://clincancerres.aacrjournals.org/content/23/15/4127.long Czuczman et al. 2017 (DLC-001)]
| style="background-color:#1a9851" |Phase II/III (E)
|Investigator's choice of:<br> 1. [[#Etoposide_monotherapy|Etoposide]]<br> 2. [[#Gemcitabine_monotherapy|Gemcitabine]]<br> 3. [[#Oxaliplatin_monotherapy|Oxaliplatin]]<br> 4. [[#Rituximab_monotherapy_3|Rituximab]]
| style="background-color:#d9ef8b" |Might have superior ORR
|-
|}
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21

'''28-day cycles'''

===References===
# '''NHL-002:''' Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008 Oct 20;26(30):4952-7. Epub 2008 Jul 7. [http://jco.ascopubs.org/content/26/30/4952.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18606983 PubMed]
# '''NHL-003:''' Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, Bouabdallah R, Haioun C, Tilly H, Guo P, Pietronigro D, Ervin-Haynes AL, Czuczman MS. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011 Jul;22(7):1622-7. Epub 2011 Jan 12. [http://annonc.oxfordjournals.org/content/22/7/1622.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21228334 PubMed]
# '''DLC-001:''' Czuczman MS, Trněný M, Davies A, Rule S, Linton KM, Wagner-Johnston N, Gascoyne RD, Slack GW, Brousset P, Eberhard DA, Hernandez-Ilizaliturri FJ, Salles G, Witzig TE, Zinzani PL, Wright GW, Staudt LM, Yang Y, Williams PM, Lih CJ, Russo J, Thakurta A, Hagner P, Fustier P, Song D, Lewis ID. A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator's choice in patients with relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res. 2017 Aug 1;23(15):4127-4137. Epub 2017 Apr 5. [http://clincancerres.aacrjournals.org/content/23/15/4127.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28381416 PubMed]

==Lenalidomide & Rituximab {{#subobject:d4c873|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Variant #1 {{#subobject:a04708|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nature.com/leu/journal/v27/n9/full/leu201395a.html Wang et al. 2013]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 20 mg PO once per day on days 1 to 21
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per week on weeks 1 to 4 of cycle 1, only

'''28-day cycles'''

===Variant #2 {{#subobject:ad1aa9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(11)00023-1/abstract Zinzani et al. 2011]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 20 mg PO once per day on days 1 to 21
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days 1 & 21

'''28-day cycle for 4 cycles'''
====Subsequent treatment====
*SD or better: [[#Lenalidomide_monotherapy_2|Lenalidomide maintenance]]

===References===
# Zinzani PL, Pellegrini C, Gandolfi L, Stefoni V, Quirini F, Derenzini E, Broccoli A, Argnani L, Pileri S, Baccarani M. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):462-6. Epub 2011 May 4. [http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(11)00023-1/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21859554 PubMed]
## '''Update:''' Zinzani PL, Pellegrini C, Derenzini E, Argnani L, Pileri S. Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. Hematol Oncol. 2013 Dec;31(4):223-4. Epub 2013 Apr 26. [https://onlinelibrary.wiley.com/doi/10.1002/hon.2049/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23620452 PubMed]
# Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013 Sep;27(9):1902-9. Epub 2013 Apr 2. [https://www.nature.com/leu/journal/v27/n9/full/leu201395a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23545991 PubMed]

==Mitoxantrone monotherapy {{#subobject:6e3e59|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:b18da6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/3282421 Bajetta et al. 1988]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Mitoxantrone (Novantrone)]] 14 mg/m<sup>2</sup> IV over 30 minutes once on day 1

'''21-day cycles'''

===References===
# Bajetta E, Buzzoni R, Valagussa P, Bonadonna G. Mitoxantrone: an active agent in refractory non-Hodgkin's lymphomas. Am J Clin Oncol. 1988 Apr;11(2):100-3. '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/3282421 PubMed]
# '''PIX301:''' Pettengell R, Coiffier B, Narayanan G, de Mendoza FH, Digumarti R, Gomez H, Zinzani PL, Schiller G, Rizzieri D, Boland G, Cernohous P, Wang L, Kuepfer C, Gorbatchevsky I, Singer JW. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2012 Jul;13(7):696-706. Epub 2012 May 30. Erratum in: Lancet Oncol. 2012 Jul;13(7):e285. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70212-7/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22652183 PubMed]

==Obinutuzumab monotherapy {{#subobject:9d2627|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:7475e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.bloodjournal.org/content/119/22/5126.long Salles et al. 2012 (GAUGUIN)]
|style="background-color:#91cf61"|Phase I/II
|-
|}
''Note: this is the phase II dosing reported in Morschhauser et al. 2013.''
====Chemotherapy====
*[[Obinutuzumab (Gazyva)]] as follows:
**Cycle 1: 1600 mg (diluted to 10 mg/mL) IV once per day on days 1 & 8
**Cycles 2 to 8: 800 mg IV once on day 1
**Initial infusion rate is 50 mg/hour. In the absence of infusion-related reactions (IRRs), the rate is then increased by 50 mg/hour every 30 minutes, up to a maximum of 400 mg/hour.

====Supportive medications====
*[[Acetaminophen (Tylenol)]] or paracetamol 650 to 1000 mg PO once 30 minutes prior to [[Obinutuzumab (Gazyva)]]
*[[:Category:Antihistamines|"An antihistamine"]] 30 minutes prior to [[Obinutuzumab (Gazyva)]]; if there were no infusion-related reactions (IRRs) requiring medication or infusion interruption, antihistamine could be omitted for subsequent infusions
*Premedication with [[:Category:Steroids|corticosteroids]] recommended for patients at high risk of infusion-related reactions (IRRs)
*Use of [[:Category:Granulocyte colony-stimulating factors|G-CSF]] allowed for severe neutropenia
*Antibiotic prophylaxis allowed

'''21-day cycle for 8 cycles'''

===References===
# '''GAUGUIN:''' Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H, Bieska G, Asikanius E, Carlile D, Birkett J, Pisa P, Cartron G. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood. 2012 May 31;119(22):5126-32. Epub 2012 Mar 19. [http://www.bloodjournal.org/content/119/22/5126.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22431570 PubMed]
## '''Subgroup analysis:''' Morschhauser FA, Cartron G, Thieblemont C, Solal-Céligny P, Haioun C, Bouabdallah R, Feugier P, Bouabdallah K, Asikanius E, Lei G, Wenger M, Wassner-Fritsch E, Salles GA. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013 Aug 10;31(23):2912-9. Epub 2013 Jul 8. [http://jco.ascopubs.org/content/31/23/2912.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23835718 PubMed]
## '''Subgroup analysis:''' Salles GA, Morschhauser F, Solal-Céligny P, Thieblemont C, Lamy T, Tilly H, Gyan E, Lei G, Wenger M, Wassner-Fritsch E, Cartron G. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013 Aug 10;31(23):2920-6. Epub 2013 Jul 8. [http://jco.ascopubs.org/content/31/23/2920.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23835715 PubMed]
## '''Subgroup analysis:''' Cartron G, de Guibert S, Dilhuydy MS, Morschhauser F, Leblond V, Dupuis J, Mahe B, Bouabdallah R, Lei G, Wenger M, Wassner-Fritsch E, Hallek M. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood. 2014 Oct 2;124(14):2196-202. Epub 2014 Aug 20. [http://www.bloodjournal.org/content/124/14/2196 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25143487 PubMed]

==Ofatumumab monotherapy {{#subobject:5ba252|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:4f5008|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.12537/full Coiffier et al. 2013 (415 Study)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Ofatumumab (Arzerra)]] 300 mg IV on cycle 1 day 1, then 1000 mg IV once per week x 7 weeks (total of 8 doses)

====Supportive medications====
*[[Acetaminophen (Tylenol)]] (or equivalent) 1000 mg PO once 30 minutes to 2 hours prior to [[Ofatumumab (Arzerra)]]
*[[Cetirizine (Zyrtec)]] (or equivalent) 10 mg PO once 30 minutes to 2 hours prior to [[Ofatumumab (Arzerra)]]
*[[Prednisolone (Millipred)]] (or equivalent) 100 mg (route not specified) once 30 minutes to 2 hours prior to [[Ofatumumab (Arzerra)]] for first 2 infusions, only

'''One course'''

===References===
# Coiffier B, Radford J, Bosly A, Martinelli G, Verhoef G, Barca G, Davies A, Decaudin D, Gallop-Evans E, Padmanabhan-Iyer S, Van Eygen K, Wu KL, Gupta IV, Lin TS, Goldstein N, Jewell RC, Winter P, Lisby S; 415 study investigators. A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. Br J Haematol. 2013 Nov;163(3):334-42. Epub 2013 Aug 23. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.12537/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24032456 PubMed]

==Oxaliplatin monotherapy {{#subobject:308526|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 100 mg/m<sup>2</sup> {{#subobject:1fc8c3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/10/3/351.long Germann et al. 1999]
|style="background-color:#ffffbe"|Phase II, <20 pts in this subgroup
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70212-7/fulltext Pettengell et al. 2012 (PIX301)]
|style="background-color:#91cf61"|Phase III, <20 pts in this arm (C)
|[[#Pixantrone_monotherapy|Pixantrone]]
|style="background-color:#fc8d59"|Seems to have inferior CR/CRu rate
|-
|[http://clincancerres.aacrjournals.org/content/23/15/4127.long Czuczman et al. 2017 (DLC-001)]
| style="background-color:#1a9851" |Phase II/III (C)
|[[#Lenalidomide_monotherapy_3|Lenalidomide]]
| style="background-color:#fee08b" |Might have inferior ORR
|-
|}
''Germann et al. give a range of 100 to 130 mg/m<sup>2</sup>. To our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Oxaliplatin (Eloxatin)]] 100 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles (maximum of 6 cycles in PIX301 & DLC-001)'''

===Variant #2, 130 mg/m<sup>2</sup> {{#subobject:1bc18a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/10/3/351.long Germann et al. 1999]
|style="background-color:#ffffbe"|Phase II, <20 pts in this subgroup
| style="background-color:#d3d3d3" |
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.21219/full Oki et al. 2005]
|style="background-color:#91cf61"|Phase II
| style="background-color:#8c6bb1" |ORR: 27% (95% CI, 13–47)
|-
|}
''Germann et al. give a range of 100 to 130 mg/m<sup>2</sup>.''
====Chemotherapy====
*[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===References===
# Germann N, Brienza S, Rotarski M, Emile JF, Di Palma M, Musset M, Reynes M, Soulié P, Cvitkovic E, Misset JL. Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients. Ann Oncol. 1999 Mar;10(3):351-4. [http://annonc.oxfordjournals.org/content/10/3/351.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10355582 PubMed] 
# '''Review:''' Webb MS, Saltman DL, Connors JM, Goldie JH. A literature review of single agent treatment of multiply relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2002 May;43(5):975-82. Review. [https://www.tandfonline.com/doi/full/10.1080/10428190290021632 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12148908 PubMed]
# Oki Y, McLaughlin P, Pro B, Hagemeister FB, Bleyer A, Loyer E, Younes A. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer. 2005 Aug 15;104(4):781-7. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.21219/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15973667 PubMed]
# '''PIX301:''' Pettengell R, Coiffier B, Narayanan G, de Mendoza FH, Digumarti R, Gomez H, Zinzani PL, Schiller G, Rizzieri D, Boland G, Cernohous P, Wang L, Kuepfer C, Gorbatchevsky I, Singer JW. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2012 Jul;13(7):696-706. Epub 2012 May 30. Erratum in: Lancet Oncol. 2012 Jul;13(7):e285. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70212-7/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22652183 PubMed]
# '''DLC-001:''' Czuczman MS, Trněný M, Davies A, Rule S, Linton KM, Wagner-Johnston N, Gascoyne RD, Slack GW, Brousset P, Eberhard DA, Hernandez-Ilizaliturri FJ, Salles G, Witzig TE, Zinzani PL, Wright GW, Staudt LM, Yang Y, Williams PM, Lih CJ, Russo J, Thakurta A, Hagner P, Fustier P, Song D, Lewis ID. A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator's choice in patients with relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res. 2017 Aug 1;23(15):4127-4137. Epub 2017 Apr 5. [http://clincancerres.aacrjournals.org/content/23/15/4127.long link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/28381416 PubMed]

==Panobinostat monotherapy {{#subobject:6b0341|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:d71d7c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972610/ Assouline et al. 2016]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#Panobinostat_.26_Rituximab|Panobinostat & Rituximab]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: patients had a median of 2 prior treatments (range 1-8).''
====Chemotherapy====
*[[Panobinostat (Farydak)]] 30 mg PO three times per week (e.g., MWF)

'''21-day cycles'''

===References===
# Assouline SE, Nielsen TH, Yu S, Alcaide M, Chong L, MacDonald D, Tosikyan A, Kukreti V, Kezouh A, Petrogiannis-Haliotis T, Albuquerque M, Fornika D, Alamouti S, Froment R, Greenwood CM, Oros KK, Camglioglu E, Sharma A, Christodoulopoulos R, Rousseau C, Johnson N, Crump M, Morin RD, Mann KK. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood. 2016 Jul 14;128(2):185-94. Epub 2016 May 10. [http://www.bloodjournal.org/content/128/2/185.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972610/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27166360 PubMed]

==Panobinostat & Rituximab {{#subobject:f7bdff|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:cc78db|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972610/ Assouline et al. 2016]
|style="background-color:#91cf61"|Randomized Phase II, <20 pts (E)
|[[#Panobinostat_monotherapy|Panobinostat]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: patients had a median of 3 prior treatments (range 2-9).''
====Chemotherapy====
*[[Panobinostat (Farydak)]] 30 mg PO three times per week (e.g., MWF)
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===References===
# Assouline SE, Nielsen TH, Yu S, Alcaide M, Chong L, MacDonald D, Tosikyan A, Kukreti V, Kezouh A, Petrogiannis-Haliotis T, Albuquerque M, Fornika D, Alamouti S, Froment R, Greenwood CM, Oros KK, Camglioglu E, Sharma A, Christodoulopoulos R, Rousseau C, Johnson N, Crump M, Morin RD, Mann KK. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood. 2016 Jul 14;128(2):185-94. Epub 2016 May 10. [http://www.bloodjournal.org/content/128/2/185.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972610/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27166360 PubMed]

==Pixantrone monotherapy {{#subobject:bedd78|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:7fef70|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70212-7/abstract Pettengell et al. 2012 (PIX301)]
|style="background-color:#1a9851"|Phase III (E)
|Investigator's choice of:<br> 1. [[#Etoposide_monotherapy|Etoposide]]<br> 2. [[#Gemcitabine_monotherapy|Gemcitabine]]<br> 3. [[#Ifosfamide_monotherapy|Ifosfamide]]<br> 4. [[#Mitoxantrone_monotherapy|Mitoxantrone]]<br> 5. [[#Oxaliplatin_monotherapy|Oxaliplatin]]<br> 6. [[#Vinorelbine_monotherapy|Vinorelbine]]
|style="background-color:#91cf60"|Seems to have superior CR/CRu rate
|-
|}
====Chemotherapy====
*[[Pixantrone (Pixuvri)]] 85 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycle for up to 6 cycles'''

===References===
# '''PIX301:''' Pettengell R, Coiffier B, Narayanan G, de Mendoza FH, Digumarti R, Gomez H, Zinzani PL, Schiller G, Rizzieri D, Boland G, Cernohous P, Wang L, Kuepfer C, Gorbatchevsky I, Singer JW. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2012 Jul;13(7):696-706. Epub 2012 May 30. Erratum in: Lancet Oncol. 2012 Jul;13(7):e285. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70212-7/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22652183 PubMed]
## '''Post-hoc analysis:''' Pettengell R, Sebban C, Zinzani PL, Derigs HG, Kravchenko S, Singer JW, Theocharous P, Wang L, Pavlyuk M, Makhloufi KM, Coiffier B. Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial. Br J Haematol. 2016 Sep;174(5):692-9. Epub 2016 Apr 26. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14101/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074333/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27118109 PubMed]

==Rituximab monotherapy {{#subobject:d826ec|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:99a6d0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.bloodjournal.org/content/92/6/1927.long Coiffier et al. 1998]
| style="background-color:#1a9851" |Randomized Phase II (E)
|Higher-dose rituximab
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://clincancerres.aacrjournals.org/content/23/15/4127.long Czuczman et al. 2017 (DLC-001)]
| style="background-color:#1a9851" |Phase II/III (C)
|[[#Lenalidomide_monotherapy_3|Lenalidomide]]
| style="background-color:#fee08b" |Might have inferior ORR
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] as follows:
**Cycle 1: 375 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22
**Cycles 4, 6, 8, 10: 375 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for 10 cycles (8 doses total)'''

===References===
# Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998 Sep 15;92(6):1927-32. [http://www.bloodjournal.org/content/92/6/1927.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9731049 PubMed]
# '''DLC-001:''' Czuczman MS, Trněný M, Davies A, Rule S, Linton KM, Wagner-Johnston N, Gascoyne RD, Slack GW, Brousset P, Eberhard DA, Hernandez-Ilizaliturri FJ, Salles G, Witzig TE, Zinzani PL, Wright GW, Staudt LM, Yang Y, Williams PM, Lih CJ, Russo J, Thakurta A, Hagner P, Fustier P, Song D, Lewis ID. A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator's choice in patients with relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res. 2017 Aug 1;23(15):4127-4137. Epub 2017 Apr 5. [http://clincancerres.aacrjournals.org/content/23/15/4127.long link to original article] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/28381416 PubMed]

==R-BL {{#subobject:fe578a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-BL: '''<u>R</u>'''ituximab, '''<u>B</u>'''endamustine, '''<u>L</u>'''enalidomide

===Regimen {{#subobject:f063a7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.14049/abstract Hitz et al. 2016 (SAKK 38/08)]
|style="background-color:#91cf61"|Phase II
|ORR: 61% (95% CI 45-76%)
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Bendamustine]] 70 mg/m<sup>2</sup> IV once per day on days 1 & 2
*[[Lenalidomide (Revlimid)]] 10 mg PO once per day on days 1 to 21

'''28-day cycle for 6 cycles'''

===References===
# Hitz F, Zucca E, Pabst T, Fischer N, Cairoli A, Samaras P, Caspar CB, Mach N, Krasniqi F, Schmidt A, Rothermundt C, Enoiu M, Eckhardt K, Berardi Vilei S, Rondeau S, Mey U. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08. Br J Haematol. 2016 Jul;174(2):255-63. Epub 2016 Mar 28. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14049/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27018242 PubMed]

==R-CVEP {{#subobject:cea36|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-CVEP: '''<u>R</u>'''ituximab, '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''orinostat, '''<u>E</u>'''toposide, '''<u>P</u>'''rednisone

===Regimen {{#subobject:d9b3c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/bjh.13195/full Straus et al. 2014]
|style="background-color:#91cf61"|Phase II
|-
|}

''The MTD for vorinostat was 300 mg in this phase I/II trial.''
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Vorinostat (Zolinza)]] 300 mg PO once per day on days 1 to 10
*[[Etoposide (Vepesid)]] 70 mg/m<sup>2</sup> IV once on day 1
*[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 10

'''28-day cycle for 6 cycles'''

===References===
# Straus DJ, Hamlin PA, Matasar MJ, Lia Palomba M, Drullinsky PR, Zelenetz AD, Gerecitano JF, Noy A, Hamilton AM, Elstrom R, Wegner B, Wortman K, Cella D. Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation. Br J Haematol. 2015 Mar;168(5):663-70. Epub 2014 Oct 15. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13195/full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25316653 PubMed]

==R-GemOx {{#subobject:bb9813|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-GemOx: '''<u>R</u>'''ituximab, '''<u>Gem</u>'''citabine, '''<u>Ox</u>'''aliplatin
GEMOX-R: '''<u>GEM</u>'''citabine, '''<u>OX</u>'''aliplatin, '''<u>R</u>'''ituximab
===Variant #1, 14-day cycles {{#subobject:a875bf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/18/8/1363.long El Gnaoui et al. 2007]
|style="background-color:#91cf61"|Phase II
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815173/ Mounier et al. 2013]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV at a fixed dose rate of 10 mg/m<sup>2</sup>/min once on day 2
*[[Oxaliplatin (Eloxatin)]] 100 mg/m<sup>2</sup> IV over 2 hours once on day 2

====Supportive medications====
*[[Methylprednisolone (Solumedrol)]] 1 mg/kg IV once prior to [[Rituximab (Rituxan)]]
*[[Acetaminophen (Tylenol)]] 1000 mg PO once prior to [[Rituximab (Rituxan)]]
*[[Dexchlorpheniramine (Polaramine)]] 6 mg PO once prior to [[Rituximab (Rituxan)]]
*Primary prophylaxis with G-CSF was not permitted

'''14-day cycle for up to 8 cycles'''

===Variant #2, 21-day cycles {{#subobject:b976d9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1600-0609.2007.00996.x/full López et al. 2008]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once on day 1
*[[Oxaliplatin (Eloxatin)]] 100 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 6 to 8 cycles'''
===References===
# El Gnaoui T, Dupuis J, Belhadj K, Jais JP, Rahmouni A, Copie-Bergman C, Gaillard I, Diviné M, Tabah-Fisch I, Reyes F, Haioun C. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol. 2007 Aug;18(8):1363-8. Epub 2007 May 11. [http://annonc.oxfordjournals.org/content/18/8/1363.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17496309 PubMed]
# López A, Gutiérrez A, Palacios A, Blancas I, Navarrete M, Morey M, Perelló A, Alarcón J, Martínez J, Rodríguez J. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol. 2008 Feb;80(2):127-32. Epub 2007 Nov 20. [https://onlinelibrary.wiley.com/doi/10.1111/j.1600-0609.2007.00996.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18005385 PubMed]
# Mounier N, El-Gnaoui T, Tilly H, Canioni D, Sebban C, Casasnovas RO, Delarue R, Sonet A, Beaussart P, Petrella T, Castaigne S, Bologna S, Salles G, Rahmouni A, Gaulard P, Haioun C. Rituximab plus gemcitabine and oxaliplatin in refractory/relapsed patients with diffuse large B-cell lymphoma who are not candidates for high-dose therapy: a phase II Lymphoma Study Association trial. Haematologica. 2013 Nov;98(11):1726-31. Epub 2013 Jun 10. [http://www.haematologica.org/content/98/11/1726.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815173/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23753028 PubMed]

==R-INO {{#subobject:429f9a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
R-INO: '''<u>R</u>'''ituximab, '''<u>INO</u>'''tuzumab ozogamicin
===Regimen {{#subobject:9a3b4b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878046/ Fayad et al. 2013]
|style="background-color:#91cf61"|Phase I/II
|ORR: 74%
|-
|}
====Chemotherapy====
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1
*[[Inotuzumab ozogamicin (Besponsa)]] 1.8 mg/m<sup>2</sup> IV once on day 2

'''28-day cycle for up to 8 cycles'''

===References===
# Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, Rohatiner A, Advani A, Foran J, Hess G, Coiffier B, Czuczman M, Giné E, Durrant S, Kneissl M, Luu KT, Hua SY, Boni J, Vandendries E, Dang NH. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013 Feb 10;31(5):573-83. Epub 2013 Jan 7. [http://jco.ascopubs.org/content/31/5/573.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878046/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23295790 PubMed]

==Temsirolimus monotherapy {{#subobject:4baa29|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:21e303|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020703/ Smith et al. 2010]
|style="background-color:#91cf61"|Phase II
| style="background-color:#8c6bb1" |ORR: 28%
|-
|}
====Chemotherapy====
*[[Temsirolimus (Torisel)]] 25 mg IV over 30 minutes once per week

'''28-day cycle for up to 6 cycles'''

===References===
# Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, Smith S, Stiff P, Lester E, Modi S, Doyle LA, Vokes EE, Pro B. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 2010 Nov 1;28(31):4740-6. Epub 2010 Sep 13. [http://jco.ascopubs.org/content/28/31/4740.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020703/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20837940 PubMed]

==Tisagenlecleucel monotherapy {{#subobject:d68f14|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:60fc19|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1804980 Schuster et al. 2018 (JULIET)]
|style="background-color:#91cf61"|Phase II
| style="background-color:#9ebcda" |ORR: 59% (95% CI, 44‐72)
|-
|}
''The range given is the FDA-recommended dose.''
====Preceding treatment====
*Lymphodepleting therapy with [[Autologous_HSCT#FC|FC]] or [[Autologous_HSCT#Bendamustine_monotherapy|Bendamustine]]

====Immunotherapy====
*[[Tisagenlecleucel (Kymriah)]] 0.6 to 6.0 x 10<sup>8</sup> CTL019 transduced viable T-cells

'''One course'''

===References===
<!-- # '''Abstract:''' Schuster SJ, Bishop MR, Tam C, et al. Global Pivotal Phase 2 Trial of the CD19‐Targeted Therapy CTL019 in Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B‐Cell Lymphoma (DLBCL)—an Interim Analysis. Hematological Oncology. 2017;35(S2):27. [https://onlinelibrary.wiley.com/doi/full/10.1002/hon.2437_6 link to abstract] -->
# '''JULIET:''' Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT; JULIET Investigators. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018 Dec 1. [Epub ahead of print] [https://www.nejm.org/doi/full/10.1056/NEJMoa1804980 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30501490 PubMed]

==TTR {{#subobject:934c01|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TTR: '''<u>T</u>'''axol (Paclitaxel), '''<u>T</u>'''opotecan, '''<u>R</u>'''ituximab

===Regimen {{#subobject:4882ef|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279071/ Westin et al. 2014]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV once on day 2
*[[Topotecan (Hycamtin)]] 1 mg/m<sup>2</sup> IV once per day on days 2 to 6
*[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day from day 7 until neutrophil recovery
*[[Dexamethasone (Decadron)]] 20 mg IV once 30 minutes prior to [[Paclitaxel (Taxol)]]
*[[Diphenhydramine (Benadryl)]] 50 mg IV once 30 minutes prior to [[Paclitaxel (Taxol)]]

'''21-day cycle up to a maximum of 6 cycles'''

===References===
# Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2014 Oct;167(2):177-84. Epub 2014 Jul 8. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13014/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279071/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25039868 PubMed]

==Vinorelbine monotherapy {{#subobject:29c647|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:f0bd7f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/7/9/970.long Balzarotti et al. 1996]
|style="background-color:#ffffbe"|Non-randomized, <20 pts in this subgroup
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70212-7/fulltext Pettengell et al. 2012 (PIX301)]
|style="background-color:#91cf61"|Phase III, <20 pts in this arm (C)
|[[#Pixantrone_monotherapy|Pixantrone]]
|style="background-color:#fc8d59"|Seems to have inferior CR/CRu rate
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22

'''28-day cycle for up to 6 cycles'''

===References===
# Balzarotti M, Santoro A, Tondini C, Fornier M, Bonadonna G. Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma. Ann Oncol. 1996 Nov;7(9):970-2. [http://annonc.oxfordjournals.org/content/7/9/970.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9006750 PubMed]
# '''Review:''' Webb MS, Saltman DL, Connors JM, Goldie JH. A literature review of single agent treatment of multiply relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2002 May;43(5):975-82. Review. [https://www.tandfonline.com/doi/full/10.1080/10428190290021632 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12148908 PubMed]
# '''PIX301:''' Pettengell R, Coiffier B, Narayanan G, de Mendoza FH, Digumarti R, Gomez H, Zinzani PL, Schiller G, Rizzieri D, Boland G, Cernohous P, Wang L, Kuepfer C, Gorbatchevsky I, Singer JW. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2012 Jul;13(7):696-706. Epub 2012 May 30. Erratum in: Lancet Oncol. 2012 Jul;13(7):e285. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70212-7/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22652183 PubMed]
## '''Post-hoc analysis:''' Pettengell R, Sebban C, Zinzani PL, Derigs HG, Kravchenko S, Singer JW, Theocharous P, Wang L, Pavlyuk M, Makhloufi KM, Coiffier B. Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial. Br J Haematol. 2016 Sep;174(5):692-9. Epub 2016 Apr 26. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.14101/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074333/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27118109 PubMed]

=Maintenance after further lines of therapy=
==Lenalidomide monotherapy {{#subobject:9ce5ad|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:829190|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(11)00023-1/abstract Zinzani et al. 2011]
|style="background-color:#91cf61"|Phase II
|-
|}
====Preceding treatment====
*[[#Lenalidomide_.26_Rituximab|Lenalidomide & Rituximab]] x 4
====Chemotherapy====
*[[Lenalidomide (Revlimid)]] 20 mg PO once per day on days 1 to 21

'''28-day cycle for 8 months'''

===References===
# Zinzani PL, Pellegrini C, Gandolfi L, Stefoni V, Quirini F, Derenzini E, Broccoli A, Argnani L, Pileri S, Baccarani M. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):462-6. Epub 2011 May 4. [http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(11)00023-1/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21859554 PubMed]
## '''Update:''' Zinzani PL, Pellegrini C, Derenzini E, Argnani L, Pileri S. Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. Hematol Oncol. 2013 Dec;31(4):223-4. Epub 2013 Apr 26. [https://onlinelibrary.wiley.com/doi/10.1002/hon.2049/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23620452 PubMed]

=Response criteria=
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979083/ Lugano Classification criteria (2014)] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979083/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25113753 PubMed]
*[http://jco.ascopubs.org/content/25/5/579.long International Harmonization Project on Lymphoma revised criteria (2007)] [https://www.ncbi.nlm.nih.gov/pubmed/17242396 PubMed]
*[http://jco.ascopubs.org/content/17/4/1244.long NCI Sponsored International Working Group criteria (1999)] [https://www.ncbi.nlm.nih.gov/pubmed/10561185 PubMed]

=Prognosis=

==IPI and age-adjusted IPI (1993)==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
To be completed
# A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993 Sep 30;329(14):987-94. [https://www.nejm.org/doi/full/10.1056/NEJM199309303291402 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8141877 PubMed]

==Revised International Prognostic Index, R-IPI (2007)==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
To be completed
# Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007 Mar 1;109(5):1857-61. Epub 2006 Nov 14. [http://www.bloodjournal.org/content/109/5/1857.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17105812 PubMed]

==CNS-IPI (2016)==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Risk factors===
*Age greater than 60 years
*Elevated LDH
*[[Performance_status#ECOG_performance_status_.28WHO.2FGOG.2FZubrod_score.29|ECOG PS]] greater than 1
*Advanced stage (III or IV)
*Involvement of more than one extranodal site
*Involvement of the kidney and/or adrenal glands
===Risk stratification===
*'''Low risk:''' 0 or 1 risk factors (''2-year rate of CNS disease less than 5%'')
*'''Intermediate risk:''' 2 or 3 risk factors (''2-year rate of CNS disease less than 5%'')
*'''High risk:''' 4 to 6 risk factors (''2-year rate of CNS disease greater than 10%'')
===References===
# Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, Glass B, Scott DW, Gascoyne RD, Connors JM, Ziepert M, Pfreundschuh M, Loeffler M, Savage KJ. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016 Sep 10;34(26):3150-3156. Epub 2016 Jul 5. [http://jco.ascopubs.org/content/34/26/3150.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27382100 PubMed]

=Investigational agents=
''These are drugs under study with at least some promising results for this disease.''

*[[Coltuximab ravtansine (CoR, SAR3419)]]
*[[Fostamatinib (R788)]]
*[[Pidilizumab (CT-011)]]

[[Category:Diffuse large B-cell lymphoma regimens]]
[[Category:Disease-specific pages]]
[[Category:Aggressive lymphomas]]
